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ABSTRACT
DESIGN AND SYNTHESIS OF SELECTIVE ESTROGEN RECEPTOR β
AGONISTS AND THEIR PHARMACOLOGY

K. L. Iresha Sampathi Perera, B.Sc. (Hons), M.Sc.

Marquette University, 2017

Estrogens (17β-estradiol, E2) have garnered considerable attention in influencing
cognitive process in relation to phases of the menstrual cycle, aging and menopausal
symptoms. However, hormone replacement therapy can have deleterious effects leading
to breast and endometrial cancer, predominantly mediated by estrogen receptor-alpha
(ERα) the major isoform present in the mammary gland and uterus. Further evidence
supports a dominant role of estrogen receptor-beta (ERβ) for improved cognitive effects
such as enhanced hippocampal signaling and memory consolidation via estrogen activated
signaling cascades.
Creation of the ERβ selective ligands is challenging due to high structural similarity
of both receptors. Thus far, several ERβ selective agonists have been developed, however,
none of these have made it to clinical use due to their lower selectivity or considerable side
effects. The research in this dissertation involved the design of non-steroidal ERβ selective
agonists for hippocampal memory consolidation. The step-wise process to achieve the
ultimate goal of this research includes: (1) design and synthesis of (4hydroxyphenyl)cyclohexyl or cycloheptyl derivatives, (2) in vitro biological evaluation of
synthesized compounds to identify highly potent and selective candidates, and (3) in vivo
biological evaluation of selected candidates for hippocampal memory consolidation.
Several (4-hydroxyphenyl)cyclohexyl or cycloheptyl derivatives were synthesized
having structural alterations on both aromatic and cyclohexyl/heptyl ring scaffolds. ERβ
agonist potency was initially evaluated in TR-FRET ERβ ligand binding assay and
compounds having high potency were re-evaluated in functional cell based assays for
potency and ERβ vs. ERα selectivity. Two compounds from each series, ISP 163-PK4 and
ISP 358-2 were identified as most selective ERβ agonists. Both compounds revealed high
metabolic stability, solubility and no cross reactivity towards other nuclear receptors. In
vivo efficiency of ISP 358-2 was evaluated in ovariectomized mice (C57BL/6) with object
recognition (OR) and object placement (OP) tasks. The results indicate improved memory
consolidation at 100 pg/ hemisphere and 0.5 mg/Kg via DH infusion and IP injection
respectively. The information learned from this project serves as a foundation for
development of other cycloheptyl/hexyl based ERβ agonists or antagonists having
acceptable pharmacological profiles.
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CHAPTER 1

BACKGROUND AND GOALS OF RESEARCH

The goal of this research is the design, synthesis and biological evaluation of
estrogen receptor β (ERβ) selective agonists for hippocampal memory consolidation for
potential use by postmenopausal women.
1.1 Discovery of Estrogen Receptors
Estrogens, such as 17β-estradiol (E2, Figure 1.1), play an important role in the
growth, development and maintenance of a variety of tissues which are mainly mediated
by the estrogen receptor (ER), a ligand-activated transcription factor.1-2 There are two
distinct subtypes of estrogen receptors, ERα and ERβ, which are found to diverge with
respect to their transcriptional activities and tissue distribution. 2-4

Since the first

observations by Jensen and co-workers in 19685 that exogenous estrogen binds to a specific
receptor protein in the rat uterus, this estrogen receptor protein (ERα) has been extensively
studied.

The gene which encodes for ERα (ESR1 located on chromosome 6) was

successfully cloned in 1986.4 Until 1995, it was believed that there was a single ER which
was responsible for facilitating all the biological effects of estrogens. Thus, it was a
surprise when, in 1995, a second distinct estrogen receptor from rat prostate was reported
by the Gustafson’s group. This later estrogen receptor is known as ERβ and the gene which
encodes for ERβ is located on chromosome 14.4, 6-8

2

Figure 1.1: Structure of 17β-estradiol (E2)
The two receptors, ERα and ERβ, display overlapping but distinct patterns of tissue
distributions as well as different types of transcriptional regulation. 9-10 ERα is highly
expressed in the breast, liver and uterus and contributes to the malignant growth in these
tissues, whereas ERβ has counteractive anti-proliferative effects on breast cancer cell
lines.11-13

In addition, ERβ is expressed in the lungs, prostate, colon, brain and

gastrointestinal tract and upon binding of estradiol, it exerts beneficial effects in these
organs/ tissues without the risk of breast cancer. 9, 11, 14 These differential effects prompted
researchers to develop novel ERβ selective ligands (agonists / antagonists)9
1.2 Estrogen Receptors and Human Disease

The prevalence of breast cancer remains highest among all the cancers in women
and it is the leading cause of cancer-related mortality within the United States.15-16 While
initiation and progression of breast cancer involves several environmental and genetic
factors, estrogen and ERs plays a vital role in the progression and treatment of this disease.
Approximately 70% of breast cancers are ERα positive and respond to the selective
estrogen receptor modulator (SERMs) prodrug tamoxifen as part of anti-estrogen
therapy.4, 17-18 While, tamoxifen has relatively low binding to either ERα or ERβ (7% and
6% relative binding affinity (RBA) compared to estradiol), it is metabolized by cytochrome
P450 enzymes into 4-hydroxytamoxifen (4-OHT) which has greatly increased binding
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affinity (178% and 338% RBA compared to estradiol)(Scheme 1.1). 19 Competitive binding
of 4-OHT to ERα effects a decrease in expression of cyclin D1 (important for cell
progression through the G1 phase), and c-myc (which regulates cell growth). These
changes eventually lead to repression of Bcl2, which regulates anti-apoptosis, thus leading
to increased cell death.4, 20 In estrogen-sensitive malignancies ERα usually act as an
oncogene whereas ERβ is a tumor suppressor which clearly reveals a divergent relationship
(yin/yang relation) between the ER subtypes.4

Scheme 1.1: The major metabolic pathway involves initial conversion of tamoxifen to Ndesmethyl-tamoxifen and 4-hydroxy-tamoxifen followed by conversion to
endoxifen via CYP450s21
Estrogen and its receptors are essential for the development and branching
morphogenesis of the prostate. ERβ is predominantly expressed in both human and rodent
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prostate in comparison to ERα. So far, ERβ shows anti-proliferative effects for certain
prostate cancer

cell lines (DU145)

by repressing key oncogenes

such as

phosphatidylinositol 3-kinase (PI3K), c-myc, cyclin E (which is involved in promotion of
cells from the S phase to the G1 phase) and stimulating the expressions of anti-proliferative
genes such as the phosphatase and tension homolog (PTEN), Forkhead box O3 protein
(FOXO3) which functions as a trigger for apoptosis, and cyclin-dependent kinase inhibitor
1 (CDKN1A) which regulates cell cycle progression at the G1 and S phases. 4, 22-23
Osteoporosis is defined as the loss of bone mass and strength, mainly due to
increased bone resorption and this condition is associated with estrogen deficiency.3 In
ERα knock-out (αERKO) mice, shorter bone lengths and reduced mineral density were
observed in comparison to wild type mice.3, 24 Conversely, adult female ERβ knock-out
(βERKO) mice were found to have slightly higher bone mineral density, signifying a
regulatory role for ERβ in bone growth.3, 25 Similarly, male mice deficient in ERα, or both
ERα and ERβ, (due to knock-out) exhibited reduced bone mineral density, bone diameter
and length, while male mice with only ERβ knockout did not exhibit these reductions.3, 26
These observations suggest the significance of ERα in bone mass regulation.
ERs also have profound effects in the brain, mainly in brain injury,
neurodegeneration and cognitive decline.27 Both ERs are distributed in numerous regions
of the brain such as the hypothalamus, hippocampus, cerebral cortex, forebrain and
midbrain.23 Dubal, et al., demonstrated that the removal of ERα completely abolished the
protective role in brain injury, whereas the protection is preserved in the absence of ERβ
in ovariectomized / ischemia mice models.23, 27 Another study, where stroke was induced
from reversible middle cerebral artery (MCA) occlusion, found that no enhanced tissue
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damage was observed in female αERKNO mice.28 This indicates the subtype independent
nature of estrogen action towards brain injury prevention. Impressively, Gustafsson, et al.
showed an abundance of morphological abnormalities such as neuronal loss and
proliferation of astroglial cells in the brains of βERKO mice and.no changes were observed
in αERKO mice.29 Moreover, several researchers conclude that ERβ is crucial for neuron
survival and its valuable influence on treatment of neurodegenerative diseases including
Alzheimer disease, Parkinson disease, and schizophrenia.7, 23, 30
1.2.1 Estradiol, the Hippocampus and Memory

A plethora of literature accumulated over last twenty years has demonstrated that
17β-estradiol (E2) is an important trophic factor that mediates the function of cognitive
regions of the brain.31 “The importance of estrogen in cognitive function has been
highlighted by examining cognition in relation to phases of the menstrual cycle,
menopausal symptoms, circulating hormone levels and aging.”32 The decline in E2
production as a result of menopause is linked with etiology of dementia, depression and
cognitive decline in women, as well as rapid memory decline in animal models.31
According to recent studies, it is evident that E2 governs the dendritic length in the
basal forebrain and neuronal dendritic spine density in the somatosensory cortex, the
amygdala, and the prefrontal cortex of the brain.33

Similarly, estradiol controls

morphology and synaptic plasticity in the hippocampus; the major brain region responsible
for cognitive activity. So far, several mechanisms of action for the effects of estradiol on
cognitive functions of the hippocampus have been recognized through several distinct
pathways. E2 promotes the formation of new dendritic spines and excitatory synapses, and
stimulates the expression of N-methyl-D-aspartate (NMDA) mediated synaptic activity.

6

Moreover, E2 increases the phosphorylation of the cAMP response element binding
protein (CREB) and long term potentiation (LP) which are highly responsible for the
learning and long-term memory.32-34
ERα and ERβ are confined in several compartments in hippocampal neurons, such
as the nucleus, axon terminals and dendritic spine synapses. In the nucleus, ERs mediate
the estrogen effects on the classical genomic pathway leading to the gene transcription.
However, the localization of ERs at distal sites, such as dendritic spines and axon terminals,
proposed the possibility of a “non-genomic” or “non-classical” mechanism of estrogen
receptors. Indeed, binding of both ERs to the metabotropic glutamate receptor 1 (mGluR1)
triggers the hippocampal extracellular signal-regulated kinase (ERK) signaling and
promotes CREB phosphorylation. The interaction of E2 with NMDA receptor also triggers
ERK signaling as well as local protein synthesis. Both ERK and CERB play pivotal role
in hippocampal memory consolidation.

Besides intracellular ERs, several putative

membrane bound ERs have been identified (e.g. GPER, ER-X and Gq-ER). E2 binds to
these receptors and enhances the memory consolidation by activating the c-Jun N-terminal
kinase (JNK) cascade, which eventually facilitates gene transcription and protein
translation (Figure 1.2)31, 33
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Figure: 1.2: Schematic illustration of non-classical mechanisms required for E2 and ERs
to enhance hippocampal memory consolidation33
Though estrogen has been involved in influencing cognitive functions, the sub type
of estrogen receptor responsible for these effects remain unclear. However, accumulating
biochemical, pharmacological and behavioral studies support the key role of ERβ for
hippocampal memory and synaptic plasticity. A few selected examples are discussed
here.32-33
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In general, hippocampal memory in rodents have been primarily evaluated in
spatial tasks, including object placement, the Morris water maze and the radial arm maze,
as well as through object recognition tasks.33

In 2002, Gustafsson and coworkers,

demonstrated that removal of either receptor (by ERα or ERβ knockouts) impairs the
spatial memory in the Morris water maze

31, 35-36

Semple-Rewland, et al., showed that

spatial memory deficit induced by ERα knockouts can be restored by viral vector-mediated
delivery of the ERα gene to the hippocampus. However, the same delivery of the ERα
gene to the hippocampus did not restore memory deficit in ERβ knockout mice.31,
Moreover, both Walf, et al.31,

38-39

37

and Brandon, et al.32showed that exogenously

administrated E2 did not enhanced the hippocampal memory in female ERβ knockout
mice.
Besides the memory related studies, Brandon and coworkers examined the
molecular events driven by ERβ in the hippocampus.32 Since estrogen exerts effects on
synaptic physiology by activating non-genomic signaling cascades (MAPK), the
abundance of pCREB levels were monitored in ovariectomized rats.

Dosing

ovariectomized rats with ERβ selective agonist (WAY-200070) and estradiol significantly
increased the phosphorylated cAMP response element binding (pCREB) levels; there were
not pCREB level increases observed with administration of the ERα selective agonist PPT
(Figure 1.3).32
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Figure 1.3: Structure of ERα and ERβ selective agonists
1.2.2 Estrogen Decrease in Menopause and Hormone Replacement Therapy

Estrogen levels decrease in both sexes as humans age, but drop more precipitously
in women during the menopausal transition. Lower estrogen levels during menopause is
correlated with “diseases of the skeleton (osteoporosis), cardiovascular system (coronary
heart disease) and central nervous system (Alzhimer’s disease).”1 Hormone replacement
therapy (HRT), the prolonged administration of estrogen and progesterone supplements,
was initially developed to address the lower production of these important mediators. HRT
reduced the risk of dementia, mild cognitive impairment and prevented the spine and hip
fraction in postmenopausal women. However, the safety of continuous administration of
estrogen supplements in HRT is currently under scrutiny due an increased risk of breast
and endometrial cancer.40-43 The etiology of HRT carcinogenicity is complex, but an
increasing amount of evidence supports the formation of catecholic estrogens via CYP450
and their subsequent oxidation to tumor-initiative quinones (Scheme 1.2). 44-48
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Scheme 1.2: Mechanism of quinone formation and DNA adduction
Nevertheless, estradiol has garnered considerable attention over the past decades in
influencing cognitive processes in relation to phases of the menstrual cycle, aging and
menopausal symptoms. Accumulating evidence supports the dominant role of estrogen
receptor-beta (ERβ); the predominant isoform in the hippocampus for improved cognitive
effects.32 ERβ mediates estradiol’s effects on neural plasticity, neuroprotection, enhanced
hippocampal signaling and memory consolidation via estrogen activated signaling
cascades, via the extracellular signal-regulated kinase/mitogen-activated protein kinase
pathway (ERK/MAPK).49-50 Due to the deleterious effects of activating ERα compared to
beneficial effects of activating ERβ, selective ERβ agonists are an exciting new direction
in drug discovery for the treatment of cognitive deficits in postmenopausal women.
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1.3 Estrogen Receptor Structure and Mechanism of Action
“ERα and ERβ belong to the nuclear hormone receptor family whose members are
ligand-controlled transcription factors.”7 ERα is a 66 kDa, 595-residue protein whereas
ERβ is a 62 kDa, 530-residue protein.2 Both ERs exhibit similar architecture, having six
regions of the primary amino acid sequence (A-F) and composed of three major functional
domains: the N-terminal or A/B domain (NTD), the DNA-binding domain (DBD), and the
C-terminal D/E/F or ligand-binding domain (LBD) (Figure 1.4). The two human ERs
share ~ 97% similarity between the DBD domains, 59% similarity in the LBD domains,
but only 16% similarity in the NTD domain. The two receptors are functionally not
interchangeable.2, 4, 6

Figure 1.4: Schematic representation of structural domain of human ERα and ERβ4
The N-terminal domain (NTD) of ER consists of ligand-independent activation
function (AF1) where it involves the protein-protein interactions and transcriptional
activation. In ERα, the AF1 domain shows higher activity in stimulation of reporter gene
expression via estrogen response element (ERE) whereas AF1 activity of ERβ appeared to
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be diminished under the same conditions. This dissimilarity in N-terminal region accounts
for the difference in activity of ERα and ERβ towards various exogenous ligands.6-7
The DNA binding domain (DBD) of both receptors shares a high degree of
sequence homology and each contains a zone called “zinc fingers”. This region is rich in
cysteine residues and four cysteine residues are coordinated to the zinc atom to form the
finger structure, having a loop of 15 to 22 aminoacids.51

Zinc fingers are common to

transcription factors and there are two zinc fingers for each receptor. These play an integral
role in receptor- DNA binding in that they offer “an optimum architecture for the mutual
recognition between specific sequences of amino acids and nucleotides”51. This eventually
establishes the hydrogen bridges (via H-bonding) in order to form the stable ER-DNA
complex.8, 51

Figure 1.5: Formation of Zinc fingers in DNA binding domain. (Adapted from Selective
Estrogen Receptor Modulators, A. Cano, et al., Springer, 2006, pg 20)51
The C-terminal ligand binding domain (LBD) governs the target gene expression
via ligand binding, receptor dimerization and subsequent dimer-nuclear translocation. The
LBDs of both receptors have higher homology with respect to their amino acid sequences
and have similar tertiary architecture. LBD usually comprises of 12 helices (H1-H12) in
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three anti parallel layers. It incorporates an activation function 2 segment (AF2), whose
structure and function are mainly mediated by incoming ligands. AF2 interaction surface
is composed of amino acids in helix 3, 4, 5, and 12 and the positioning of helix 12 is
effected by incoming ligands based on their agonist or antagonist nature. Overall, the
ligand-binding domains of ERs have a net hydrophobic character, which is an essential
prerequisite for attachment of low molecular weight organic molecules. 2,

6-7

Small

differences between the LBDs of ERα and ERβ influence the shape of their ligand binding
pockets there by engendering unique affinities for ligands. 6 These differences in the LBD
will be discussed in more detail in Section 1.4.
The ERs are mostly localized in the cytoplasm in complex with heat-shock proteins
(Hsp) 50, 70 and 90 which stabilize the receptors in an inactive state. 4 “The action of ERs
is tripartite, as it involves the receptor, ligands (natural or synthetic) and coregulatory
proteins.”52 In the classical mode of action, binding of estrogen to the LBD of ER induces
receptor conformational changes (mainly dissociation of ER-Hsp chaperone complex),
leading to receptor dimerization (ER2). This dimer binds to a specific sequence of DNA
in the promoter region known as the estrogen response element (ERE). This binding
promotes the recruitment and interaction with coregulators from the nucleus, and formation
of a pre-initiation complex. Finally, the receptor-DNA-coregulator complex undergoes
DNA transcription to form mRNA and thereby desired proteins which lead to an alteration
in cell function (Figure 1.6).4, 8, 51
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Figure 1.6: Classical mechanism action of estrogen receptor53
In addition to its classical mode of action, it is now accepted that ERs can mediate
gene expression without directly binding to DNA. One possible pathway is transcriptional
cross-talk, where the E2-receptor complex is tethered to a transcription factor (TF) that
interacts with the DNA, thus avoiding a direct ER-DNA interactions (Figure 1.7).4, 6, 8, 54
Examples for transcriptional cross talk include interaction of ERs at activating protein 1
(AP1), specificity protein 1 (Sp1), cAMP response element-binding protein (CREB),
nuclear factor κB (NFκB), p53 binding sites. Interaction of ER with the nuclear factor κB
(NFκB) prevents the NFκB binding to interleukin-6 (IL-6) promoter leading to repression
of cytokine IL-6 protein. ERs regulate several genes by this mechanism and both AP1 and
Sp1 mediated gene expression vary with the ligand, cell and receptor subtype.4, 6, 54-55
Furthermore, “ERs stimulate transcriptional responses in the absence of estradiol.
Epidermal growth factor receptor (EGFR) and insulin-like growth factor 1 receptor
(IGF1R) can initiate the protein kinase cascade, thus phosphorylation and activation of ERs
in the absence of the ligand.”8
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a

b

c

d

Figure 1.7: a) classical mechanism of action. b,c,d) “indirect effects of estrogen receptors
on transcriptional activation”6
Likewise, accumulating evidence supports for the rapid and non-genomic effects
of membrane bound and cytoplasmic ERs where binding of estradiol activates the
following proteins: mitogen-activated protein kinase (MAPK), phosphatidylinositol 3kinase (PI3K), nitric oxide synthase 3 (NOS3), human epidermal growth factor receptor 2
(HER2) and G proteins (GP). Finally, these proteins can signal to regulate the gene
expression via activation of other transcriptional factors.6, 8
1.4 Important Interactions within the Ligand Binding Domain

While the ligand binding domains (LBDs) of ERs share less than 60% of amino
acid sequence, the ligand binding pockets (LBP) of the two isoforms have only minute
variations in structure and composition.11 The crystal structure of estradiol bound to ERα
revealed a hydrogen bonding network between the endogenous ligand and surrounding
amino acid residues.56 The phenolic OH group interacts with a bound water molecule and
two amino acid residues of the ER LBP (Glu353 and Arg394 in ERα, Glu305 and Arg346
in ERβ, Figure.1.8) and the 17β-hydroxy group is involved in an additional hydrogen bond
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interaction to His524 (ERα) or His475 (ERβ).57 The two LBPs are composed of 23 amino
acid residues, 21 of which are conserved and only two of which are variant. The residues
Leu384 and Met421 in ERα are replaced with Met 336 and Ile373 in ERβ respectively.
Furthermore, the interchanged Leu384/ Met336 residues are positioned above the B- and
C-rings of estradiol whereas the interchanged Met421/Ile373 residues are positioned below
the estradiol D-ring within the LBP. These minute alterations in amino acid sequence plus
other small variations in tertiary structure make the ERβ LBP smaller in volume (279 Å3)
in comparison to the LBP of ERα (379 Å3). However, the creation of ERβ selective ligands
seems to be a real challenge due to higher structural similarity of LBP of both receptors. 11,
47, 57-60

Figure 1.8: “Principal interactions of estradiol with ERα and ERβ conserved and
nonconserved residues”60
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1.5 Estrogen Receptor – Agonists, Antagonist and Selective Estrogen Receptor
Modulators
The molecules that bind to ERs possess significant variations in the process of
uptake, binding, and/or recruitment of coregulator(s) leading to different transcriptional
responses. The conformational changes that occur at the LBD upon formation of ERmolecular complex determine its transcriptional responses relative to the native estrogen. 61
Natural and synthetic ligands may be classified as agonists, antagonists or selective
estrogen receptor modulators (SERMs). Ligands that form complexes in a similar but not
identical manner to those formed by estradiol are known as ER agonists. They recruit a
similar set of cofactors and eventually produce similar but not identical transcriptional
responses.51, 61 On the contrary, ligands that form complexes at the LBD, but create
different conformational changes compared to estradiol, are termed as ER-antagonists or
antiestrogens. These complexes fail to dimerize or recruit the same set of cofactors as
estradiol or recruit different cofactors leading to a blocking of transcriptional responses. 51,
61

ER agonists and antagonists bind at the same site of the LBD with different binding
orientations or modes. For this reason, agonist or antagonist activity is mainly due to the
spatial repositioning of helix 12 (H12) after binding; the location of this helix is a key factor
for the subsequent recruitment of the transcription cofactors.2, 62 Indeed, the binding of an
agonist restructures the ligand binding domain, making helix 12 rotate in a way that it is
positioned over the ligand binding pocket. This facilitates the movement of coactivators
while removing the corepressors from their original site. In contrast, antagonist ligands
lodge into the hydrophobic groove conferred by helices 3, 4, and 5 and disrupts helix 12
conformation for coactivator interaction. Figure 1.9 depicts the difference in positioning
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of H12 of ERα upon binding of agonist (diethylstilbestrol) and antagonist (4hydroxytamoxifen) to the LBD.

a)

b)

Figure 1.9: a) The conformation of H12 of ERα due to diethylstilbestrol (agonist) binding
(yellow) and tamoxifen (antagonist) binding (magenta) b) Ligand-dependent
structural deviation between agonists (red) and antagonists (white)
conformations. 2
The folded yellow and extended pink portions represents the H12 helix in agonist
and antagonist mode respectively and are readily discernable. Moreover, the superposition
of both agonist and antagonist forms of LBD without any modification clearly reveal the
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conformationally conservative nature of the LBD (blue colored) aside from the H12
orientation. 2, 6, 62
ERα agonists (red in Figure 1.10a) primarily interact with Glu353, Arg394 and
His524, whereas ERα antagonists (white) have an additional interaction with Asp351
(upper left corner of Figure 1.10a). This additional interaction is responsible for the
antagonism which prevents the conformational change of helix 12. Similar amino acid
residues in ERβ are engaged in these interactions (Figure 1.10b); these differ only in
residue numbering (Glu305, Arg346, His475, Asp303).2
Selective estrogen receptor modulators (SERMs) are a structurally diverse class of
therapeutic agents that interact with estrogen receptors but that exhibit a selective ER
agonist vs antagonist profile which is tissue/organ specific.

63

To date several SERMs

drugs are developed and some are approved for clinical use. For an example, tamoxifen is
used as an antagonist for the treatment of breast cancer, but shows agonist effects on bone
mineral density and serum lipids on postmenopausal women. Raloxifene, is used for
treatment of osteoporosis and vertebral fractures, even though it is a failed breast cancer
drug.17, 51, 63 Table 1.1 shows the classification of SERMs and Figure 1.11 shows some of
their chemical structures.51
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a)

b)

Figure 1.10: a) The binding interactions in the ERα for agonists (red) and antagonists
(white). b) binding interactions in ERβ for agonist (blue) and antagonist
(green) 2
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Table 1.1: “Classification of SERMs” (Adapted from Selective Estrogen Receptor
Modulators, Cano, et. al, Springer, 2006, pg 51)51
Chemical Class
Triphenylethylenes

SERM
Tamoxifen*
Toremifene*

AstraZeneca
Orion

Droloxifene#

Pfizer

#

Idoxifene

Smithkline Beecham

Benzothiophenes

Raloxifene*,†
Arzoxifene†

Eli Lilly & Co
Eli Lilly & Co

Naphthylenes

Lasofoxifene†

Pfizer

Trioxifene

#

Indoles

Bazedoxifene†
Pipendoxifene†

Wyeth
Wyeth

Benzopyrans

EM-800†
Acolbifene†
Levormeloxifene*

Schering Plough
Schering Plough
Novo-Nordisk

* Commercialized for different indications: breast cancer treatment, contraception,
Ovulation induction, prevention and treatment of postmenopausal osteoporosis.
† Phase III clinical research
# Clinical development cancelled
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a) Triphenylethylene derivatives

b) Benzothiophenes and Napththalene derivatives

c) Indoles and Benzopyran derivatives

Figure: 1.11: Selected chemical structures of SERMs 51
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1.6 Review of ERβ Subtype Selective Ligands

Estradiol has nearly equivalent binding affinity for ERβ and ERα. While there are
a considerable amount of compounds known which have greater selectivity for ERα, only
a limited number molecules with greater selectivity for ERβ have been reported.60 Among
natural products, coumestrol, genistein, liquiritigenin, naringenin and apigenin are some
examples of ERβ-selective agonists (Figure 1.12).

They are found in many plants

(phytoestrogen) and foods, especially in soybeans. The isoflavone genistein shows nearly
20 to 30-fold selectivity for ERβ over ERα and it was the first ERβ selective natural product
characterized from X-ray crystallography (Figure 1.13).64 Coumestrol, liquiritigenin,
naringenin, and apigenin also show considerable selectivities for ERβ in binding affinity
assays (β/α 7, 11, 20, and 30 respectively).7, 10, 60, 65-67

Figure 1.12: Examples of natural ERβ-selective agonists60
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a)

b)

Figure 1.13: a) “Schematic representations of hERβ–GEN complex. Helices are depicted
as rods and H12 is colored in green.” b) “Comparison of ligand-binding
mode of GEN (protein-light blue; ligand, green) in hERβ-LBD and E2
(protein-red; ligand-purple) in hERα-LBD (PDB code: 1ERE) within the
cavity. The ligands are viewed looking down from the β-face of the cavity
and only those side chains that interact with the bound ligand or exhibit
different orientations are shown. Hydrogen bonds are depicted as broken
lines”64
1.6.1 Design of Non-Steroidal ERβ Selective Agonists

The design and development of non-steroidal ERβ selective agonists has piqued
much interest due to their potential lower carcinogenic properties compared to steroidal
molecules.60 To date, several non-steroidal selective ERβ agonists have been synthesized
and a few selected examples are discussed here.
In 2001, Katzenellenbogen and co-workers at the University of Illinois; discovered
2,3-bis(4-hydroxyphenyl)propionitrile (DPN), a chiral molecule, as one of the most potent
and selective ERβ agonists (Figure 1.14).60,

68

The racemic molecule has 70-fold higher

relative binding affinity for ERβ compared to ERα and 170-fold higher relative potency in
transcription assays (ERβ vs ERα).68 Due to its present commercial availability, several
researchers have used (±)-DPN as a pharmacological probe to evaluate the unique biology
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of ERβ in both in vivo and in vitro biological studies.60, 69-70 Subsequently; in 2009 Handa,
et.al, separated the enantiomers by chiral HPLC.

They reported that (S)-DPN

demonstrated a higher affinity for ERβ compared to (R)-DPN, and that (S)-DPN showed
nearly 80-fold selectivity for ERβ.71 In 2012, the Katzenellenbogen group prepared the
(S)-and (R)- DPN by enantioselective synthesis. They confirmed the high affinity and
potency preference of both enantiomers toward the ERβ (80-300), however, in this study,
authors reported that (R)-DPN as the preferred agonist for ERβ activity.72 Computational
docking of the (S)-stereoisomer with either ERα or ERβ shows that the hydroxyl group of
the β - ring (see structures for aromatic ring designation) exerts a favorable H-bonding
network with Glu353 and Arg394 in ERα (or Glu305 and Arg346 in ERβ) while the
hydroxyl group of the α-ring interacts with His524 in ERα (or His475 in ERβ). In this
orientation, the CN group of DPN interacts with the sulfur atom of Met336 in ERβ in a
more favorable manner than with the similarly positioned Leu384 residue of ERα. In
contrast, computational docking of (R)-DPN shows that the CN group projects in the
opposite direction in comparison to the S-enantiomer and thus exerts a weaker interaction
with the surrounding amino acid residues (Figure 1.14). These docking studies suggest
that the selectivity of DPN racemate towards ERβ mainly stems from the strongly
interacting geometry of S-DPN and not from R-DPN at the ligand binding pocket.60, 68, 73
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Figure 1.14: “Crossed stereo view of S-DPN (Panel A) and R-DPN (Panel B) docked and
minimized in the ER and ER LBD Pockets, respectively. DPN and the ERβ
pocket residues are shown with standard atom colors, whereas in the ERα
complex, DPN and the pocket residues are shown in orange.”73
In 2004, the Wyeth research group reported a series of ERβ selective agonists
belonging to the benzoxazoles family.60 The ERB-041, WAY-292, WAY-659, WAY-818,
and WAY-200070 are some examples from the Wyeth compound library (Figure 1.15). 9,
60, 74

Among these, ERB-041 showed a 250-fold highest selectivity for ERβ having binding

affinities (IC50) of 1200 nM and 5.4 nM for ERα and ERβ respectively. Both docking and
X-ray crystallographic studies reveal that the hydroxyl group of the 3-fluoro-4-
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hydroxyphenyl moiety forms H-bonds with nearby Glu305 and Arg346 of ERβ residues
while the benzoxazole hydroxyl group hydrogen bonds to His475. These interactions are
common to both estrogen receptors (Figure 1.16).

Notably, the benzoxazole vinyl

substituent is positioned in close proximity to Ile373 of ERβ while in ERα the vinyl group
interacts with the Met421 residue (Figure 1.17). It was suggested that the increased steric
interaction of the vinyl group with the larger Met residue, as compared to the more compact
Ile373 was responsible for the higher selectivity of ERB-041 with ERβ compared to ERα.9,
60, 74-75

Figure 1.15: Examples of ERβ-selective agonists from Wyeth library60

28

Figure 1.16: Schematic representation of ERB-041 complexed with ERα and ERβ,
showing key interactions within the ligand binding domain9

Figure 1.17: ERB-041 binding interactions with ERα and ERβ60
In 2006, Eli Lilly group developed a series of polycyclic benzopyran (PBP)
derivatives as selective ERβ agonists (Figure 1.18).

Figure 1.18: Racemic unadorned and racemic all-cis 3,4-cyclofused- (n= 1-3)
benzopyrans60, 76
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The racemic cyclopentyl annulated benzopyran (n = 1) exhibited good activity
(0.47nM for ERβ and 4.34nM for ERα) and modest selectivity (β/α = 9). The enantiomers
were separated by chiral chromatography and named as SERBA1 and SERBA-2. SERBA1 demonstrated the higher affinity for both ERβ and ERα (ERβ, Ki = 0.19 nM; ERα Ki =
2.68 nM) compared to the enantiomer SERBA-2 (ERβ, Ki = 1.54 nM; ERα Ki = 14.5 nM).
Moreover, the ERβ/ERα selectivity was greater for SERBA-1 (14.1) compared to SERBA2 (9.4). This selectivity is mainly attributed to the two different binding orientations of
SERBA-1 in both receptors. According to the X-ray crystal structures (Figure 1.19), the
most efficient interactions arise with ERβ, where the hydroxy of the phenol group is
hydrogen bonded to Arg346/Glu305 while the benzopyran hydroxyl forms a H-bond with
His475. The fused cyclopentane ring lodges a small hydrophobic pocket, near to Ile373
residue in ER β complex. In ERα, the presence of Met421 makes the pocket too small to
accommodate the cyclopentane ring. Thus, binding of SERBA-1 in ERα forces a rotation
of 180° along its central axis. This orientation preserves the Arg/Glu H-bonding network,
but the OH-His524 H-bonding interaction is weakened due to the greater distance between
these groups (Figure 1.20).60, 76-77
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Figure 1.19: “Surface diagram of the X-ray structure of SERBA-1 complexed to ERα (1A)
and ERβ (1B)”77

Figure 1.20: SERBA-1 binding interactions with ERα and ERβ60
In 2011, the Katzenellenbogen group prepared estrogen analogs lacking the B ring
(i.e. ACD- pseudosteroids), as ERβ selective agonists (Figure 1.21).47 While these authors
initially reported78 the preparation of a trans-hydrindane skeleton, this was later corrected79
to a cis- hydrindane (ACD-1, Figure 1.21) on the basis of X-ray crystallography. The
trans-hydrindane structure was eventually prepared80 and binding assays were performed
on these compounds as well as on selected A-ring substituted variants. From their ACD
library, all compounds showed lower overall affinity but more importantly greater
selectivity towards ERβ.
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ACD-1
RBA α = 1.5±0.26
RBA β = 21.5±4.6
β/α = 14.6

ACD-2
RBA α = 1.04±0.09
RBA β = 8.7±1.5
β/α = 8.4

ACD-3
RBA α = 2.38±0.19
RBA β = 10±1.3
β/α = 4.2

ACD-4
RBA α = 1.7±0.15
RBA β = 6.84±0.41
β/α = 4.1

Figure 1.21: Design of ACD-pseudosteroids as ERβ selective agonists
In addition to the aforementioned compounds, several other ERβ agonists with
varied structural scaffolds (naphthalenes, quinolines, aromatic aldoximes, sulfonamides,
salicylaldoximes, and carboranes etc.) have been developed by several research groups.5860

However, only limited number of compounds display comparable selectivity and

potency simultaneously with the acceptable pharmacological profile.

Therefore, the

challenge faced by ERβ targeted drug design process is to develop novel molecules with
improved ERβ selectivity, potency, as well as reduced side effects.
1.7 Design of 4-Cyclohexyl or Cycloheptyl Phenolic Derivatives as Selective ERβ
Agonists

The basic requirements for any pharmacophore depends on size, shape and specific
interactions with the surrounding residues of the target receptor. While there is a variety
of structural classes of molecules that possess greater affinity for the ERβ, there are some
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significant prerequisites in guiding the development of ER β selective pharmacophores. A
phenolic OH is essential to establish the hydrogen bond network involving Arg346, Glu305
and water triad in the ERβ binding cavity. A second hydroxyl group, should be positioned
nearly 11.0 ± 0.5 Å relative to the phenolic OH in order to exert hydrogen bonding
interaction with His475 as well as Thr 299 in ERβ. This Thr299-OH interaction is specific
to ERβ and might contribute to the ERβ subtype selectivity. Further, the presence of
Met336 and Ile373 residues seems significant since they determine the size of a
substituents that can be accommodated within the cavity and thereby ERβ selectivity. 60
Based on these prerequisites, our research group focused on the design of nonsteroidal ERβ selective agonists for hippocampal memory consolidation in postmenopausal women.

In this regards, the Donaldson laboratory developed a unique

structural class of compound, cis-4-(4-hydroxyphenyl)cycloheptane methanol from
organoiron methodology (Scheme 1.3). The compound is comprised of a phenolic and
cycloheptane-hydroxymethyl core; the 1st generation synthesis is outlined in Scheme 1.3.81

Scheme 1.3: 1st generation synthesis of cis-4-(4hydroxyphenyl)cycloheptane methanol
[reagents: a, vinylmagnesium chloride/THF/CH2Cl2 (57%); b, 4acetoxystyrene (2 eq), 5% Grubbs’ 1st generation catalyst (64%); c, H2O2/HO, d, LiAlH4, then 140˚C. (32%); e, H2,10% Pd/C (50%)]
The cis-4-(4-hydroxyphenyl)cycloheptane methanol proved to be a potent agonist
in cell-based ERβ agonist assays with an IC50 of 5.4 ± 0.3 nM and nearly 1000-fold
selectivity for ERβ over ERα, making (±)-1.5 the most selective ERβ agonist reported.81
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Figure 1.22: Predicted binding orientation of the lead compound A) in ERβ agonist
conformation B) in antagonist conformation C) Overlay of estradiol (black)
and lead compound (yellow)81
In Figure 1.22 is shown the lowest energy docking representation into human ERα
and ERβ in agonist and antagonist conformations of our lead compound. Initial docking
studies were conducted with estradiol crystal structure to confirm the method validity and
obtained results were as expected. Docking pose predictions indicate a higher ERβ affinity
in agonist conformation where it forms two hydrogen bonds, one with tightly bound water
and the other with His 475. On the contrary, a different binding mode is shown in the ERβ
antagonist conformation where hydrogen bonding of the phenolic hydroxyl is to Thr299
rather than His 475. Moreover, molecular overlay of estradiol and our lead compound
reveals the well-aligned nature of both oxygen atoms of the two molecules in the ERβ
pocket.81
Using 4-(1-hydroxyphenyl)-1-hydroxymethylcycloheptane as a starting point, the
research described in this dissertation seeks to expand on these results. A second scaffold
has been developed which exhibits high ERβ vs ERα selectivity, as evidenced by cellbased functional assays. Compounds from these two scaffolds were taken forward into
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animal model studies for the consolidation of memory acquisition, and information on
interactions with hERG, cytochromes and other nuclear receptors was obtained.
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CHAPTER 2

DEVELOPMENT OF 4-(4-HYDROXYPHENYL)CYCLOHEPTANEMETHANOL
AND ANALOGUES

2.1
Background
and
1st
Generation
(hydroxyphenyl)cycloheptanemethanol

Synthesis

of

4-(4-

As part of initial efforts in the Donaldson laboratory to prepare estradiol analogs,
an iron- mediated synthesis of 2,6-cycloheptadiene-1-methanols was adapted with olefin
cross-metathesis.82-83

The

first

generation

synthesis

of

4-(4-

hydroxyphenyl)cycloheptanemethanol, as carried out by Dr. Rajesh Pandey, is presented
in Scheme 2.1. The precursor, 1-methoxycarbonylpentadienyl) Fe(CO)3+ cation I, was
prepared from furan in 5 steps (32.8% yield) according to the previously published
procedure.84 Addition of vinyl magnesium chloride to cation I, in CH2Cl2 as reaction
medium, gave the 2-vinyl-3-pentene-1,5-diyl complex II in moderate yield (57%,
Scheme 2.1). The cross-metathesis reaction of II with 4-acetoxystyrene (2 equivalents)
gave complex III, along with the self-metathesis products, in 64% yield. Oxidatively
induced-reductive elimination of III, followed by ester reduction and thermal Cope [3,3]
rearrangement

afforded

(±)-(4-(hydroxymethyl)cyclohepta-2,5-dien-1-yl)phenol

RKP35C in 32% yield over two steps. Finally exhaustive hydrogenation of RKP35C
yielded desired (±)-4-(4-(hydroxyphenyl)cycloheptanemethanol in 50% unoptimized
yield.81

Thus the 1st generation synthesis gave 2.0 in 10 steps, 1.9% yield from

commercially available furan. While this approach gave initial access to 2.0 for ER
binding assays, it has several limitations. These include low overall chemical yield (ca.
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2%), preparation of racemic material, use of stoichiometric iron, access to only the cisstereoisomer and difficulties in translation to other analogs. In addition, attempts to
prepare additional samples of 2.0 by this pathway were problematic as the crossmetathesis reaction did not prove robust in a subsequent student’s hands. Therefore, a
second-generation route to 2.0 was pursued.

Scheme 2.1: 1st Generation synthesis of 4-(4-hydroxyphenyl)cycloheptanemethanol
from organoiron methodology
2.2 2nd Generation Synthesis of 4-(4-hydroxyphenyl)cycloheptanemethanol

In order to circumvent a number of the low yielding steps, it was decided to
pursue the preparation of 2.0 from a non-organoiron approach. This strategy involved
preparation of a protected analog of 4-(4-hydroxyphenyl)cycloheptanone (2.7), followed
by introduction of the hydroxymethyl substituent (Scheme 2.2).
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Scheme 2.2: Retrosynthetic analysis for preparation of 4-(4-hydroxyphenyl)-1hydroxymethylcycloheptane
To this end, esterification of commercially available para-anisic acid 2.1 with
thionyl chloride in the presence of methanol led to the formation of methyl 4methoxybenzoate (2.2, Scheme 2.3), which was identified by comparison of its 1H and
13

C NMR spectral data with the literature values.85 The Grignard reaction of 2.2 with in

situ generated 3-butenyl magnesium bromide in 1:4 ratio under dry conditions gave the
3° alcohol 2.3a as a major product (85%). Obtaining these yields was dependent on a
number of crucial experimental conditions. Use of 4-equivalents of Grignard reagent
was necessary; use of only 2 equivalents of 3-butenyl magnesium bromide gave a lower
yield (13%). In addition, the length of time for exposure of the crude reaction mixture
to the NH4Cl workup conditions must be kept short, since longer exposure led to the
formation of triene 2.3b (Scheme 2.3) as a by-product. The formation of compound 2.3b
can be rationalized by slow dehydration of 2.3a in the presence of acidic ammonium
chloride (pKa = 9.24) (Scheme 2.4).
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Scheme 2.3: Preparation of tertiary alcohol intermediate 2.3a

Scheme 2.4: Mechanism of formation of compound 2.3b
The structures of 2.3a and 2.3b were assigned on the basis of their NMR spectral
data. In particular, the signals at δ 4.88 – 4.98 (m, 4 H) and 5.73 - 5.84 (m, 2 H) ppm in
the 1H NMR spectra of each are characteristic for the vinyl protons while two doublets
of doublets at  6.88 and 7.28 ppm are typical for a 1,4-disubstituted phenyl substituents.
The peak at δ 76.9 ppm in the

13

C NMR spectrum of 2.3a was assigned to the tertiary

alcohol carbon. A triplet signal at δ 5.8 ppm in the 1H NMR spectrum of 2.3b was
assigned to the proton of the trisubstituted olefin.
Reaction of 2.3a with Grubbs’ 1st generation catalyst (G-I) under optimum
experimental conditions (0.01 M concentration, slow addition of 4% of G-I over 8 h via
syringe pump, 45 °C, and G-I quench with 50 equiv. DMSO) led to 2.4a as a major product
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in 70- 75% yield (Scheme 2.5). However, in certain instances the formation of self- or
cross metathesis (CM) product 2.4b from 2.3a was observed (Scheme 2.5).

Scheme 2.5: Ring closing metathesis and ionic reduction
The structural assignment for 2.4a was based on its NMR spectral data. In
particular, signals at δ 5.83-5.86 (m, 2 H) and at δ 1.82-1.90 (m, 2 H), 1.97–2.10 (m, 4 H),
2.44-2.55 (m, 2 H) in the 1H NMR spectrum of 2.4a correspond to the hydrogens within
the cycloheptenol ring, while signals at δ 113.5 and 76.5 ppm in the

13

C NMR spectrum

correspond to the cycloheptenol olefinic and alcohol carbons respectively.
Ionic reduction86 2.4a with 5 equivalents of triethylsilane and 10 equivalents of
trifluoroacetic acid, in dry CH2Cl2, gave 2.5 (90%). The removal of the OH group was
confirmed by the presence of a signal at δ 49.4 ppm in the 13C NMR spectrum and a triplet
of triplets at  2.69 ppm in 1H NMR spectrum which correspond to the benzylic carbon and
its attached proton.
Our first strategy for olefin-to-ketone conversion relied on epoxidation of 2.4a with
meta-chloroperoxybenzoic acid to provide a mixture of cis- and trans-epoxides 2.5a (I and
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II, Figure 2.1) in good yield (74%). The structure of 2.5a was assigned based on its 1H
NMR spectral data; no olefinic proton signals were observed and instead two new triplets
of triplets and three multiplets were observed in  2.14-3.19 ppm region. The same
behavior was observed in the

13

C NMR spectrum where the eighteen signals appear as a

doublet set of nine for each stereoisomer.

2.5a - I

2.5a - II

Figure 2.1: Diastereomers of compound 2.5a (I and II)
Lewis acid-mediated ring opening of epoxide 2.5a was carried out with boron
trifluoride etherate in anhydrous benzene to give the known87 cycloheptanone 2.7, albeit in
low yield (26%).

Moreover, an aldehydic by-product was observed which can be

rationalized by the following mechanism (Scheme 2.6).

Scheme 2.6: Possible mechanism for generation of 2.7 and aldehydic by-product
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Alternatively, hydroboration of compound 2.5 with BH3.THF followed by
oxidation from 30% H2O2 and 1N NaOH gave alcohol 2.6 in 93% yield (Scheme 2.7).
Notably, attempted oxidative workup with sodium borate gave 2.6 in lower yields (2030%). The absence of the olefinic signals and the presence of two multiplets at δ 3.90-4.06
ppm (1H) in 1H NMR spectrum of 2.6 and the presence of two new peaks at δ 72.7, 71.5
ppm in its

13

C NMR spectrum support the presence of this product as a mixture of

diastereomers.

Scheme 2.7: Transformation of olefin 2.5 into cycloheptanone 2.7
Oxidation of the secondary alcohol 2.6 to the corresponding ketone 2.7 was effected
using either pyridinium chlorochromate and silica or celite as an adsorbent (55% yield), or
n-propylmagnesium bromide and 1,1’-(azodicarbonyl)dipiperidine (20% yield),88 or DessMartin periodinane with addition of 2-5 drops of water (50% yield, Scheme 2.7). The
product was identified by comparison of its spectral data with the literature values. 87
Wittig reaction of 2.7 with two equivalents of the ylide generated from reaction of
methyltriphenylphosphonium bromide with nbutyllithium provided the exocyclic olefin 2.8
(79%, Scheme 2.8). The structural assignment of 2.8 was supported by the presence of
characteristic peaks for the exocyclic alkene at δ 4.77 (2H) ppm in the 1H NMR spectrum
and δ113.8 and 110.9 ppm in the 13C NMR spectrum.
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Hydroboration of 2.8 with BH3.THF, followed by oxidation with 30% H2O2 and 3N
NaOH afforded alcohol 2.9 (48-60%) as a mixture of cis- and trans- diastereomers
(Scheme 2.8). The doublet at δ 3.46 ppm (2H) in the 1H NMR spectrum of 2.9 and peaks
at δ 68.6 and 68.4 in 13C NMR spectrum were evidence of this mixture.
Finally, deprotection of the methyl ether was achieved under BBr3 conditions to
give the desired 4-(4-(hydroxyphenyl)cycloheptanemethanol 2.10 (ISP163) (28%) as a
mixture of cis- and trans-isomers (Scheme 2.8). The cis-stereoisomer was identified by
comparison of its NMR spectral data with the literature values, 81 while the doubling of
many of the peaks was taken as evidence of the trans-stereoisomer. This assignment of
the

13

C NMR signals for the trans-stereoisomer was eventually corroborated by HPLC

separation of the stereoisomers as well as X-ray crystallography (vide infra)

Scheme 2.8: Conversion of 2.7 into 4-(4-(hydroxyphenyl)cycloheptanemethanol
The overall route (summarized in Scheme 2.9) requires 9 steps from commercially
available material, and while it proceeded in a slightly improved overall yield (2.1%),
compared to the original synthesis, the harsh conditions of the final step dictated the need
for a different phenolic protecting group.

43

2.3 3rd Generation Synthesis of 4-(4-hydroxyphenyl)cycloheptanemethanol

Our next focus was to introduce a readily cleavable protecting group. Protection of
commercially available methyl 4-hydroxybenzoate 2.11 as the t-butyldimethylsilyl ether
provided 2.12 (84%, Scheme 2.10). Characteristic signals for the t-butyl and two methyl
groups appear at δ 0.99 (9H) and 0.22 (6H) ppm in the 1H NMR spectrum and at δ 18.1/25.7
and -4.3 ppm respectively in the

13

C NMR spectrum of 2.12. The same 7 step synthetic

sequence (Grignard addition, RCM, ionic reduction, hydroboration/oxidation, Wittig
olefination, hydroboration/oxidation) eventually led to 2.19 under optimized conditions.
However, the ionic reduction of 2.14 under acidic conditions, proceeded in a lower 60%
yield due to silyl ether cleavage to give the degraded by-product 2.15a. The by-product
2.15a could be recycled by further TBDMS protection. Use of 3N NaOH in the oxidative
workup for hydroboration/oxidation of 2.18 also resulted in cleavage of the TBDMS group
and afforded lower yields (40%). Alternatively, use of 1N NaOH for the workup gave the
product 2.19 without silyl ether cleavage (66%). Deprotection of 2.19 was carried out
under TBAF conditions to give 2.10 (ISP163) in 88% yield as a clean product. Following
this procedure, the mixture of stereoisomers was obtained in 9 steps from commercially
available methyl 4-hydroxybenzoate, and in 10.7% overall yield.
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Scheme 2.9: 9-Step, 2nd generation synthesis of 4-(4-(hydroxyphenyl)cycloheptane
methanol (2.1% yield)
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Scheme 2.10: 3rd Generation synthesis of 4-(4-(hydroxyphenyl)cycloheptanemethanol
(10.7% yield)
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2.4 4th Generation Synthesis of 4-(4-hydroxyphenyl)cycloheptanemethanol
While the 3rd generation synthesis (Scheme 2.10) proceeded in 4.4% yield, the
length of this route (9 steps) and the use of expensive precursors (4-bromo-1-butene, $
248/mol) and reagents (Grubbs’ 1 st generation catalyst, Dess-Martin periodinane)
necessitated the development of a shorter synthesis of intermediate 2.17. This synthesis
commenced from commercially available 4-(4-hydroxyphenyl)cyclohexanone 2.20 that
was protected with TBDMSCl to give the silyl ether 2.21 (95%, Scheme 2.11). The
presence of peaks at δ 0.98 (9H) and 0.19 (6H) ppm in 1H NMR verifies the product
formation. Ring expansion of cyclohexanone ring to cycloheptanone ring (2.22) was
achieved under Büchner–Curtius–Schlotterbeck conditions89 with the use of ethyl
diazoacetate and boron trifluoride etherate in dry ether (81%).

Krapcho-

decarboethoxylation of keto-ester 2.22 with LiCl/ H2O in DMSO at 160 ˚C furnished the
key intermediate 2.17 in 78% yield. Subsequent transformation of 2.17 to 2.10, by the
route previously developed in Scheme 2.10, resulted in an 6-step, 20% overall yield route
to a mixture of cis- and trans isomers of 4-(4-(hydroxyphenyl)cycloheptanemethanol.
Utilizing this route, a sample of 2 g of 2.10 was eventually prepared. This mixture of
stereoisomers was subjected to ER binding assays; the results of these assays are described
in Chapter 4.
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Scheme 2.11: Preparation of 4-(4-(hydroxyphenyl)cycloheptanone intermediate by ring
expansion
2.5 Separation of Stereoisomers of 4-(4-(hydroxyphenyl)cycloheptanemethanol
Since the 2nd, 3rd, and 4th generation syntheses furnished the target compound as a
mixture of four stereoisomers, the next aim was to separate these isomers in order to
identify the most potent candidate. Figure 2.2 depicts the analytical HPLC chromatogram
of ISP163 using a chiral cellulose 2(OZH) column with isopropanol : hexanes (1:4) as
eluent and UV detection at 254 nm. This clearly reveals the presence of 4 stereoisomers at
different retention times.

PK
1

PK
2

PK
3

Figure 2.2: Identification of presence of four isomers of ISP163

PK
4
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Due to the prohibitive cost of a preparative HPLC column, it was decided to
contract a preparative separation of the mixture, to access the individual isomers. This
would provide sufficient quantities of the stereoisomers for ER binding assay as well as
absolute configuration determination. The company Phenomenex (Torrence, CA) was
contracted for these chromatographic services.
Initial analytical method development by Phenomenex revealed that a Lux
Cellulose-35 µm column and isocratic mobile phase of ethanol: 2-propanol: hexanes
(4.33:8.66:87) was optimal, with detection at 280 nM. The isolation process utilized a 250
x 30 mm preparative column and the aforementioned solvent system. This method
produced a 12 min HPLC run with the first desired peak eluting just before 8 minutes
(Figure 2.3). The blue color zones were collected as pure isomeric products.
.

Figure 2.3: Prep Chromatogram of ISP163 for a single injection (courtesy of Phenomenex)
Since these conditions were isocratic, stacked injections were implemented to
accelerate the process. In this regards, subsequent injections were made 6 min after the
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previous injection with the products from the first injection collected shortly after the
second injection was made (Figure 2.4).

Figure 2.4: Implemented Stacked Injections for ISP163 (courtesy of Phenomenex)
Analytical QC was developed to assess the separation. Two Lux Cellulose-35 µm
150 x 4.6 mm columns were used in series with ethanol : 2-propanol : hexanes (2 : 7 : 91)
as an isocratic solvent system (Figure 2.5). The analytical QC chromatograms confirmed
separation of the stereoisomers and indicated that each fraction was of > 94% enantiomeric
excess.
However, these chromatograms also indicated “system” impurity peaks at ca. 7.5
and 9.5 min. Furthermore, 1H NMR analysis of the fractions returned by Phenomenex
indicated signals due to an unidentifiable contaminant. Fortunately, this contaminant was
considerably more soluble in CDCl3 than the desired compound, and thus extracting the
solids with this solvent gave a solid product which was essentially contaminant free by 1H
NMR spectroscopy (Figure 2.6).
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Figure 2.5: Analytical QC chromatograms of all four isomers of ISP163 (courtesy of
Phenomenex)
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Figure 2.6: 1H NMR analysis of all four isomers of ISP163
Comparison of the 13C NMR spectra of peaks 3 and 4 with that previously obtained
for cis-4-(4-(hydroxyphenyl)cycloheptanemethanol (obtained from the 1 st generation
synthesis), indicated that these fractions corresponded to the cis-isomer, and by deduction
the lack of correspondence of the 13C NMR spectra for peaks 1 and 2 with the previously
obtained material indicated that they had the trans-stereochemistry. These spectroscopic
assignments were eventually corroborated by single crystal X-ray diffraction of three of
the fractions. Figure 2.7 contains the ORTEP projections of peak 3 and peak 4 isomers,
including not only relative configuration (cis) but also absolute stereochemistry (7R, 10S
for peak 3; 7S, 10R for peak 4, crystallographic numbering). The 7-membered ring in each
structure has a somewhat twisted long chair confirmation.
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a

b

c

Figure

2.7:a) ORTEP projections of the stereoisomers of trans- 4-(4(hydroxyphenyl)cycloheptanemethanol; a) peak 3 (7R, 10S); b) peak 4 (7S.
10R); c) 3D-crystal packing of peaks 3 and 4 (identical) in solvent
The X-ray crystal structure of the peak 1 isomer contains two symmetrically

independent molecules of the same chirality (Figure 2.8). The ordered 7-membered ring
in structure a has a long chair conformation with both substituents in an equatorial
orientation. However, the situation with structure b is more complex since it has a
disordered 7-membered ring structure with an overlap of 7/10,11-chair over 10/7,13-chair.
Thus, the absolute configuration of this isomer was indeterminate.
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a

b

c

Figure 2.8: a) and b) Two possible X-ray crystal structure of pk1 isomer c) 3D-crystal packing
in solvent
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2.6 Synthesis of Other 4-Cycloheptylphenol Analogues for SAR Studies

Having established ISP163 (compound 2.10) as a lead compound, our next
approach was to design a series of 4-cycloheptylphenol based analogs with various
functional moieties in order to test the SAR studies.

Scheme 2.12: Synthesis of analog 2.23
Treatment of the mixture of diastereomeric epoxides 2.5a with three equivalents of
lithium aluminum hydride in dry THF, gave a mixture of two diastereomeric alcohols 2.6
in low yield (35%) which were identified by comparison of their NMR spectra with that
previously prepared. (Scheme 2.12). Since the two diastereomers did not show clear
separation by TLC, the mixture was carried forward in the next reaction step. The mixture
of diastereomers 2.6 was subjected to the ether cleavage using excess BBr3 in anhydrous
CH2Cl2 to afford compound 2.23 (86%, ISP58).

The product was a mixture of

diastereomers (1:1 ratio) and the presence of the phenol group was confirmed by a singlet
at 4.84 ppm assigned to the phenolic hydrogen in its 1H NMR spectrum.
Cycloheptanone 2.7 was demethylated with 48% HBr under refluxing conditions
to afford phenol 2.24 (49%, ISP242, Scheme 2.13). The use of BBr3 conditions was
problematic, as the 1H NMR spectrum of the crude product did not show any peaks
belonging to a ketone functionality. The removal of the methyl ether in 2.24 was evidenced
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by an absence of the signals for the OMe group. Reaction of 2.24 with hydroxylamine
hydrochloride in the presence of NaHCO3 gave oxime 2.25 (52%, ISP166) as a mixture of
E- and Z- stereoisomers. The occurrence of characteristic signals at δ 140.4 and 141.3
ppm in the

13

diastereomers.

C NMR spectrum of 2.25 corresponded to the C=N carbons of the
Alternatively, treatment of phenolic cycloheptanone 2.24 with 2.2

equivalents of MeLi. LiBr complex provided the diastereomeric tertiary alcohol 2.26 (40%,
ISP362). The two singlets at δ 1.23 and 1.21 ppm in 1H NMR spectrum, integrating to
three protons in total, correspond to the methyl group of the diastereomeric product.

Scheme 2.13: Synthesis of analogs 2.24, 2.25 and 2.26
Horner–Wadsworth–Emmons olefination of 2.7 with the anion generated from the
reaction of trimethyl phosphonoacetate with NaH gave 2.27 as a mixture of E- and Zstereoisomers (31%, Scheme 2.14).

Formation of the 3,3-disubstituted enoate was

evidenced by the presence of a singlet at δ 5.74 ppm and two singlets at δ 3.69 ppm in the
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H NMR spectrum of this product, which correspond to the olefinic CH and the OMe

protons of the two stereoisomers. Reduction of the methyl ester with DIBAL furnished the
primary allylic alcohols 2.28 (43%), again as a mixture of E- and Z- stereoisomers. The
multiplet at δ 5.42-5.50 ppm and the doublet at δ 4.19 ppm in 1H NMR spectrum of this
product correspond to the olefinic C-H and alcohol methylene protons respectively.
Subsequent hydrogenation of 2.28 followed by demethylation with BBr3 provided the 4(2-hydroxyethyl)cycloheptyl)phenol 2.30 (ISP248) in low yield over 2 steps (7%). This
low yield was primarily attributed to the harsh methyl ether cleavage conditions.

Scheme 2.14: Synthesis of 4-(2-hydroxyethyl)cycloheptyl)phenol
3-Methyl-4-hydroxybenzoic acid 2.31 was converted into its methyl ester 2.32 by
reaction with thionyl chloride in methanol under refluxing conditions (88%, Scheme 2.15).
Formation of the methyl ester was confirmed by the presence of two singlets at δ 2.27 (3H)
and 3.89 (3H) ppm in the 1H NMR spectrum of 2.32, corresponding to the OMe and Ar-
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CH3 protons. Protection of 2.32 with tert-butyldimethyl silyl chloride gave the silyl ether
2.33 (84%). Transformation of 2.33 to the cycloheptanol 2.37 utilized the sequence of
steps developed in the 2nd and 3rd generation syntheses of 2.10 (i.e. Grignard addition,
RCM, ionic reduction, and hydroboration/oxidation). Deprotection of 2.37 was carried out
using TBAF/THF at reflux to obtain the 4-(4-hydroxy-3-methylphenyl)cycloheptan-1-ol
2.38 (53%, ISP275) as a mixture of diastereomers. The six-step sequence gave 6.62 %
overall yield over 6 steps. The structures of 2.34-2.38 were assigned by comparison of
their 1H NMR spectral data with that obtained for the parent compounds 2.13-2.16 and 2.23
(see Schemes 2.10 and 2.13).

.

Scheme 2.15: Synthesis of 4-(4-hydroxy-3-methylphenyl)cycloheptan-1-ol
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The primary differences appeared in the aromatic region (signals due to 1,2,4-trisubstituted
benzene vs 1,4-disubstituted benzene) and the appearance of a singlet at ca. δ 2.2 ppm due
to the aryl methyl group.
Oxidation

of

the

mixture

of

cis-

and

trans-

4-(4-

(hydroxyphenyl)cycloheptanemethanol (2.10) with DDQ in CH2Cl2 gave the tricyclic ether
2.39 (66%, ISP360, Scheme 2.16). The structural assignment for 2.39 was supported by
its NMR data. In particular, the presence of two multiplets at δ 3.84-3.90 and 3.96-4.07
ppm in 1H NMR spectrum integrating to one proton each correspond to the diastereotopic
ether protons, while signals at δ 69.9 and 76.5 ppm in the 13C NMR spectrum correspond
to the secondary and quaternary aliphatic ether carbons respectively. This cyclization is
rationalized by oxidation of 2.10 to the benzyl carbocation intermediate 2.39# (Scheme
2.16) which is trapped by intramolecular attack of the hydroxymethyl group, followed by
deprotonation.

Scheme 2.16: Oxidative cyclization of 2.10 to generate tricyclic ether 2.39
In order to explore the effects of the aliphatic ring size on ER binding affinity and
selectivity, six-and five membered analogs of 2.10 were prepared. The synthesis of 4-(4(hydroxyphenyl)cyclohexanemethanol and other derivatives are discussed in Chapter 3.
For the cyclopentyl analog, commercially available 4-(4-hydroxyphenyl)cyclohexan-1-one
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2.20 was converted into the known90 methyl ether 2.40 (44% unoptimized, Scheme 2.17)
using iodomethane and K2CO3 in DMF. The key ring contraction of 2.40 was effected with
diphenyldiselenide and 30% H2O2 in tBuOH91 to afford the carboxylic acid 2.41 in low
yield (40%). The product was identified by comparison of its NMR spectral data with the
literature values.92 Finally, reduction of 2.41 with lithium aluminium hydride, followed by
demethylation

under

BBr3

conditions

afforded

the

3-(4-

(hydroxyphenyl)cyclopentanemethanol 2.43 (36%, ISP427) as a mixture of diastereomers.

Scheme 2.17: Synthesis of 3-(4-(hydroxyphenyl)cyclopentanemethanol
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CHAPTER 3

DEVELOPMENT OF 4-[4-(HYDROXYMETHYL)CYCLOHEXYL]PHENOL
AND ANALOGUES

3.1 Synthesis of 4-[4-(Hydroxymethyl)cyclohexyl]phenol
Based on estrogen receptor literature,47 the binding site cavity for ERβ is smaller
in volume (279 Å3) than that for ERα (379 Å3). Thus, in addition to the lead compound
4-(4-(hydroxyphenyl)cycloheptanemethanol, described in the previous chapter, it was
desirable to prepare analogs with varying cycloalkane ring(s).

In particular, the

differences in molecular flexibilities between a “rigid” cyclohexane ring and a “floppy”
cycloheptane ring, as well as the O-O interatomic distance, upon ligand binding and
functional activation would shed light on important pharmacophore parameters.
Molecular mechanics calculations of the O-O interatomic distances in cis-4-(4(hydroxyphenyl)cycloheptanemethanol varied between 10.7-11.0 Å.

This range of

distances is due to (i).the flexible nature of the seven-membered ring, and (ii), rotation
about the ring-to-CH2OH bond. The calculated distances are similar to those observed in
the crystal structures (10.63-11.15 Å, see Figure 2.7 and 2.8). In comparison, the O-O
interatomic distance calculated for trans-4-[4-(hydroxymethyl)cyclohexyl]phenol (10.7
Å) is within the range for known ligands of the estrogen receptor. In this regards,
syntheses of 4-[4-(hydroxymethyl)cyclohexyl]phenol and its analogs were designed
from commercially available 4-(4-hydroxyphenyl)cyclohexan-1-one (3.1, Scheme 3.1).
Protection of the phenol hydroxyl moiety of 3.1 with tert-butyldiphenylsilyl
chloride (TBDPSCl) in CH2Cl2 gave 3.2 (93%). The formation of the silyl ether was
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confirmed by the presence of peaks at δ 7.74-7.70 (m, 4H), 7.45-7.34 (m, 6H), and 1.09
(s, 9H) ppm in 1H NMR spectrum of the product. Attempted Wittig olefination of 3.2
with the ylide generated from methoxymethyl triphenylphosphonium chloride and nbutyllithium or t-BuOK as the base, was ineffective (Scheme 3.1). In contrast, reaction
of 3.2 with the ylide generated from methyltriphenylphosphonium bromide with nbutyllithium afforded the product 3.3 (85%). The presence of a peak at δ 107.4 ppm in
the 13C NMR spectrum and a peak at δ 4.65 (narrow t, 2H) ppm in the 1H NMR spectrum
of 3.3 is characteristic of the exocyclic olefinic carbon and its attached protons.
Subsequent hydroboration of 3.3 with BH3.THF followed by oxidation with 30% H2O2
and 3N NaOH in ethanol gave 4-[4-(hydroxymethyl)cyclohexyl]phenol 3.4a (ISP171)
(28%). Notably, the use of 3N NaOH led to cleavage of the TBDPS protecting group.
This product was determined to be a mixture of cis- and trans-stereoisomers (ca. 3 : 1
ratio) by integration of the alcoholic methylene protons at δ 3.60 (1.5H) and 3.39 (0.5H)
in the 1H NMR spectrum. These relative chemical shifts are characteristic of cis- and
trans-4-substituted cyclohexanemethanols.93-95
The lower yield of the last step led us to explore an alternative protecting group
strategy. Protection of 3.1 with tert-butyldimethylsilyl chloride (TBDMSCl) provided
compound 3.5 (95%, Scheme 3.2). Signals at δ 0.99 (9H) and 0.20 (6H) ppm in the 1H
NMR spectrum and δ -4.2, 18.4 and 25.9 ppm in

13

C NMR spectrum of 3.5 are

characteristic of the t-butyldimethylsilyl ether. In a fashion similar to that in Scheme 3.1,
Wittig methenylation of 3.5 gave 3.6 (84%). Hydroboration of 3.6 with BH3.THF,
followed by oxidation with 30% H2O2, and 3N NaOH proceeded with concomitant
cleavage of the TBDMS group afforded 3.4a (40%).
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Scheme 3.1: 1st Generation synthesis of 4-(4-(hydroxymethyl)cyclohexyl)phenol
Alternatively, the TBDMS protecting group was stable under workup conditions
of 1N NaOH to afford 3.7 (66%). Under the BH3.THF conditions, the product was found
to be a 3:2 mixture of cis:trans stereoisomers by 1H NMR integration and LC/MS data.
Alternatively, use of 9-BBN instead of BH3.THF, followed by 30% H2O2/1N NaOH
produced 3.7 (74%) as a 2:3 mixture of cis:trans stereoisomers. The use of these two
borane reagents have been previously demonstrated as a method to tune the cis:trans
outcome for 4-substituted methylenecyclohexanes.96 Finally, removal of the TBDMS
group was achieved under TBAF conditions to give 3.4a (ISP171) as a mixture of cisand trans-stereoisomers (Figure 3.1). The synthesis of this mixture was achieved in 43%
overall yield over a four-step sequence.

63

Scheme 3.2: 2nd Generation synthesis of 4-(4-(hydroxymethyl)cyclohexyl)phenol
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a)

cis

b)

trans

Figure 3.1: 1H NMR spectra of 4-[4-(hydroxymethyl)cyclohexyl]phenol from a) produced
using 9-BBN b) produced using BH3.THF as hydroboration reagent (solvent
= CD3OD)
Treatment of the mixture of cis- and trans-4-[4-(hydroxymethyl)cyclohexyl]phenol
(ISP171) with 1.1 equivalent of DDQ in dichloromethane gave a separable mixture of the
bicyclic ether 3.8 (ISP358-1, 40%, Scheme 3.2), and unreacted trans-3.4b (ISP358-2, 20%
borsm). The oxidative conditions were optimized using the 2:3 mixture of cis:trans
stereoisomers produced from 9-BBN hydroboration, 0.5 equivalent of DDQ and 5 h
reaction time resulting in 47% maximum recovery of 3.4b along with 37% of cyclic ether
3.8. The structure of 3.4b (ISP358-2), tentatively assigned on the basis of its 1H NMR
spectral data, was eventually corroborated by single crystal X-Ray diffraction analysis
(Figure 3.2). The cyclohexane ring has a chair conformation with both substituents in an
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equatorial orientation. The O-O distance found in this X-ray crystal structure (10.658 Å)
is quite similar to that calculated on the basis of molecular mechanics (10.7 Å).

a

b

Figure 3.2: a) X-ray crystal structure of compound 3.4b (ISP358-2) b) Crystal packing
nature of compound 3.4b in solution
Oxidation

of

either

the

cis-

or

trans-stereoisomer

of

4-[4-

(hydroxymethyl)cyclohexyl]phenol would result in the same benzylic carbocation
intermediate 3.8# (Scheme 3.3). Thus, the formation of the separable mixture of 3.8
(ISP358-1) and the trans-isomer 3.4b (ISP358-2) is due to the faster rate of generation of
intermediate 3.8# from the cis-isomer. Since the cis-isomer is less stable, and therefore
higher in energy, compared to the trans-isomer, the barrier to oxidation of cis-3.4a to 3.8#
(plus the DDQ reduction anion) should be lower, and thus the rate of oxidation is faster,
than for trans-3.4b (plus the DDQ reduction anion).
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Scheme 3.3: Mechanistic rationale for bicyclic ether formation of cis-isomer over trans
isomer
With a route to the trans-isomer 3.4b secured, the ring opening of bicyclic ether 3.8
was examined as a selective means for preparation of the cis-isomer. Ionic reduction of
3.8 with either sodium cyanoborohydride/BF3.Et2O or triethylsilane/CF3COOH gave a
mixture of cis- and trans- 4-[4-(hydroxymethyl)cyclohexyl]phenol in 1:4 and 2:3 ratios
respectively.
3.2 Synthesis of 4-Cyclohexylphenol Analogs

To explore structure activity relationship (SAR) further, and search for compounds
with improved potencies, physiochemical and biological properties several other 4cyclohexylphenol analogs were synthesized.
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Scheme 3.4: Synthesis of analogs 3.9, 3.10, and 3.11
Reduction of 3.1 with sodium borohydride afforded the secondary alcohol 3.9
(ISP33, 90%, Scheme 3.4). Similarly, reaction of 3.1 with NH2OH.HCl in the presence of
NaHCO3 gave oxime 3.10 (ISP36, 70%). Finally, nucleophilic addition of MeLi to 3.1
gave the tertiary alcohol 3.11 (ISP361, 37%) in moderate yield under unoptimized
conditions. The alcohol 3.9 was determined to be a mixture of isomers whereas alcohol
3.11 was a single isomer from their 1H and 13C NMR spectral data.
Removal of the protecting group from 3.6 with TBAF gave 4-(4methylenecyclohexyl)phenol 3.12 (ISP365, 83%) and subsequent hydrogenation over
Pd/C furnished the 4-(4-methylcyclohexyl)phenol 3.13 (ISP366, 80%, Scheme 3.5).
Dihydroxylation of 3.6 with OsO4 in the presence of N-methylmorpholine-N-oxide (NMO)
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gave diol 3.14 in 86% yield. The presence of peaks at δ 66.2 and 72.4 ppm in 13C NMR
spectrum of 3.14 were assigned to the primary and tertiary alcohol carbons respectively.

Scheme 3.5: Synthesis of analogs 3.12, 3.13, 3.15, 3.16 and 3.17
Removal

of

TBDMS

group

(hydroxymethyl)cyclohexyl]phenol 3.15 (ISP411, 78%).

gave

4-[4-hydroxy-4-

Reaction of 3.12 with

paraformaldehyde, MgCl2 and NEt397 effected carbonylation ortho to the phenol group to
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give 3.16 (ISP384, 44%). Reaction of 3.16 with NH4OH.HCl in the presence of NaHCO3
gave oxime 3.17 (ISP389, 69%) as an inseparable mixture of E- and Z- stereoisomers.
Katzenellenbogen, et. al, have previously reported on similar salicylketoximes as potent
ERβ agonists that display antiproliferative activities in a glioma model. 98
Ortho carbonylation of bicyclic ether 3.8 was attempted using the same protocol as
mentioned previously (Scheme 3.6). The anticipated product 3.18 (ISP394) was obtained
in very low yield (17%) along with the unsaturated alcohol 3.19 (ISP393, 8%). The
structures of 3.18 and 3.19 were assigned on the basis of their 1H NMR spectral data. For
3.18, signals in its 1H NMR spectrum at δ 9.99 (s, 1H) and 4.06 (s, 2H) ppm correspond to
the aldehyde and ether methylene protons respectively, while for 3.19 signals at δ 10.01 (s,
1H), 6.10 (s, 2H) and 3.49 (d, 2H) ppm correspond to the aldehyde, olefinic and
hydroxymethylene protons respectively.
The unsaturated aldehyde 3.19 presumably arises via eliminative opening of the 7oxabicyclo[2.2.2] octane ring of 3.8 under the MgCl2/NEt3 reaction conditions. To test this
hypothesis, treatment of bicyclic ether 3.8 with MgCl2 and NEt3 in the absence of
formaldehyde gave unsaturated product 3.20 (ISP402, 78%). Peaks at δ 5.97-5.92 (m, 1H)
and 3.48 (dd, 2H) ppm in the 1H NMR spectrum correspond to the vinylic and methylene
protons respectively. Hydrogenation of 3.20 over Pd/C gave a mixture of the cis- and
trans-stereoisomers 3.4a (ISP171, 67%) in 3:2 cis : trans ratio.
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Scheme 3.6: Synthesis of analogs 3.18, 3.19 and 3.20
Horner–Wadsworth–Emmons olefination of 3.2 with trimethyl phosphonoacetate
and NaH, afforded enoate 3.21 (95%, Scheme 3.7). Peaks at δ 5.65 (s, 1H) and 3.69 (s,
3H) ppm in the 1H NMR spectrum of 3.21 correspond to the olefinic and methyl ester
protons respectively, while a signal in its 13C NMR spectrum at δ 51.1 ppm is characteristic
of the methyl ester carbon. Selective ester reduction of 3.21 was accomplished using
excess DIBAL to give the allylic alcohol 3.22 (58%). The triplet at δ 5.42 and doublet at
δ 4.17 ppm in the 1H NMR spectrum of 3.22 correspond to the olefinic C-H and the
hydroxymethylene protons. Hydrogenation of 3.22 followed by removal of the TBDPS
protecting group under TBAF conditions gave 4-[4-(2-hydroxyethyl)cyclohexyl]phenol
3.24 (RKP231IIF, 20%). The overall yield of the synthesis is 5% over 5 steps.

71

Scheme 3.7: Synthesis of 4-[4-(2-hydroxyethyl)cyclohexyl]phenol
3.3 Synthesis of Fluorine Containing 4-Cyclohexylphenol Analogs

The introduction of fluorine into drug-like molecules is promising since it generates
new pharmaceutical candidates with potentially improved pharmacological profiles. While
fluorine mimics hydrogen with respect to steric requirements (van der Waals radius: H,
1.20 Å; F, 1.35 Å), the presence of F alters electronic properties of the molecule due to its
higher electronegativity. Incorporation of fluorine into drug candidates also enhance their
in vivo metabolic stability, lipophilicity and blood-brain barrier penetration.99-100
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Scheme 3.8: Synthesis of analog 3.25b

99

Scheme 3.9: Synthesis of analogs 3.26a and 3.26b
Attempts to generate 3.25a from 3.9 by substitution using diethylaminosulfur
trifluoride [DAST] or bis(2-methoxyethyl)aminosulfur trifluoride [DeoxofluorTM] at room
temperature was ineffective and instead afforded the elimination product 1',2',3',6'tetrahydro-[1,1'-biphenyl]-4-ol 3.25b (ISP346, 51-63%, Scheme 3.8). Since secondary
alcohols favor the elimination product, deoxyfluorination of primary alcohols was
examined.101-102

Reaction of the mixture of cis- and trans-stereoisomers 3.4a with

deoxofluor gave 3.26a as a mixture of diastereomers (40%, Scheme 3.9). Encouraged by
these results, the pure trans-stereoisomer, 3.4b was then subjected to the same conditions
and afforded the desired fluoro product 3.26b (ISP441, 64%). The structure of 3.26b was
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based on its NMR spectral data. In particular, doublets at δ 89.4 ppm ( 1JC-F = 166 Hz) in
the

13

C NMR spectrum and at δ 4.23 ppm (2JH-F = 47.8 Hz) in the 1H NMR spectrum

correspond to the fluoromethylene substituent.
Ortho-fluorination of compound 3.1 or 3.9 was attempted with 1-chloromethyl-4fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) [Selectfluor TM] or Nfluorobenzenebenzenesulfonamide (NFSI) as fluorinating reagents103-105 (Scheme 3.10).
Unfortunately, in each case only starting material was recovered.

Scheme 3.10: Attempted synthesis towards analogs 3.27 and 3.28
Consequently, an alternative approach was conceived. Protection of phenol 3.29
with benzyl bromide produced 3.30 (95%, Scheme 3.11). The multiplet at δ 7.47-7.32 (5H)
ppm and a singlet at δ 5.13 (2H) ppm in the 1H NMR spectrum of 3.30 corresponds to the
benzyl group.

Addition of the Grignard reagent generated from 3.30 with 1,4-

dioxaspiro[4.5]decan-8-one afforded the tertiary alcohol 3.31 (82%). Treatment of 3.31
with 2-3 drops of concentrated H2SO4 acid in THF/water to effect hydrolysis of the cyclic
ketal proceeded with concomitant dehydration to give 3.32 in moderate yield (52%).
However, large scale synthesis was unreliable from this protocol. Alternatively, use of
trifluoroacetic acid, instead of sulfuric acid, in CH2Cl2 furnished the product 3.32 in
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excellent yield (90%). Reduction of 3.32 with H2 in the presence of 10% Pd/C proceeded
with both hydrogenation of the alkene and hydrogenolysis of the benzyl ether to deliver
the desired 3.33 (ISP452, 45%).

Scheme 3.11: Synthesis of intermediate 3.33
The triplet of triplets at δ 3.00 (1H) ppm in 1H NMR spectrum of 3.33 corresponds
to the benzylic hydrogen of the cyclohexanone ring while the peak at δ 214.1 ppm in

13

C

NMR spectrum corresponds to the carbonyl carbon. Cyclohexanone 3.33 is the orthofluoro analog of 4-(4-hydroxyphenyl)cyclohexan-1-one and as such can serve as a starting
material for synthesis of fluorinated analogs using previously established routes.
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Scheme 3.12: Synthesis of 3.38 and proposed routes to 3.39a and 3.39b
Attempted reaction of 3.33 with either TBDMSCl or TBDMSOTf as previously
demonstrated for 3.1 (see Scheme 3.2), was sluggish even at optimal conditions. The lack
of reactivity of 3.33 under these reaction conditions is most probably a consequence of the
electron withdrawing nature of the ortho fluorine atom on the nucleophilicity of the
phenolic hydroxyl group.
Alternatively, benzyl protection of 3.33 proceeded in a fashion similar to 3.29 gave
3.34 (79%, Scheme 3.12).

Subsequent Wittig methenylation of 3.34 followed by

hydroboration/oxidation using 9-BBN led to 3.36 in 16% yield over 2 steps. Finally,
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cleavage of the benzyl protection was accomplished under hydrogenation conditions to
give 2-fluoro-4-[4-(hydroxymethyl)cyclohexyl]phenol 3.37 (ISP470) as a mixture of cisand trans-stereoisomers. The overall yield of the synthesis is 1.8% over 8 steps. Reduction
of 3.33 with NaBH4 gave the corresponding cyclohexanol 3.38 (ISP450) as a mixture of
cis- and trans-stereoisomers (61%). Conversion of 3.37 to its corresponding bicyclic ether
3.39a, thereby chemical separation of trans isomer 3.39b will be conducted in future.
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CHAPTER 4
BIOLOGICAL EVALUATION OF ERβ SELECTIVE COMPOUNDS
4.1 In vitro and In vivo Biological Evaluation – Assay Summary

Compounds prepared in the previous chapters were evaluated for in vitro ER
activity, interaction with selected CYP enzymes, hERG activity, and nuclear receptor
screening, and in vivo efficacy for memory consolidation. The in vitro biological studies
with respect to ERα and ERβ activity, conducted by Alicia Schultz and Lucky Lu from the
Sem lab at Concordia University-Wisconsin, include:
•
•

•

TR-FRET (Time Resolved Fluorescence Resonance Energy Transfer) ERβ binding
assay, which measures the displacement of a fluorescently labelled estradiol from
the ligand binding domain protein;
Selected compounds were carried forward to a cell-based functional assay, which
depends upon cell membrane penetration, the ability of ligand binding to ER and
to effect dimerization and subsequent protein transcription. These were
conducted for both ERβ and ERα, in both agonism as well as antagonism mode;
CYP inhibition/binding activity, which measures the inhibition of selected CYP
liver enzymes toward the metabolism of luciferin releasing substrates

No-stress/no-reward in vivo memory consolidation studies, conducted by Jaekyoon Kim
from the Frick lab at University of Wisconsin Milwaukee, include:
•
•

Object placement (answers the “where” memory question) by direct hippocampal
and intraperitoneal injections
Object recognition (answers the “what” memory question) by direct hippocampal
and intraperitoneal injections
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4.2 Description of In vitro Assays and Results
4.2.1 TR-FRET ERβ Binding Assay
A Lanthascreen TR-FRET ERβ binding assay was conducted to assess the binding
affinity of synthesized ligands. Assays were conducted using a commercially available
ERβ assay kit from ThermoFisher and verified to work with the Spectramax M5 (white
plates) plate reader. The screen consists of ERβ ligand-binding domain (LBD) tagged with
glutathione-S-transferase and a terbium-labeled anti-GST antibody.

A proprietary

fluorescein-labeled ligand, Fluormone ES2 Green, is bound in the LBD. Excitation of the
terbium label causes fluorescence at 488 nm, which is transferred to the tagged ligand
which fluoresces at 518 nm (Figure 4.1).

When the ligand is bound, the ratio of

518nm/488nm is high; displacement of the fluorescent ligand by a competitor results in
diminished fluorescence at 518 nm, and thus a lower 518 nm/488 nm ratio. Eight different
concentrations were examined to obtain a Ki value. Typical data, as represented for the
stereoisomers of ISP163, are shown in Figure 4.2.

Figure

4.1:

Simplified schematic for TR-FRET ERβ binding assay
(http://slideplayer.com/slide/8532001/26/images/32/Receptor+binding+
assay.jpg)
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Figure 4.2: TR-FRET ERβ binding profile of ISP163 isomers
4.2.2 ERα and ERβ Cell-Based Assay

Cell based assays were carried out to investigate the agonist and antagonist activity
of synthesized ligands. Assays were conducted using a commercially available ERβ assay
kits from Indigo Biosciences. The assay involves non-human mammalian cells engineered
to express human estrogen beta (NR3A2) incorporating both the N-terminal DNA binding
domain and the C-terminal ligand binding domain. Cells incorporate the cDNA encoding
beetle luciferase. Upon binding, the encoded protein forms homo- and heterodimers that
interact with specific DNA sequences to activate transcription, including the production of
luciferase (Figure 4.3).

Quantifying changes in luciferase expression (via relative

luminescence) provides a surrogate measure of the changes in ERβ activity. As compared
to the TR-FRET assay, an increase in fluorescence indicates the increased agonism. The
assay can be used to detect either agonist activity or antagonist activity. In the antagonist
mode, where the addition of estradiol (EC75 = 3.2 nM) serves as an agonist and thus effects
transcription and production of luciferase, a decrease in fluorescence signifies that the test
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compound serves as an antagonist against the action of E2. Similar kits are available to
assess functional ERα activity.

The agonist assay was conducted under optimized

biological conditions delineated in the kit manual, verified to work with the Spectramax
M5 (white plates) plate reader, and performed in duplicate. Seven different concentrations
were examined to obtain an IC50 value. Typical data for ERβ activity, as represented for
the four isomers of ISP163, are shown in Figure 4.4.

Figure 4.3: Schematic representation of ERα and ERβ cell-based assay
(https://www.caymanchem.com/pdfs/15739.pdf)

Figure 4.4: ERβ cell-based agonist assay profile of IS163 isomers
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4.2.3 TR-FRET Results for 4-(4-(hydroxymethyl)cyclohexyl)phenol and its Analogs

The binding affinity (Ki) values of lead 4-(4-(hydroxymethyl)cyclohexyl)phenol
(ISP 171) and its analogs were first studied in Lanthascreen TR-FRET ERβ binding assay
(Table 4.1). In particular; compounds bearing a hydroxymethyl functionality attached to
the cyclohexyl core showed higher affinities in the range 80-240 nM.

Of the two

components in the mixture of cis- and trans-stereoisomers (ISP 171, IC50 = 240 nM), it
was found that the trans-isomer was more potent (ISP 358-2, IC50 = 80 nM) than the
mixture. Introduction of unsaturation within the six-membered ring (ISP 402, IC50 = 89
nM) did not greatly change the binding affinity compared to ISP358-2. Attachment of the
OH group directly to the cyclohexyl core (ISP33, ISP361) did reduce the affinity by
approximately one to two orders of magnitude. This is presumably due to the less than
optimal distance between phenolic OH and hydroxyl group for proper binding to the
receptor. The combination of both a hydroxyl and hydroxymethyl group attached to the
six-membered ring (ISP 411, 2,500 nM) exhibited a 30-fold reduction in affinity compared
to ISP358-2. This result might be attributed to the interaction of the second OH with
neighboring water molecule inside the cavity thereby creating a disruption of the optimal
conformation within the ligand binding pocket. On the other hand, extension of the chain
length to a hydroxyethyl group (RKP231IIF, 7 nM) increased the affinity, but this trend
was reversed with the insertion of an exocyclic alkene moiety (RKP228, 521 nM). This
decrease in affinity may be due to the reduced flexibility of the side arm.
Replacing the hydroxymethyl group with different polar groups such as ketone
(SM01, 4500 nM), oxime (ISP36, 215 nM) or ethyl acrylate functionality (RKP230, 681
nM) resulted in some decrease in ERβ binding. The presence of the aliphatic hydroxyl
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group was not crucial for binding affinity. In fact, ligands with hydrophobic groups
attached to the cyclohexyl ring revealed pronounced affinity (ISP366, 11 nM; RKP231IF,
15 nM) or similar affinity (ISP365, 85 nM). The ability of simple 4-alkyl phenols to bind
to ERβ and ERα has previously been reported.106 For example, 4-adamantyl phenol (AdP,
Figure 4.5) was found to have ERβ IC50 = 200 ± 1 nM and ERα IC50 = 1000 ±1000 nM
respectively.106 While these binding affinities are considerably less than for E2, they
highlight the relative importance of the hydrogen bonding between the phenol OH and
Glu/Arg residues, along with the hydrophobic interactions of the alkyl portion, in
comparison to hydrogen bonding interactions between His and an aliphatic OH group.

Figure 4.5: Reported ERβ agonist 4-adamantyl phenol (AdP)
The cyclic ether had diminished affinity (ISP358-1, 250 nM). Introduction of a 2methylenehydrazine-1-carboxamide (ML431, 16,000 nM) or 2-methylenehydrazine-1carbothioamide (ML432, 5,000 nM) to the cyclohexyl ring greatly reduced binding affinity
due to rigid and longer chain lengths.
Meanwhile, compound ISP389, bearing an oxime functionality ortho to the
phenolic oxygen showed modest affinity whereas those bearing an aldehyde ortho to
phenolic oxygen such as ISP384, ISP393, and ISP394 reflected significantly lower
binding affinities ranging from 900 -2100 nM. Furthermore, an introduction of fluorine

83

Table 4.1: TR-FRET ERβ binding data for six-membered analog

Compound

TR-FRET
Data
(nM)

Compound

960±700

TR-FRET
Data
(nM)

521±87

ISP33

RKP228

6,000±1600

215±129

ISP361

ISP36
240±14
4500±2800

ISP171

SM01
80±21
570±130

ISP358-2
ISP346
89±22
15±2
RKP231IF
ISP402

900±300

85±16
ISP365

ISP393

2,500±500
ISP411

11±2.7
ISP366

7±1
RKP231IIF

250±56
ISP358-I
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Compound

TR-FRET
Data
(nM)

Compound

1,100±430

ISP384

TR-FRET
Data
(nM)

681±240

RKP230

270±66

ISP389

16,000±8,000

ML431

21,000±5000

ISP394

5,000±2400

ML432

49.5±18.3
ISP441

4,281±2,516

ISP450

880±464

ISP452

ortho to the phenolic oxygen such as ISP450 and ISP452 decreased the affinity
dramatically (4281 nM and 880 nM respectively) compared to their non-fluorinated
analogs. However, replacing the hydroxyl group in the side chain with fluorine as in
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ISP441 showed slightly higher affinity (49.5 nM) compared to the parent molecule
(ISP358-2, 80 nM).
4.2.4 Cell-based Functional Assay Results for Selected 4-[(hydroxymethyl)
cyclohexyl)]phenol Analogs

4-[4-(Hydroxymethyl)cyclohexyl]phenol and analogs having lower IC50 values
ranging from 7 to 240 nM were further tested in cell based assays to evaluate both their
binding affinity as well as ERβ selectivity (Table 4.2). The mixture of cis- and transstereoisomers (ISP171) and the trans-only isomer (ISP358-2) showed identical ERβ
agonist potencies (IC50 31 nM) and these results indicated the compounds to be more potent
in the functional based assay than the TR-FRET ligand displacement assay. In contrast,
compounds RKP231IIF, RKP230 and ISP365 resulted in poorer ERβ potencies (IC50 72,
89, 101 nM respectively) compared to their TR-FRET assay results. These differences
may be due to the nature of the assays; the TR-FRET assay measures only displacement of
a labelled estradiol from the ligand binding domain, while the cell-based assay depends
upon effecting conformational changes in the ER such that homo-dimerization and DNA
binding/transcription must occur. Additional interactions between the aliphatic hydroxyl
group and the His475 may play a role in these latter conformational changes.

All

compounds showed no ERβ antagonist activity (> 10,000 nM), or ERα agonist or
antagonist activity thus demonstrating their pronounced selectivity towards the ERβ. Of
those, ISP358-2 gave > 3000-fold selectivity for ERβ over ERα in the cell-based functional
assay, making it the most selective agonist thus reported.
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Table 4.2: Cell-based assay data for selected six-membered analogs and comparison to
TR-FRET assay
Compound

TR-FRET
ERβ Agonist
(nM)

ERβ
Agonist
(nM)

240±14

30±15

80±21

31±7

7±1

ERβ
Antagon.
(nM)

ERα
Agonist
(nM)

ERα
Antagon.
(nM)

700,000
±80,000

>10,000

>10,000

100,000
±17,000

>10,000

72±16

>10,000

72,000±
22,000

>10,000

15±2

89±6

>10,000

25,000±13
00

>10,000

85±16

101±10

>10,000

In
progress

In
progress

>10,000

ISP171

ISP358-2

RKP231IIF

RKP231IF

ISP365
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4.2.5 TR-FRET and Cell-based Assay Results for 4-[4-(hydroxymethyl)
cycloheptyl]phenol and Analogs
The ERβ binding affinity (Ki) of lead 4-[4-(hydroxymethyl)cycloheptyl]phenol
(ISP163) and its analogs were determined in the TR-FRET assay as previously described
(Table 4.3). The lead molecule ISP163 showed higher affinity as IC50 = 44 nM. Extension
or shortening of the distance between the phenolic and aliphatic hydroxyl groups (ISP248
or ISP58, IC50 = 37 and 31 nM respectively) has similar binding affinity (within the error
limits); this change in potency was not as significant as shown in the six membered analogs
(see Table 4.1) from TR-FRET assay.
Introduction of a methyl group ortho to the phenolic oxygen (ISP275) decreased
the affinity by > 100-fold, compared to ISP58, indicating adverse steric interactions in the
ligand binding pocket. Introduction of two alkenes to the cycloheptyl ring (RKP35C, IC50
378 nM) or the bicyclic ether functionality (ISP365, IC50 400 nM) diminished the binding
affinities by 9-fold compared to ISP163, thus emphasizing the need for flexibility in the
ring system. A change in oxidation state of the hydroxyl group, to the cycloheptanone ring
(ISP242) decreased the binding affinity by 6-fold in comparison to ISP58. Compounds
having lower IC50 values were further evaluated in cell-based functional assays (Table 4.4).
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Table 4.3: TR-FRET ERβ binding data for seven-membered analogs
Compound

TR-FRET
DATA
(nM)

Compound

44±16

ISP163

TR-FRET
DATA
(nM)

182±63

ISP 242
378±97
400±100

RKP35C

ISP360
37±9

ISP248

3400±1500

ISP275

31±7
ISP58

3,370±3,560
ISP427
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Table 4.4: TR-FRET and cell-based assay data for selected seven-and five-membered
analogs
Compound

TRERβ
FRET Agonist
DATA
(nM)
(nM)

ERβ
Antagon.
(nM)

ERα
Agonist
(nM)

ERα
Antagon.
(nM)

44±16

30±9

>100,000

10,500
±200

>10,000

37±9

104±27

>10,000

45,000
±17000

>10,000

31±7

401±29

>10,000

1,400
±400

>10,000

Not
done

1,460
±305

>10,000

350,000
±250 000

>10,000

3,370
±3,560

2,100
±250

>10 000

>10,000

>10,000

ISP163

ISP248

ISP58

ISP166

ISP427
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The lead molecule, ISP163, displayed similar potency for ERβ agonist activity as
found in the TR-FRET assay. The seven-membered analogs varying in distance between
the hydroxyl groups (ISP248, and ISP58) resulted in lower potencies (IC50 > 100 nM) as
ERβ agonists, while the oxime analog (ISP166) was nearly 50-fold less potent. Similar to
the cyclohexyl compounds, these analogs did not show any ERβ antagonist activity (>
10,000 nM), or ERα agonist or antagonist activity, indicating their greater selectivity
towards the ERβ agonist activity. From those, ISP163 gave > 350-fold selectivity for ERβ
agonist activity over ERα making it as the most selective agonist among the sevenmembered

series.

The

five-membered

ring

analog

4-[3-

(hydroxymethyl)cyclopentyl]phenol (ISP427) showed very poor potency in both the TRFRET ligand displacement and cell-based functional assays. This may be due to the
inability of this smaller ring to occlude water molecules from the binding site.
4.2.6 TR-FRET and Cell-based Assay of the Stereoisomers of 4-[4-(hydroxymethyl)cycloheptyl]phenol

Since ISP163 is a mixture of four stereoisomers it was crucial to evaluate the
potency and selectivity of the individual isomers. Toward this end, binding affinity from
TR-FRET assay and agonist activity from cell based assay were evaluated (Table 4.5 and
Figure 4.6). The two trans-stereoisomers (PK1 and PK2) reflected greater affinity than
the mixture (ISP163) whereas the cis-stereoisomers PK3 (1R,4S absolute configuration)
and PK4 (1S,4R absolute configuration) reflected lower affinity in the TR-FRET assay. In
contrast, all four isomers revealed lower potency in the cell-based ERβ agonist assay (IC50
47-119 nM) in comparison to the mixture of stereoisomers. Of those, PK2 and PK4
showed higher ERβ agonist activity than for PK1 or PK3. All of the stereoisomers
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exhibited no ERβ antagonist activity (> 10μM), and no agonist or antagonist activity (>
10μM) toward ERα. However, in search for the better ERβ agonist selectivity between
isomers, percent ERα agonist activity at highest concentration was assessed. In this study,
PK4 (1S,4R absolute configuration) manifested 47% activity at 12μM compared to the
PK2 (34% activity at 10μM).
Table 4.5: TR-FRET and cell-based assay data for ISP163 stereoisomers
ISP 163
Isomers

TRFRET
ERβ
(nM)

ERβ
Agonist
(nM)

ERβ
Antagon.
(µM)

ERα
Agonist
(µM)

% Agonist
Activity @
Highest

ERα
Antagon.
(µM)

Concentration
(µM)
44±16

30±9

>100

10.5±0.2

>10

PK1

>25

68±48

>36

5±3

150% @ 36

>36

PK2

33±10

47±4

>23

>10

34% @ 10

>10

PK3

90±36

119±13

>10

>10

10% @ 10

>10

PK4

65±26

53±10

>12

>12

47% @ 12

>12

Mixture

Figure 4.6: ERβ cell-based assay profiles for individual ISP163 stereoisomers
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4.2.7 CYP450 Assay and Results for ISP358-2 and ISP163

The four-main drug metabolizing cytochrome P450 isoforms are CYP1A2,
CYP2D6, CYP2C9, and CYP3A4.107 The interaction of ligands with these CYP450
isoforms may be evaluated using P450-GloTM inhibition assay kits available from Thermo
Fisher.

Isoform-specific substrates (Luciferin-ME, Luciferin-MEEGE, Luciferin-H,

Luciferin-PPXE for CYP1A2, CYP2D6, CYP2C9, and CYP3A4 respectively) are
incubated with the appropriate CYP enzyme, NADPH regeneration system and the test
compound. Each CYP enzyme acts on a specific luminogenic P450-GloTM substrate
(Reaction A) to produce a luciferin product that generates light (chemiluminescence) upon
interaction with the luciferin detection reagent (Reaction B), which is added after the CYP
reaction has been completed (Figure 4.7). Light is used to monitor CYP activity since the
amount of light produced is proportional to the amount of luciferin product formed after
the CYP reaction.

Figure

4.7:

Schematic
diagram
for
basis
of
(http://www.lumflu.com/A_Info.asp?id=36)

CYP450

assay

93

Interaction of the ligand with the CYP, either by metabolism or by inhibition of the
CYP, causes a decrease in the luminescence. Typical data for inhibition of CYP2C9 by
ISP358-2 are shown in Figure 4.8.

Figure 4.8: CYP2C9 assay profile for ISP358-2
The results for the best six-membered ring lead (ISP358-2) and the mixture of
seven-membered ring stereoisomers (ISP163) are detailed in Table 4.6.

The

concentrations at which the two lead substances either inhibit these CYP450s and/or are
metabolized by these CYP450s are significantly greater than their effective ERβ binding
concentrations, thus confirming their suitability as drug candidates for further
development.
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Table 4.6: CYP450 assay data for ISP358-2 and ISP163
CYP Enzyme
CYP 2D6

ISP358-2
IC 50 (µM)
Did not converge

ISP163
IC 50 (µM)
>62.5

CYP 3A4

>62.5

31±2.7

CYP 1A2

>62.5

>62.5

CYP 2C9

34±4.7

1.8±0.3

4.2.8 hERG Assay results for ISP358-2
hERG (the human Ether-à-go-go-Related Gene) assay evaluates a compound’s
inhibition activity towards the Kv11.1, the alpha subunit of a voltage-gated potassium ion
channel. This channel is involved in cardiac action potential repolarization (electrical
activity) of the heart that regulates the heart's beating, inhibition of which is linked with
the fatal disorder known as ventricular arrhythmias.108

Compound ISP358-2 was

submitted to Thermo Fisher to evaluate (on a per-fee basis) the inhibition hERG ion
channel (Figure 4.9). The results indicate 13% inhibition at 100 μM, representing an IC 50
of > 100 μM. This results again indicates safety of this lead compound against irregular
heartbeat at the effective ERβ agonist concentration.
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Figure 4.9: hERG profile of ISP358-2
4.2.9 Nuclear Receptor Panel Screening

Since ER is a nuclear receptor it is important to establish if potential agonists of
ERβ are agonists towards other nuclear receptors. A selected panel of receptors consisted
of androgen receptor (AR, essential for normal female fertility and male skeletal integrity),
glucocorticoid receptor (GR, a major component of the endocrine influence, specifically
stress response), mineralocorticoid receptor (MR, important for expressing proteins which
regulate ion and water transport), peroxisome proliferator-activator receptor delta (PPARΔ, involved in development of diabetes, obesity, atherosclerosis and cancer), progesterone
receptor (PR, involved in cell proliferation), thyroid hormone receptor beta (TR-β,
mediates functions of thyroid hormone), and the vitamin D receptor (VDR, involved in
mineral metabolism) were considered. The panel screenings for ISP358-2 and ISP163PK4 were conducted by Thermo/Life (on a per-fee basis) from GeneBlazer Cell based
assay and results are summarized in Tables 4.7 and 4.8. Both compounds showed no
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activity at 0.25, 2.5 and 25 μM concentrations thus confirming no cross-reactivity towards
the aforementioned receptors at the effective ERβ agonist concentration.
Table 4.7: Nuclear receptor panel screen data for ISP358-2
Nuclear
receptor
AR
GR
MR
PPAR-δ
PR
TR-β
VDR

ISP 358-2
@ 25 µM
-6
-1
0
2
-2
-1
-1

ISP 358-2
@ 2.5 µM
-5
0
0
3
0
-1
-1

ISP 358-2
@ 0.25 µM
-6
2
-1
2
-1
-1
-1

Table 4.8: Nuclear receptor panel screen data for ISP163-PK4
Nuclear
receptor

ISP 163-PK4
@ 25 µM

AR
GR
MR
PPAR-δ
PR
TR-β
VDR

-4
1
0
2
-1
-2
0

ISP 163PK4
@ 2.5 µM
-6
-1
0
2
-2
-1
0

ISP 163PK4
@ 0.25 µM
-5
-1
1
3
-1
0
-1

4.3 Description of In vivo Assays and Results

4.3.1 Assessment of Memory Consolidation in Ovariectomized Mice

The effects of lead compounds on memory consolidation were assessed.

In

particular, two types of behavioral tasks were utilized and which diverge in terms of the
protocol for testing. The object recognition (OR) task tests the knowledge of object identity
(“what”) and object placement task (OP) tests the knowledge of object location or spatial
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memory (“where”). These tasks are sensitive to E2, exert low stress on subjects and a
single training trial is ideal for mediating rapid biochemical activations to memory
formation.33,

69, 109

Prior to testing, female mice (C57BL/6) used in this study were

ovariectomized. For assay of administration directly to the brain, these mice were also
implanted with a bilateral guide cannula aimed at the dorsal hippocampus. After one week
of recovery, mice were trained in a square arena and were allowed to accumulate 30 s
exploring two identical objects placed near the adjacent corners. Immediately after this
training, mice were administered, either by dorsal hippocampal infusion (DH) or
intraperitoneal injection (IP), with either vehicle (negative control); DPN, a known agonist
(positive control), or the lead compound (ISP358-2) in different concentrations. For OP
retention, animals were retested after 24 h with one of the objects in a different position;
for OR retention animals were tested after 48 h with one new/novel object in place of a
familiar object (Figure 4.10).

Figure 4.10: Illustration of object placement (OP) and object recognition (OR) protocols
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Since mice are inherently drawn to novelty110 under unthreatened environment,
mice who remember the training objects spend more time than chance (15 s) with either
the new placement (OP assay) or novel object (OR assay) and less time than chance
exploring the familiar object in these assays.
4.3.2 Assessment of Memory Consolidation by Dorsal Hippocampal Infusion
Due to its potency and high ERβ selectivity, as well as its ease of preparation, trans4-[4- (hydroxymethyl)cyclohexyl]phenol (ISP358-2) was selected for initial screening by
single DH infusion. Five groups of mice (10 mice per group) were tested with each group
receiving either vehicle (1% DMSO in saline), or DPN (10 pg/hemisphere), or ISP358-2
(10 pg/ hemisphere, 100 pg/hemisphere, 1 ng/hemisphere). For the object recognition task,
mice receiving vehicle or the 10 pg dose of ISP358-2 did not spend more than chance time
with the novel object, while mice receiving the known ERβ agonist DPN, or ISP358-2 at
the 100 pg or 1 ng/hemisphere dose spent statistically significant more time than chance
with the novel object (Figure 4.11a). Similar results were obtained for the object placement
task; neither administration of the vehicle nor the 10 pg dose of ISP358-2 exhibited
differences in exploring the familiar vs. the moved object, while treatment with DPN, 100
pg and 1 ng/hemisphere of ISP358-2 did result in statistically significant more time spent
with the moved object vs. the familiar object (Figure 4.11b). These data were confirmed
by one-sample t-test, one-way ANOVA, and Fisher’s LSD posthoc tests70, 109 and suggest
that 100 pg and 1 ng of ISP358-2, administered by dorsal hippocampal infusion, enhances
object recognition and object placement memory consolidation in the ovariectomized
mouse model.
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a)

b)

Figure 4.11: a) Amount of time (of 30 sec total) spent with the novel object in OR assay;
b) Amount of time (of 30 sec total) spent with the novel in OP assay [DH
infusion]
4.3.3 Assessment of Memory Consolidation by Intraperitoneal Administration
While the above results demonstrate the effectiveness of ERβ agonist ISP358-2 for
memory consolidation in this animal model, dorsal hippocampal infusion is a less than
ideal means of therapeutic administration. Studies of CNS drugs indicate that optimal
characteristics for crossing the blood-brain barrier correspond to molecular weight ≤ 400,
clog P = 1.5-2.7, polar surface areas (PSA) = 60-70 Å3, number of (nitrogen + oxygen
atoms) ≤ 5, and low molecular flexibility.111-112. ISP358-2 fits the majority of these criteria
except that it has PSA ~ 40 Å3. In order to determine if this compound is capable of passing
the blood-brain barrier and arriving at the hippocampus, object recognition and object
placement tasks were conducted after a single intraperitoneal administration (IP) of
ISP358-2 (Figure 4.12 a and b). Four groups (10 mice per group) of mice were tested:
vehicle (1% DMSO in saline), positive control DPN (0.05 mg/kg) and two doses of ISP358-2 (0.5 mg/kg and 5 mg/kg). These doses of ISP358-2 were based in relationship to
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the known effective dose of DPN previously established by the Frick group. For the object
recognition task, mice receiving vehicle did not spend time more than chance with the
novel object while mice receiving the 0.5 mg/kg or 5 mg/kg dose of ISP358-2 by IP
injection spent more time with the novel object. The same trend was observed in the object
placement task, and both OR and OP data were confirmed by one-sample t-test, one-way
ANOVA, and Fisher’s LSD posthoc tests.70, 109 These results suggest that 0.5 mg and 5
mg of ISP358-2 enhanced the object recognition and object placement memory
consolidation after intraperitoneal administration. Gratifyingly, these results confirmed
both effectivity and blood-brain barrier (BBB) permeability of ISP358-2 which is an
essential requirement of central nervous system (CNS) drugs.

a)

b)

Figure 4.12: a) Amount of time (of 30 sec total) spent with the novel object in OR assay;
b) Amount of time (of 30 sec total) spent with the novel in OP assay [IP
injection]
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CHAPTER 5

CONCLUSIONS AND OUTLOOK

5.1 Summary

The overall goal of this research was the design, synthesis and biological evaluation
of ERβ selective agonists for hippocampal memory consolidation in postmenopausal
women. Two major types of non-steroidal compounds were synthesized and evaluated for
in vitro ERβ vs. ERα agonism, and in vivo effect on memory consolidation in an
ovariectomized mouse model.
After identifying important prerequisites from the literature and from docking
studies, research was focused towards the design of (4-hydroxyphenyl)cyclohexyl or
cycloheptyl derivatives as selective ERβ agonists.

Toward this end, cis-4-(4-

(hydroxymethyl)cycloheptyl)phenol was first prepared from organoiron methodology and
found to be an ERβ agonist in the 50 nM range with >1000- fold selectivity for ERβ over
ERα in cell-based assays.81 While these biological results were promising, the organoiron
synthetic route was problematic and difficult to replicate. Three alternative syntheses were
established using cheaper starting materials and more robust synthetic protocols; the most
efficient route proceeded in fewer steps and with greater yields (20% in six steps). These
new

protocols

gave

a

racemic

mixture

of

diastereomers

of

4-(4-

(hydroxymethyl)cycloheptyl)phenol (ISP163); the individual stereoisomers were obtained
by preparative chiral HPLC.

The relative stereochemistry of the diastereomers was

established by NMR spectroscopy, while the absolute configuration of the individual cisisomers were determined by single crystal X-ray diffraction analysis. A second lead
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molecule, 4-(4-(hydroxymethyl)cyclohexyl)phenol (ISP171) was synthesized by sharing
common synthetic pathways as in ISP163. The product was a mixture of cis- and transstereoisomers and a chemical separation of the mixture, via faster oxidative cyclization of
the cis-isomer, afforded the trans- isomer ISP358-2 in 47% yield under optimal conditions.
Several other 4-cyclohexyl and cycloheptyl phenolic analogs were prepared with varying
functional groups, chain lengths, and molecular rigidity in order to establish structure
activity relationships (SARs).
A TR-FRET ERβ binding assay was conducted as an initial screen for the binding
affinity of the synthesized ligands. The incorporation of an aliphatic hydroxyl functionality
at the end of the side chain, but not directly to the ring core appeared to have a stronger
effect on the binding affinity of both six- and seven-membered ring scaffolds (ISP163,
ISP171, ISP358-2, ISP402, ISP248 and RKP231IIF). In contrast, introduction of an
alkene functionality, and thereby rigidity within the ring structure decreased the binding
affinity of ligands (ISP346 and RKP35c). To supplement the TR-FRET findings, cellbased assays were conducted for selected compounds having higher binding affinity to
investigate their potential for binding and ability to effect transcription. Among the sixmembered series the trans isomer ISP358-2 revealed the highest potency as ERβ agonists
(~ 30 nM). The same trend was observed in the seven-membered series where ISP163
exhibited the highest ERβ agonist activity (~ 30 nM). In general, all compounds which
were tested in cell based assay did not have any observable effect on ERβ antagonist, ERα
agonist or ERα antagonist activity. Of particular note is that ISP358-2 and ISP163 exhibit
> 3000-fold and > 300-fold selectivity for ERβ over ERα, thus making these compounds
the most selective ERβ agonists yet reported. Finally, the cell based assay for the individual
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ISP163 stereoisomers (PK1-PK4) revealed that ISP163-PK4 [4(S)-(4-hydroxyphenyl)-1(R)-hydroxymethylenecycloheptane] possessed the best combination of potency (~ 53 nM)
and ERβ:ERα selectivity (226-fold).
Having recognized ISP163 and ISP358-2 as best ERβ agonist from each series,
their metabolic stability was evaluated. Both compounds exhibited poor inhibitory activity
(> 30 µM) against four known drug metabolizing CYP450s, thus confirming their stability
inside the liver. The exception was ISP163 which exhibited IC50 = 1.8 µM for CYP2C9.
This value is still considerably poorer than the ERβ IC50 (30 nM). Neither ISPI63-PK4
nor ISP358-2 exhibited cross reactivity with other common nuclear receptors (<2%
activation at 25 µM). Additionally, ISP358-2 did not show any observable effect on hERG
inhibition indicating its non-cardiotoxicity.
Memory consolidation in ovariectomized mice (C57BL/6) was assessed for
ISP358-2 via DH infusion and IP administration. A statistically significant effect was
observed for memory consolidation in both object placement and object recognition tests
at the 100 pg/hemisphere (DH) and 0.5 mg/Kg (IP) dose level.

These are both

approximately one order of magnitude less potent in comparison to the DPN; 10
pg/hemisphere (DH) and 0.05mg/Kg (IP). These relative efficacies are consistent with the
relative ERβ agonist activity of ISP358-2 compared to DPN. The IP data also provides
strong evidence for the blood-brain-barrier (BBB) permeability of ISP358-2.
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5.2 Conclusion

The results presented in this dissertation demonstrate the development of two types
of non-steroidal selective ERβ agonists. Among those, [4(S)-(4-hydroxyphenyl)-1-(R)hydroxymethylenecycloheptane]

(ISP163-PK4)

and

trans-4-(4-

(hydroxymethyl)cyclohexyl)phenol (ISP358-2) display > 225-fold and > 3000-fold
selectivity for ERβ over ERα respectively. ISP358-2 was shown to have a statistically
significant effect on memory consolidation in ovariectomized mice by either DH and IP
administration. The lack of off-target nuclear receptor activity, as well as lack of hERG
activity, and the high metabolic stability (compared to effective dose) highlight the
potential for this compound as a potential therapeutic for hippocampal memory
consolidation.
5.3 Outlook

It is evident that great deal of research over the past two decades has focused on the
design of estrogen receptor beta selective ligands as drug candidates. There is extensive
literature on relationships between ERβ agonists and hippocampal physiology for the
development of new CNS drugs.
The (4-hydroxyphenyl)cyclohexyl or cycloheptyl based ERβ agonists, specifically
ISP163 and ISP358-2, described herein serve as a foundation for the development of small
non-steroidal molecules as ERβ agonists. Nevertheless, scalable stereo-specific synthesis
of those is essential for further biological studies. Moreover, it is important to synthesize
the cis-ISP171 to compare its potency with respect to trans-stereoisomer (ISP358-2). One
potential route to this compound is outlined in Scheme 5.1.
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The crystal structures of ISP358-2 with ERβ and ERα should provide valuable
information into the origin of its selectivity. It will be necessary to establish collaborations
for these studies. Additionally, while ISP358-2 interacts with the panel of four CYP
enzymes at concentrations 1,000-fold greater than the ERβ IC50 value, it will be important
to assess the metabolic products produced from this compound with human liver
microsomes. Furthermore, while the memory consolidation efficacy of ISP358-2 via
intraperitoneal administration demonstrates the ability of this compound to pass the bloodbrain barrier, the ability of this compound to be transported across intestinal mucosa is, yet,
unknown. This will require assessment of this lead molecule to be transported across a
Caco-2 cell monolayer. A correlation between the Caco-2 monolayer permeability and in
vivo absorption is well recognized.113-114 Additionally, OP and OR testing via oral (gavage)
administration could provide evidence for intestinal adsorption.
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Scheme 5.1: Proposed synthetic protocol for cis- and trans-ISP171
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CHAPTER 6

SYNTHESIS AND CHARACTERIZATION

6.1 Chemicals and General Methods

All the chemicals were purchased from Sigma-Aldrich, Matrix scientific, or Alfa
Aesar and used as received. Reactions with moisture- or air-sensitive reagents were
conducted under an inert atmosphere of nitrogen in oven-dried glassware with anhydrous
solvents. Reactions were followed by TLC on precoated silica plates (60 Å, F254, EMD
Chemicals Inc) and were visualized by UV lamp (UVGL-25, 254/365 nm). Flash column
chromatography was performed by using flash silica gel (32–63 μ). NMR spectra were
recorded on Varian UnityInova 400 MHz instrument. CDCl3, [D6] dimethylsulfoxide and
[D6] acetone were purchased from Cambridge Isotope Laboratories. 1H NMR spectra were
calibrated to  = 7.26 ppm for residual CHCl3,  = 2.50 ppm for d5-DMSO and  = 3.30
ppm for residual d3-CD3OD.

13

C NMR spectra were calibrated from the central peak at 

= 77.23 ppm for CDCl3,  = 39.52 ppm for d6-DMSO and  = 49.00 ppm for CD3OD.
6.2 Experimental Details

Methyl 4-methoxybenzoate (2.2). Para anisic acid 2.1 (8.010 g, 52.56 mmol) was
dissolved in methanol (200 mL) and SOCl2 (10 mL, 6.8 mmol) was added dropwise with
stirring at 0 °C over 30 min. The system was heated at 65 ˚C for 12 h under N2. The
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resulting mixture was cooled to room temperature and diluted with water (50 mL).
Methanol was evaporated and the pH was adjusted to pH = 7 with saturated sodium
bicarbonate solution (5 mL). The resulting solution was extracted with ethyl acetate (3 ×
30 mL). The combined organic extracts were washed with brine (20 mL), dried (MgSO 4),
and concentrated to give 2.2 as a colorless solid (7.16 g, 82%). 1H NMR (400 MHz, d6DMSO) δ 7.04 and 6.17 (AA’BB’, JAB = 8.7 Hz, 4H), 2.95 (s, 3H), 2.93 (s, 3H) ppm.

13

C

NMR (100 MHz, d6-DMSO) δ 165.9, 163.2, 131.2, 121.8, 114.0, 55.5, 52.0 ppm. The
NMR spectral data for 2.2 are consistent with the literature values. 115

5-(4-Methoxyphenyl)-1,8-nonadien-5-ol (2.3a). Dry magnesium turnings (3.654 g, 152.1
mmol) were placed in a flame dried three-necked flask followed by THF (30 mL). The
system was connected to the N2 environment while stirring and fitted with a condenser and
an addition funnel. The addition funnel was loaded with a solution of 4-bromo-1-butene
(7.72 mL, 76.1 mmol) in THF (20 mL). A little amount of the bromobutene solution (2
mL) was added slowly to the magnesium turnings, and the contents were heated to reflux.
Once the Grignard formation had started, the remaining bromide solution was added
dropwise maintaining a gentle reflux. The reaction was stirred until most of the magnesium
had reacted. A solution of methyl 4-methoxybenzoate 2.2 (2.528 g, 15.20 mmol) in THF
(30 mL) was loaded into the addition funnel and added dropwise over 30 min. After stirring
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overnight at ambient temperature, a saturated solution of NH 4Cl (30 mL) was added to
quench the reaction. The resultant emulsion was stirred for 2 h and the solution was
extracted with ether (3 x 40 mL). The combined organic layers were washed with water
(30 mL), then brine (2 x 20 mL) and dried (MgSO 4). The solvent was evaporated to give
alcohol 2.3a as a yellow oil (3.182 g, 85%). 1H NMR (400 MHz, CDCl3) δ 7.29 and 6.88
(AA’BB’, JAB = 8.9 Hz, 4H), 5.84-5.73 (m, 2H), 4.98–4.88 (m, 4H), 3.81 (s, 3H), 1.96–
1.84 (m, 8H) ppm.

13

C NMR (100 MHz, CDCl3) δ 158.2, 139.0, 137.9, 126.6, 114.8,

113.7, 77.1, 55.3, 42.4, 28.1 ppm.

1-(4-Methoxyphenyl)-4-cyclohepten-1-ol (2.4a). Alcohol 2.3a (1.015 g, 4.126 mmol)
was dissolved in dry CH2Cl2 (415 mL, 0.01 M) to give a colorless solution. A solution of
Grubbs I catalyst (0.136 g, 0.165 mmol, 4%) in CH2Cl2 (15 mL) was added slowly through
the syringe pump over 10 h and the mixture was heated at 40 °C with stirring for 12-18 h.
The reaction mixture was cooled to room temperature, quenched with DMSO (50 eq, 0.600
mL) and continued to stir for 12 h. The mixture was concentrated to dryness and the crude
material was purified by column chromatography (SiO2, hexanes-diethyl ether = 80:20) to
give 2.4a (0.675 g, 75%) as a green oil.

1

H NMR (400 MHz, CDCl3) δ 7.43 and 6.87

(AA’BB’, JAB = 9.0 Hz, 4H), 5.86-5.83 (m, 2H), 3.80 (s, 3H), 2.55-2.44 (m, 2H), 2.10-1.97
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(m, 4H), 1.90-1.82 (m, 2H), ppm.

13

C NMR (100 MHz, CDCl3)  158.3, 142.3, 132.1,

125.8, 113.5, 76.5, 55.2, 40.1, 23.0 ppm.

5-(4-Methoxyphenyl)-1-cycloheptene (2.5). Alcohol 2.4a (1.720 g, 7.880 mmol) was
dissolved in dry CH2Cl2 (50 mL) to give a light green solution. Triethylsilane (1.4 mL, 8.8
mmol) was added followed by TFA (6.2 mL, 79 mmol). The mixture was stirred at room
temperature for 48 h while monitoring the reaction by TLC. After complete disappearance
of starting material, the solution was concentrated to a bilayer oil and purified by column
chromatography (SiO2, hexanes-ethyl acetate = 50:50) to give 2.5 as a brown oil (1.433 g,
90%). 1H NMR (400 MHz, CDCl3)  7.11 and 6.84 (AA’BB’, JAB = 8.6 Hz, 4H), 5.915.87 (m, 2H), 3.79 (s, 3H), 2.69 (tt, J = 11.3, 3.2 Hz, 1H), 2.35-2.25 (m, 2H), 2.23-2.13 (m,
2H), 1.91-1.83 (m, 2H), 1.54-1.43 (m, 2H) ppm.

13

C NMR (100 MHz, CDCl3)  157. 9,

141.8, 132.5, 127.7, 113.9, 55.5, 49.6, 35.2, 28.2 ppm.
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1,2-Epoxy-5-(4-methoxyphenyl)cycloheptane (2.5a). A solution of cycloheptene 2.5
(0.551g, 2.73 mmol) in freshly distilled CH2Cl2 (20 mL) was stirred for 10 min. To this
solution was added dropwise a solution of m-chloroperoxybenzoic acid (mCPBA) (1.008
g, 70% wt, 4.090 mmol) in freshly distilled CH2 Cl2 (10 mL). The solution was stirred
under nitrogen and the reaction was followed by TLC. The solvent was evaporated and
residue was treated with saturated sodium bicarbonate solution (20 mL) with stirring for
30 min. The mixture was extracted with CH2Cl2 (3 x 20 mL), concentrated and purified
by column chromatography (SiO2, hexanes-ethyl acetate = 50:50) to give 7 (0.441 g, 74%)
as a yellow oil. This was determined to be a mixture of cis- and trans-stereoisomers by 1H
and 13C NMR spectroscopy. 1H NMR (400 MHz, CDCl3)  7.12-7.05 (m, 4H), 6.86-6.79
(m, 4H), 3.78 (s, 3H), 3.77 (s, 3H), 3.20-3.16 (m, 2H), 3.13-3.07 (m, 2H), 2.55 (tt, J = 11.1,
3.3 Hz, 1H), 2.41-2.28 (m, 4H), 2.13 (tt, J = 11.1, 2.2 Hz, 1H), 1.93-1.84 (m, 2H), 1.831.77 (m, 2H), 1.75-1.67 (m, 2H), 1.66-1.57 (m, 4H), 1.51-1.39 (m, 2H) ppm.

13

C NMR

(100 MHz, CDCl3)  157.8/157.6, 141.2, 139.9, 127.6/127.3, 113.8/113.7, 56.1, 55.1, 49.2,
48.0, 32.6, 32.0, 28.8, 27.5 ppm.
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4-(4-Methoxyphenyl)cycloheptanol (2.6). Epoxide 2.5a (0.100 g, 0.460 mmol) was
dissolved in dry THF under N2. To this solution was added LiAlH4 (0.048 g, 1.4 mmol)
and AlCl3 (0.056 g, 0.46 mmol). The resulting mixture was stirred for 12 h, then treated
with water (15 drops) and diluted with saturated aqueous KOH (3 mL) and water (10 mL).
The mixture was filtered through celite and extracted with ether (3 × 20 mL). The
combined organic extracts were dried (MgSO4), and solvent was evaporated. The residue
was purified by column chromatography (SiO2, hexanes-ethyl acetate = 20:80) to give 2.6
(0.032 g, 32%) as a light-yellow oil. This product was determined to be a mixture of cisand trans-stereoisomers on the basis of 1H and

13

C NMR spectroscopy.

1

H NMR (400

MHz, CDCl3) δ 7.11 and 7.09 (2 × d, J = 8.3 Hz, 2H total), 6.83 (d, J = 8.2 Hz, 2H), 4.064.00 and 3.99-3.90 (2 × m, 1H total), 3.78 (s, 3H), 2.72–2.56 (m, 1H), 2.15-2.05 (m, 1H),
2.02–1.50 (m, 10H) ppm.

13

C NMR (100 MHz, CDCl3)  157.6, 141.4, 127.5, 113.7, 72.7,

71.6, 55.2, 46.2, 38.2, 37.6, 36.9, 35.7, 31.7, 29.6, 23.3, 21.3 ppm.
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4-(4-Methoxyphenyl)cycloheptanol (2.6). To a solution of cycloheptene 2.5 (1.24 g, 6.14
mmol) in freshly distilled THF (25 mL) at 0 ˚C, was added dropwise a solution of boranetetrahydrofuran complex (1M in THF, 11.3 mL, 11.3 mmol). The solution was gradually
warmed to room temperature and stirred for 20 h under N2. The reaction mixture was
cooled to 0 ˚C, and water (440 mL) was added slowly followed by 30% hydrogen peroxide
(8.50 mL) and 1N sodium hydroxide (14.5 mL). The resulting solution was stirred at room
temperature for 30 min and extracted with ethyl acetate (2 x 20 mL), concentrated and
purified by column chromatography (SiO2, hexanes-ethyl acetate = 60:40) to give 2.6
(1.150 g, 85%) as a yellow oil. This was determined to be a mixture of diastereoisomers
by 1H and 13C NMR spectroscopy by comparison to a sample previously prepared.

4-(4-Methoxyphenyl)cycloheptanone (2.7). A solution of epoxide 2.5a (0.038 g, 0.17
mmol) in benzene (20 mL) was treated with borontrifluoride etherate (0.15 mL, 0.87 mmol)
under N2. The light yellow solution became darker in color and was stirred for 1 h. The
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mixture was treated with saturated aqueous sodium carbonate (25 mL), and the organic
layer was separated and dried (MgSO4). The solvent was evaporated under reduced
pressure to give a yellow crude oil. The residue was purified by column chromatography
(SiO2, hexanes-ethyl acetate = 80:20) to afford 2.7 (0.010 g, 26%) as a colorless oil. 1H
NMR (400 MHz, CDCl3) δ 7.10 and 6.84 (AA’BB’, JAB = 8.7 Hz, 4H), 3.79 (s, 3H), 2.77–
2.53 (m, 4H), 2.16–1.52 (m, 7H) ppm.

13

C NMR (100 MHz, CDCl3) δ 215.0, 157.9, 139.9,

127.4, 113.9, 55.3, 47.9, 43.8, 42.9, 38.6, 32.2, 23.8 ppm. The spectral data obtained for 9
was consistent with the literature values.87

4-(4-Methoxyphenyl)cycloheptanone (2.7). Method A: To a solution of cycloheptanealcohol 2.6 (0.701g, 3.19 mmol) in CH2Cl2 (30 mL) at room temperature, were added
pyridinium chlorochromate (1.39 g, 6.44 mmol) and silica (or celite) (1.52 g), and the
resulting mixture was stirred at room temperature for 4 h. The solution was filtered through
a small pad of silica gel eluting with CH2Cl2. The filtrate was concentrated in vacuo, and
the residue was purified by column chromatography (SiO2, hexanes-ethyl acetate = 80:20)
to afford 2.7 (0.389 g, 55%) as a colorless oil. The 1H NMR spectrum of the product was
identical to that previously obtained.
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Method B: Dry magnesium turnings (0.152 g, 6.33 mmol) were placed in a flame dried
three-necked flask followed by THF (10 mL). A solution of propylbromide (0.200 mL,
1.27 mmol) in THF (2 mL) was added dropwise while refluxing under nitrogen
environment. Once the Grignard formation was completed, the mixture was cooled to
room temperature and a solution of 1,1’-(azodicarbonyl)dipiperidine (0.319g, 2.53 mmol)
in THF (4 mL) was added dropwise over 15 min. Then alcohol 2.6 (0.132 g, 0.600 mmol)
was slowly added while stirring overnight at ambient temperature. A saturated solution of
NH4Cl (30 mL) was added to quench the reaction. The resultant emulsion was stirred for
30 min and the solution was extracted with ether (2 x 20 mL). The combined organic layers
were washed with water (30 mL), then brine (20 mL) and dried (MgSO4). The solvent was
evaporated and purified by column chromatography (SiO2, hexanes-ethyl acetate = 80:20)
to afford 2.7 (0.027 g, 20%) as a colorless oil. The 1H NMR spectrum of the product was
identical to that previously obtained.
Method C: To a solution of cycloheptane-alcohol 2.6 (0.787 g, 3.58 mmol) in CH2Cl2 (38
mL) at room temperature, were added Dess–Martin periodinane (4.55 g, 10.7 mmol) and
water (0.2 mL) and mixture was stirred at room temperature for 6 h. The mixture was
quenched with 1:1 mixture of saturated Na2S2O3 and NaHCO3 solution and continued to
stir for 30 min. The resulting solution was stirred at room temperature for 30 min and
extracted with ethyl acetate (2 x 20 mL), dried (MgSO4) concentrated and purified by
column chromatography (SiO2, hexanes ethylacetate = 80:20) to afford 2.7 (0.389 g, 50%)
as a colorless oil. The 1H NMR spectrum of the product was identical to that previously
obtained.
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1-(4-Methoxyphenyl)-4-methylenecycloheptane (2.8).

To a stirred solution of

PPh3CH3Br (1.25 g, 3.50 mmol) in anhydrous THF (30 mL) at -10˚C under N2, was added
a solution of n-butyl lithium (1.6 M in hexanes, 2.3 mL, 3.7 mmol) dropwise. After
complete addition, the deep yellow mixture was stirred for another 45 min at -10˚C before
slowly adding a solution of 2.7 (0.380 g, 1.74 mmol) in THF (6 mL). The solution changed
from a deep to light yellow in color, and the mixture was gradually warmed to room
temperature and stirred overnight. The solution was diluted with water (20 mL) and
aqueous layer was extracted with ethyl acetate (2 × 20 mL). The combined organic extracts
were washed with brine and dried (MgSO4).

The residue was purified by column

chromatography (SiO2, hexanes-ethyl acetate = 80:20) to give 2.8 (0.296 g, 79%) as a lightyellow oil. 1H NMR (400 MHz, CDCl3) δ 7.10 and 6.83 (AA’BB’, JAB = 8.4 Hz, 4H), 4.77
(s, 2H), 3.79 (s, 3H), 2.61–2.45 (m, 2H), 2.32 (broad t, J = 12.2 Hz, 2H), 2.00–1.84 (m,
3H), 1.71–1.48 (m, 4H) ppm.

13

C NMR (100 MHz, CDCl3) δ 157.6, 151.9, 141.6, 127.7,

113.8, 110.9, 55.5, 47.5, 37.9, 37.2, 36.1, 35.3, 27.4 ppm.
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(4-(4-Methoxyphenyl)cycloheptyl)methanol (2.9). To a solution of 2.8 (0.296 g, 1.37
mmol) in freshly distilled THF (10 mL) at 0 ˚C, was added dropwise a solution of boranetetrahydrofuran complex (1M in THF, 2.75 mL, 2.7 mmol). The resulting mixture was
warmed to room temperature and stirred for 20 h. The reaction mixture was cooled to 0
˚C, and pure ethanol (115 mL) was added slowly followed by 30% hydrogen peroxide (2
mL) and 3N sodium hydroxide (10 mL). The mixture was heated at reflux for 1 h, extracted
with ethyl acetate (2 × 20 mL), dried (MgSO4), and the solvent evaporated. The crude
material was purified by column chromatography (SiO2, hexanes-ethyl acetate = 60:40) to
give 2.9 (0.155 g, 48%) as a colorless gum. This was determined to be a mixture of
diastereoisomers by 1H and 13C NMR spectroscopy. 1H NMR (400 MHz, CDCl3) δ 7.11
and 6.83 (AA’BB’, JAB = 8.8 Hz, 4H), 3.77 (s, 3H), 3.46 (d, J = 6.4 Hz, 2H), 2.69–2.55 (m,
1H), 2.00–1.72 (m, 8H), 1.68–1.39 (m, 4H) ppm.

13

C NMR (100 MHz, CDCl3) δ 157.6,

142.1, 141.8, 127.7, 113.8, 68.6, 68.4, 55.4, 47.2, 46.0, 42.2, 41.0, 38.8, 36.8, 36.5, 33.0,
31.5, 30.6, 29.9, 28.5 ppm.
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4-(4-(Hydroxymethyl)cycloheptyl)phenol (2.10). To a stirred solution of 2.9 (0.180 g,
0.769 mmol) in anhydrous CH2Cl2 (10 mL) at -78 ˚C, was added dropwise a solution of
boron tribromide (1M in CH2Cl2, 2.31 mL, 2.31 mmol). After complete addition, the
reaction mixture was stirred for 30 min at -78˚C and gradually warmed to room temperature
over a 2 h period. The mixture was quenched with water (10 mL) and the aqueous layer
was extracted with CH2Cl2 (3 × 20 mL). The combined organic extracts were washed with
brine and dried (MgSO4). Evaporation of the solvent and purification from column
chromatography (SiO2, hexanes-ethyl acetate = 50:50) gave 2.10 (0.048 g, 28%) as a
colorless solid.

This product was determined to be a mixture of cis- and trans-

stereoisomers on the basis of 1H and 13C NMR spectroscopy. mp 60-63 °C. 1H NMR (400
MHz, CDCl3) δ 7.03 and 6.74 (AA’BB’, JAB = 8.5 Hz, 4H), 5.10 (s, 1H),3.48 (d, J = 6.6
Hz, 2H), 2.67–2.49 (m, 1H), 1.97–1.32 (m, 11 H) ppm.

13

C NMR (400 MHz, CDCl3) δ

153.8, 142.0, 141.8, 127.9, 127.8, 115.4, 68.6, 68.5, 47.2, 46.1, 42.2, 41.3, 38.9, 36.7, 36.5,
33.0, 31.5, 30.6, 29.9, 28.5, 27.4, 24.3 ppm.
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Methyl 4-((tert-butyldimethylsilyl)oxy)benzoate (2.12). To a stirred solution of methyl4-hydroxybenzoate 2.11 (8.000 g, 52.5 mmol) in anhydrous CH2Cl2 (80 mL) under N2 was
added imidazole (10.7 g, 157 mmol) while stirring at 0 ˚C. After 45 min, tert-butyldimethyl
silyl chloride (11.9 g, 78.9 mmol) was added and stirred at 0 ˚C for 2 h, and at room
temperature overnight.

The resulting mixture was diluted with brine (70 mL) and

partitioned with CH2Cl2 (3 x 30 mL). The combined organic extracts were dried (MgSO4),
concentrated and purified by column chromatography (SiO2, hexanes -ethyl acetate =
90:10) to give 2.12 as a colorless gum. (11.73 g, 84%). 1H NMR (400 MHz, CDCl3) δ 7.93
and 6.84 (AA’BB’, JAB = 8.9 Hz, 4H), 3.86 (s, 3H), 0.97 (s, 9H), 0.21 (s, 6H) ppm.

13

C

NMR (100 MHz, CDCl3) δ 170.0, 160.2, 131.5, 123.2, 119.9, 51.9, 25.7, 18.1, -4.3 ppm.
The spectral data for this compound were consistent with the literature values.116
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5-(4-((tert-Butyldimethylsilyl)oxy)phenyl)nona-1,8-dien-5-ol (2.13). Dry magnesium
turnings (6.75 g, 0.281 mmol) were placed in a flame dried three-necked flask followed by
THF (25 mL). The system was under N2 while stirring and fitted with a condenser and an
addition funnel. The addition funnel was loaded with a solution of 4-bromo-bute-1-ene
(11.5 mL, 0.113 mol) in THF (20 mL). A slight amount of bromobutene solution (3 mL)
was added slowly to the magnesium turnings, and the contents were heated at 65 ˚C to
reflux. Once the Grignard formation was started, the remaining bromide solution was
added dropwise. The reaction was stirred until most of the magnesium had reacted and a
solution of 2.12 (5.000 g, 18.8 mmol) in THF (25 mL) was loaded into the addition funnel
and added dropwise over 45 min.

The mixture was stirred overnight at ambient

temperature and a saturated solution of NH4 Cl (30 mL) was added to quench the reaction.
The resultant emulsion was stirred for 1 h and the solution was extracted with ether (3 x 30
mL). The combined organic extracts were washed with water (30 mL), followed by brine
(2 x 20 mL) and dried (MgSO4). The solvent was evaporated to give pure alcohol 2.13 as
a colorless oil (5.208 g, 80%). 1H NMR (400 MHz, CDCl3) δ 7.23 and 6.82 (AA’BB’, JAB
= 8.6 Hz, 4H), 5.85-5.73 (m, 2H), 5.01–4.86 (m, 4H), 2.13–1.80, (m, 9H), 1.01 (s, 9H),
0.22 (s, 6H) ppm.

13

C NMR (100 MHz, CDCl3) δ 154.2, 140.0, 138.4, 126.4, 119.6, 114.6,

76.8, 42.2, 28.2, 25.8, 18.3, -4.3 ppm.
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1-(4-((tert-Butyldimethylsilyl)oxy)phenyl)cyclohept-4-en-1-ol (2.14). To a solution of
2.13 (0.313 g, 0.903 mmol) in dry CH2Cl2 (100 mL, 0.01 M) was added a solution of
Grubbs I catalyst (0.029 g, 0.032 mmol, 4%) in CH2Cl2 (10 mL) via syringe pump over 10
h and the mixture was stirred at 40 °C for 24 h. Reaction mixture was cooled to room
temperature, quenched with DMSO (50 eq, 0.15 mL) and continued to stir for another 12
h. The mixture was concentrated to a dark brown crude material and directly subjected to
the column chromatography (SiO2, hexanes- diethyl ether = 80:20) to give 2.14 (0.247 g,
86%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.35 and 6.79 (AA’BB’, JAB = 8.7
Hz, 4H), 5.86-5.79 (m, 2H), 2.54-2.43 (m, 2H), 2.10–1.94 (m, 4H), 1.90-1.82 (m, 2H), 1.73
(s,1H), 0.99 (s, 9H), 0.20 (s, 6H) ppm.

13

C NMR (100 MHz, CDCl3)  154.5, 142.9, 132.3,

125.9, 119.8, 76.7, 40.3, 25.7, 23.2, 18.3, -4.2 ppm.

tert-Butyl(4-(cyclohept-4-en-1-yl)phenoxy)dimethylsilane (2.15). To a solution of 2.14
(1.601 g, 5.034 mmol) in anhydrous CH2Cl2 (20 mL) was added triethylsilane (0.8 mL, 5.0
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mmol) followed by TFA (4.0 mL, 20 mmol). The mixture was stirred at room temperature
for 3 h while monitoring the reaction by TLC. After detecting the decomposition of both
starting material and product, the solution was concentrated to a dark brown oil and directly
subjected to the column chromatography (SiO2, hexanes = 100%) to give 2.15 as a lightyellow oil (0.906 g, 60%). 1H NMR (400 MHz, CDCl3)  7.05 and 6.78 (AA’BB’, JAB =
8.7 Hz, 4H), 5.92-5.89 (m, 2H), 2.69 (tt, J = 11.2, 3.2 Hz, 1H), 2.36-2.27 (m, 2H), 2.242.14 (m, 2H), 1.93-1.85 (m, 2H), 1.55-1.44 (m, 2H), 1.01 (s, 9H), 0.22 (s, 6H) ppm.

13

C

NMR (100 MHz, CDCl3)  153.6, 142.1, 132.7, 127.7, 120.0, 49.8, 35.2, 28.1, 25.9, 18.3,
-4.2 ppm.

tert-Butyl(4-(cyclohept-4-en-1-yl)phenoxy)dimethylsilane (2.15).

To a solution of

phenol 2.15a (0.212 g, 1.13 mmol) in anhydrous CH2Cl2 (20 mL) was added imidazole
(0.230 g, 3.38 mmol) while stirring at 0 ˚C under N2. After 30 min tert-butyldimethyl silyl
chloride (0.254 g, 1.69 mmol) was added at 0 ˚C and mixture was gradually warmed to
room temperature overnight. The resulting mixture was diluted with brine (20 mL) and
extracted with CH2Cl2 (2 x 20 mL). The combined organic extracts were dried (Na2SO4),
concentrated and purified by column chromatography (SiO 2, hexanes-ethyl acetate =
90:10) to give 2.15 as a light-yellow oil (0.240, 70%). The 1H NMR spectral data was
identical to that previously obtained.
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4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)cycloheptan-1-ol (2.16). To a solution of
2.15 (0.906 g, 2.99 mmol) in freshly distilled THF (20 mL) at 0 ˚C under N2 was added
dropwise a solution of borane-tetrahydrofuran complex (1M in THF, 6.0 mL, 6.0 mmol).
The solution was gradually warmed to room temperature and stirred for 18 h. The reaction
mixture was cooled to 0 ˚C, and water (250 mL) was added slowly followed by 30%
hydrogen peroxide (4.5 mL) and 1N sodium hydroxide (7.5 mL). The resulting solution
was stirred at room temperature for another 30 min and extracted with ethyl acetate (2 x
25 mL), concentrated and purified by column chromatography (SiO2, hexanes-ethyl acetate
= 80:20) to give 2.16 (0.880 g, 92%) as a yellow oil. This was determined to be a mixture
of diastereoisomers by 1H and 13C NMR spectroscopy. 1H NMR (400 MHz, CDCl3) δ 7.01
(m, 2H), 6.74 (m, 2H), 4.06-3.99 and 3.98-3.90 (2 x m, 1H total), 2.69-2.53 (m, 1H), 2.141.49 (m, 11H), 0.97 (s, 9H), 0.18 (s, 6H) ppm.

13

C NMR (100 MHz, CDCl3)  153.6, 142.1,

127.5, 120.0, 73.0, 71.9, 46.4, 46.1, 38.3, 37.8, 37.3, 37.1, 37.0, 35.9, 31.8, 29.8, 25.9, 23.5,
21.5, 18.4, - 4.2 ppm.
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4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)cycloheptan-1-one (2.17). To a solution of
2.16 (0.050 g, 0.16 mmol) in CH2Cl2 (10 mL) at room temperature, was added Dess–Martin
periodinane (0.132 g, 0.312 mmol) and water (0.1 mL) and mixture was stirred at room
temperature for 6 h. The mixture was quenched with 1:1 mixture of saturated Na2S2O3 and
NaHCO3 solution and continued to stir for another 30 min. The resulting solution was
extracted with CH2Cl2 (2 x 20 mL), dried (Na2SO4), concentrated and purified by column
chromatography (SiO2, hexanes-ethyl acetate = 80:20) to afford 2.17 (0.036 g, 72%) as a
colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.01 and 6.75 (AA’BB’, JAB = 8.6 Hz, 4H),
2.72–2.51 (m, 5H), 2.13–2.06 (m, 1H), 2.04–1.95 (m, 2H), 1.86–1.68 (m, 2H), 1.62–1.52
(m, 1H), 0.97 (s, 9H), 0.18 (s, 6H) ppm.

13

C NMR (100 MHz, CDCl3) δ 215.3, 153.9,

140.6, 127.5, 120.1, 48.1, 44.0, 43.1, 38.7, 32.2, 25.9, 24.1, 18.3, -4.2 ppm.
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tert-Butyldimethyl(4-(4-methylenecycloheptyl)phenoxy)silane (2.18).

To a stirred

solution of PPh3CH3Br (0.476 g, 1.33 mmol) in anhydrous THF (20 mL) at -10˚C under
N2, was added a solution of n-butyl lithium (1.6 M in hexanes, 0.83 mL, 1.3 mmol)
dropwise. After complete addition, the deep yellow mixture was stirred for another 45 min
at -10˚C before slowly adding a solution of 2.17 (0.212 g, 0.667 mmol) in THF. The
solution changed from a deep to light yellow in color, and the mixture was gradually
warmed to room temperature and stirred overnight. The solution was diluted with water
(20 mL) and aqueous layer was extracted with ethyl acetate (2 × 25 mL). The combined
organic extracts were washed with brine and dried (Na2SO4). Removal of the solvent and
purification from column chromatography (SiO2, hexanes–ethyl acetate = 90:10) gave 2.18
(0.120 g, 57%) as a light-yellow oil.

1

H NMR (400 MHz, CDCl3) δ 7.03 and 6.75

(AA’BB’, JAB = 8.7 Hz, 4H), 4.76 (s, 2H), 2.59–2.45 (m, 2H), 2.37–2.26 (m, 2H), 2.01–
1.85 (m, 3H), 1.70–1.48 (m, 4H), 1.00 (s, 9H), 0.20 (s, 6H) ppm.

13

C NMR (100 MHz,

CDCl3) δ 153.4, 151.9, 142.3, 127.7, 120.0, 110.7, 47.6, 40.0, 37.2, 36.3, 35.4, 27.6, 25.9,
18.4, -4.2 ppm.

126

4-(4-(Hydroxymethyl)cycloheptyl)phenol (2.10). To a solution of 2.18 (0.320 g, 1.01
mmol) in freshly distilled THF (10 mL) at 0 ˚C, was added dropwise a solution of boranetetrahydrofuran complex (1M in THF, 2.1 mL, 2.1 mmol). The resulting mixture was
warmed to room temperature and stirred for 18 h. The reaction mixture was cooled to 0
˚C, and pure ethanol (85 mL) was added slowly followed by 30% hydrogen peroxide (2.0
mL) and 3N sodium hydroxide (2.5 mL). The mixture was stirred for 1 h at room
temperature, extracted with ethyl acetate (2 × 20 mL), dried (Na2SO4), and the solvent
evaporated. The crude material was purified by column chromatography (SiO2, hexanesethyl acetate = 60:40) to give 2.10 (0.088 g, 40%) as a colorless solid. This was determined
to be a mixture of diastereoisomers by 1H and 13C NMR spectroscopy. mp 60-63 °C. 1H
NMR (400 MHz, CDCl3) δ 7.03 and 6.74 (AA’BB’, JAB = 8.7 Hz, 4H), 5.53 (s, OH), 3.48
(d, J = 6.4 Hz, 2H), 2.65–2.49 (m, 1H), 1.97–1.30 (m, 12H).

13

C NMR (100 MHz, CDCl3)

δ 153.8, 142.0, 141.8, 127.7, 115.4, 68.8, 68.5, 47.2, 46.1, 42.2, 41.3, 38.9, 36.7, 36.5, 33.0,
31.5, 30.6, 29.9, 28.5, 27.5, 24.3 ppm. The NMR spectral data is consistent with previously
observed values.
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(4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)cycloheptyl)methanol (2.19) To a solution
of 2.18 (0.821 g, 2.60 mmol) in freshly distilled THF (10 mL) at 0 ˚C, was added dropwise
a solution of borane-tetrahydrofuran complex (1M in THF, 5.4 mL, 5.4 mmol). The
resulting mixture was warmed to room temperature and stirred for 18 h. The reaction
mixture was cooled to 0 ˚C, and 1N sodium hydroxide (3.2 mL) was added slowly followed
by 30% hydrogen peroxide (1.5 mL). The mixture was stirred for 1 h at room temperature,
extracted with ethyl acetate (2 × 25 mL), dried (Na2SO4), and the solvent evaporated. The
crude material was purified by column chromatography (SiO2, hexanes-ethyl acetate =
80:20) to give 2.19 (0.572 g, 66%) as a colorless oil. This was determined to be a mixture
of diastereoisomers by 1H and 13C NMR spectroscopy. 1H NMR (400 MHz, CDCl3) δ 7.02
and 6.74 (AA’BB’, JAB = 8.3 Hz, 4H), 3.45 (d, J = 6.5 Hz, 2H), 2.67–2.53 (m, 1H), 1.98–
1.38 (m, 11H), 1.29-1.09 (m, 1H), 0.98 (s, 9H), 0.19 (s, 6H) ppm.

13

C NMR (100 MHz,

CDCl3) δ 153.5, 142.6, 142.4, 127.6, 127.5, 119.9, 68.7, 68.5, 47.3, 46.1, 42.2, 41.2, 38.9,
36.8, 36.4, 33.1, 31.5, 30.7, 30.0, 28.5, 27.6, 26.1, 24.2, 18.3, -4.2 ppm.
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4-(4-(Hydroxymethyl)cycloheptyl)phenol (2.10). To a solution of 2.19 (0.873 g, 2.61
mmol) in anhydrous THF (20 mL) was added a solution of TBAF (1M in THF, 10.0 mL,
0.010 mol) while stirring. The mixture was heated to reflux at 70 ˚C overnight and cooled
to room temperature. The solution was partitioned between ethyl acetate and water. The
organic layer was washed with brine, dried (Na2SO4) and concentrated. Purification by
column chromatography (SiO2, hexanes-ethyl acetate = 60:40) gave 2.10 (0.508 g, 88%)
as a colorless solid. mp 60-63 °C. The 1H NMR spectral data is consistent with that
previously obtained.

4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)cyclohexan-1-one (2.21).

To a stirred

solution of 4-(4-hydroxyphenyl)cyclohexanone 2.20 (4.0 g, 0.021 mol) in anhydrous
CH2Cl2 (40 mL) at 0 ˚C was added imidazole (4.3 g, 0.063 mol) under N2. After 30 min
tert-butyldimethyl silyl chloride (4.6 g, 0.032 mol) was added at 0 ˚C and mixture was
gradually warmed to room temperature overnight. The resulting mixture was diluted with
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brine (25 mL) and partitioned with CH2Cl2 (2 x 30 mL). The combined organic extracts
were dried (Na2SO4), concentrated and purified by column chromatography (SiO2,
hexanes-ethyl acetate = 90:10) to give 2.21 (6.081 g, 95%) as a colorless solid. mp 39-42
°C. 1H NMR (400 MHz, CDCl3) δ 7.08 and 6.78 (AA’BB’, JAB = 8.4 Hz, 4H), 2.96 (br t,
J = 12.3 Hz, 1H), 2.56–2.40 (m, 4H), 2.25–2.14, (m, 2H), 1.97–1.82 (m, 2H), 0.98 (s, 9H),
0.19 (s, 6H) ppm.

13

C NMR (400 MHz, CDCl3) δ 211.6, 154.3, 137.7, 127.7, 120.1, 42.2,

41.6, 34.6, 25.9, 18.4, -4.2 ppm.

Ethyl

5-(4-((tert-butyldimethylsilyl)oxy)phenyl)-2-oxocycloheptane-1-carboxylate

(2.22). To a solution of ketone 2.21 (1.14 g, 3.74 mmol) in anhydrous diethyl ether (15
mL) at 0 ˚C under N2 was added an aliquot of BF3.Et2O (0.92 mL, 7.5 mmol). A solution
of ethyl diazoacetate (0.77 mL, 7.47 mmol) in anhydrous ether (5 mL) was added dropwise
over a period of 20 min and the resulting solution was stirred at room temperature for 12
h. The reaction mixture was cooled to 0 °C and neutralized with saturated sodium
bicarbonate solution (20 mL). The resulting mixture was extracted with CH3Cl3 (3 x 15
mL), the combined organic extracts washed with brine (20 mL), dried (Na2SO4) and
concentrated. The dark yellow crude oil was purified by column chromatography (SiO2,
hexanes-diethyl ether = 70:30) to give keto ester 2.22 (1.182 g, 81%) as a colorless oil.
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The product is in equilibrium with its keto-enol tautomer. 1H NMR (400 MHz, CDCl3) δ
12.74 (s, 0.4H), 7.02-6.97 (m, 2H), 6.77-6.72 (m, 2H), 4.27-4.16 (m, 2H), 3.64-3.56 (m,
0.3H), 2.94–2.78 (m, 1H), 2.72-2.58 (m, 2H), 2.48-2.24 (m, 1H), 2.16-1.76 (m, 4H), 1.651.54 (m, 1H), 1.32 and 1.29 (2 x t, J = 7.2 Hz, 3H total), 0.97 (s, 9H), 0.18 (s, 6H) ppm.
13

C NMR (100 MHz, CDCl3) δ 209.0, 208.8, 178.9, 173.0, 170.6, 154.0, 140.9, 139.9,

127.7, 127.5, 120.2, 120.0, 101.5, 61.4, 60.7, 59.6, 58.5,49.6, 47.9, 47.2, 42.2, 36.8, 35.4,
34.6, 32.8, 32.2, 27.8, 25.9, 23.9, 22.6, 18.4, 14.5, -4.2 ppm.

4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)cycloheptan-1-one (2.17).

To a stirred

solution of 2.22 (1.74 g, 4.46 mmol) in DMSO (20 mL) at room temperature was added
sequentially lithium chloride (1.3 g, 0.031 mol) and water (2.8 mL) at room temperature.
The mixture was heated to reflux at 160 °C for 5 h, cooled to room temperature and poured
into water. The resulting solution was extracted with ether and ethyl acetate (3 x 20 mL),
washed with brine, dried (Na2SO4) and evaporated in vacuo to provide desired product 2.17
(1.114 g, 78%) as a colorless oil. The NMR spectral data for the product is consistent with
that previously obtained.
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4-(4-Hydroxycycloheptyl)phenol (2.23). To a stirred solution of 2.6 (0.028 g, 0.13 mmol)
in anhydrous CH2Cl2 (30 mL) at -78˚C, was added dropwise a solution of boron tribromide
in CH2Cl2 (1M, 0.3 mL, 0.03 mmol). After complete addition, the reaction mixture was
stirred for 30 min at -78˚C and gradually warmed to room temperature over a 2 h period.
The mixture was quenched with water (10 mL) and aqueous layer was extracted with
CH2Cl2 (3 × 20 mL). The combined organic extracts were washed with brine and dried
(MgSO4). Evaporation of the solvent gave 2.23 (0.024 g, 86%) as a yellow crystalline
solid. This product was determined to be a mixture of cis- and trans-stereoisomers on the
basis of 1H and

13

C NMR. 1H NMR (400 MHz, CDCl3) δ 7.11-6.99 (m, 2H), 6.80-6.70

(m, 2 H), 4.85 (s, OH), 4.56-4.48 and 4.42-4.34 (2 × m, 1H total), 2.78–2.59 (m, 1H), 2.53–
1.38 (m, 11H) ppm.

13

C NMR (100 MHz, CDCl3)  153.5, 141.0, 127.7, 115.9, 56.1, 55.7,

45.9, 45.3, 40.0, 39.4, 39.2, 37.7, 37.6, 36.3, 34.2, 31.3, 25.2, 23.5 ppm.
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4-(4-Hydroxyphenyl)cycloheptanone (2.24). A sample of 2.7 (0.074 g, 0.339 mmol) was
dissolved in 48 % HBr (8 mL) and the mixture heated to reflux at 115 ˚C for 2 h. Then the
mixture was cooled to room temperature and portioned between ethyl acetate and water.
The organic layer was washed with sodium bicarbonate solution, followed by brine, dried
(Na2SO4) and concentrated. The residue was purified by column chromatography (SiO2,
hexanes-ethyl acetate = 20:80) to give 2.24 (0.057 g, 82%) as a brown syrup. 1H NMR
(400 MHz, CD3OD) δ 6.98 and 6.70 (AA’BB’, JAB = 8.5 Hz, 4H), 4.98 (s, 1H), 2.77–2.39
(m, 4H), 2.02–1.47 (m, 7H) ppm.

13

C NMR (100 MHz, CD3OD) δ 218.1, 156.4, 140.3,

128.5, 116.1, 49.0, 44.6, 43.7, 39.6, 33.1, 24.3 ppm.

4-(4-Hydroxyphenyl)cycloheptanone oxime (2.25). To a solution of 2.24 (0.048 g, 0.23
mmol) in ethanol (10 mL), was added sodium bicarbonate (0.024 g) and hydroxylamine
hydrochloride (0.023 g, 0.32 mmol). The mixture was stirred at room temperature for 5 h
and extracted with ethyl acetate (2 × 10 mL). The combined organic extracts were dried
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(MgSO4) and concentrated. Purification of the residue by column chromatography (SiO2,
hexanes-ethyl acetate = 65:35) gave 2.25 as a light brown gum (0.026 g, 52%). 1H NMR
(400 MHz, CD3OD) δ 6.98 and 6.67 (AA’BB’, JAB = 8.5 Hz, 4H), 2.86-2.30 (m, 4H), 2.091.20 (m, 8H) ppm.

13

C NMR (100 MHz, CD3OD) δ 165.0, 164.8, 156.4, 156.3, 141.3,

140.4, 128.5, 128.3, 116.1, 40.0, 39.7, 37.1, 34.1, 33.7, 33.3, 29.6, 28.4, 27.9, 24.8 ppm.

4-(4-hydroxyphenyl)-1-methylcycloheptan-1-ol (2.26). To a solution of 2.24 (0.158 g,
0.773 mmol) in dry Et 2O (15 mL) at -78 °C under N2, was added slowly a solution of
methyllithium-lithium bromide complex (1.5 M in ether, 1.1 mL, 1.7 mmol). The mixture
was stirred for another 30 min at -78 °C, warmed to room temperature and stirred for
another 1 h. The mixture was cooled to 0 °C and quenched with water. The mixture was
extracted with diethyl ether (2 × 30 mL), dried (Na2SO4) and concentrated. The residue
was purified from column chromatography (SiO2, hexanes-ethyl acetate = 80:20) to give
2.26 (0.068 g, 40%) as a colorless solid. 1H NMR (400 MHz, MeOD) δ 6.97 and 6.67
(AA’BB’, JAB = 8.5 Hz, 4H), 2.63–2.44 (m, 1H), 1.97–1.30 (m, 10H), 1.23 (s, 1H) 1.21 (s,
2H) ppm.

13

C NMR (100 MHz, MeOD) δ 156.3, 141.7, 128.6, 128.4, 116.0, 74.6, 74.5,

64.4, 44.2, 43.4, 42.8, 40.8, 40.4, 39.0, 38.5, 31.5, 31.2, 23.7, 23.6 ppm.
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Methyl-2-(4-(4-methoxyphenyl)cycloheptylidene)acetate (2.27). Sodium hydride (32
mg, 55% in mineral oil, 0.80 mmol) was added to a stirring solution of trimethyl
phosphonoacetate (0.130 mL, 0.80 mmol) in dry THF (3 mL) at 0 °C. After 45 min, a
solution 4-(4-methoxyphenyl)cycloheptanone 2.27 (0.147 g, 0.673 mmol) in dry THF (5
mL) was added and the reaction mixture was stirred at room temperature for 12 h. The
mixture was diluted with water (15 mL) and the resulting mixture was extracted with ether
(2 × 20 mL), dried (MgSO4) and concentrated. The residue was purified by column
chromatography (SiO2, hexanes–ethyl acetate = 90:10) to give 2.27 (0.057 g, 31%) as a
colorless oil. The product was determined to be a mixture of E and Z stereoisomers from
1

H and 13C NMR spectroscopy. 1H NMR (400 MHz, CDCl3) δ 7.08 and 6.82 (AA’BB’,

JAB = 8.1 Hz, 4H), 5.74 (s, 1H), 3.78 (s, 3H), 3.69 (d, J = 3.6 Hz, 3H), 2.86 (broad t, J =
14.9 Hz, 1H), 2.72-2.36 (m, 3H), 2.10-1.86 (m, 3H), 1.80-1.44 (m, 6H) ppm. (Solvent
peaks are overlapped in 1.30-2.20 ppm region).

13

C NMR (100 MHz, CDCl3) δ 167.2,

167.1, 166.8, 166.6, 157.9, 157.8, 141.1, 140.7, 127.6, 115.5, 113.9, 77.6, 55.4, 51.0, 47.7,
47.1, 38.9, 38.2, 38.0, 37.4, 36.7, 35.3, 32.6, 31.3, 27.2, 25.9, 22.9, 14.3 ppm.
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(Z)-2-(4-(4-Methoxyphenyl)cycloheptylidene)ethan-1-ol (2.28). To a solution of 2.27
(0.200 g, 0.730 mmol) in dry CH2Cl2 (5 mL) under nitrogen at –40 ˚C was added a solution
of diisobutylaluminum hydride in CH2Cl2 (1.58 mL, 1.2 M, 1.9 mmol). After 90 min,
saturated aqueous potassium sodium tartrate was added and reaction mixture was gradually
warmed to room temperature. After 4 h the mixture was filtered through a pad of celite
and extracted several times with water (2 × 15 mL). The combined organic layers were
dried (MgSO4), and concentrated to give 2.28 (0.078 g, 43%) as a colorless gum. The
crude product was used in the next step without any further purification. 1H NMR (400
MHz, CDCl3) δ 7.09 and 6.83 (AA’BB’, JAB = 8.7 Hz, 4H), 5.50-5.42 (m, 1H), 4.19 (d, J
= 7.2 Hz, 2H), 3.79 (s, 3H), 2.67-2.19 (m, 4H), 2.14-1.85 (m, 4H), 1.69-1.44 (m, 3H) ppm.
13

C NMR (100 MHz, CDCl3) δ 157.7, 145.1, 141.5, 141.3, 129.4, 127.6, 127.6, 124.2,

124.1, 113.8, 59.2, 55.4, 47.6, 47.0, 38.3, 37.6, 37.4, 36.8, 36.1, 30.2, 29.2, 27.8, 26.5 ppm.
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4-(4-(2-Hydroxyethyl)cycloheptyl)phenol (2.30). To a solution of compound 2.28 (0.078
g, 0.32 mmol) in methanol (10 mL) was added 10% Pd/C (0.040 g, 10 mol %). The mixture
was stirred under H2 balloon at room temperature for 12 h. The reaction mixture was
filtered through a pad of celite, concentrated and dried (MgSO4) to give the crude
hydrogenated product (0.080 g, 0.323 mmol).

The crude product was dissolved in

anhydrous CH2Cl2 (8 mL), cooled to -78˚C, and a solution of boron tribromide (1M in
CH2Cl2, 0.97 mL, 0.97 mmol) was added dropwise. After complete addition, the reaction
mixture was stirred for 30 min at -78˚C and gradually warmed to room temperature over a
2 h period. The mixture was quenched with water (5 mL) and the aqueous layer was
extracted with CH2Cl2 (3 × 10 mL). The combined organic extracts were washed with
brine and dried (MgSO4).

Evaporation of the solvent and purification by column

chromatography (SiO2, hexanes-ethyl acetate = 65:35) gave 2.30 (0.005 g, 7%) as a light
brown solid. This was determined to be a mixture of diastereoisomers by 1H and 13C NMR
spectroscopy. 1H NMR (400 MHz, CDCl3) δ 7.04 and 6.74 (AA’BB’, JAB = 8.7 Hz, 4H),
3.71 (td, J = 6.9, 1.4 Hz, 2H), 2.66-2.48 (m, 1H), 1.96-1.13 (m, 13H) ppm.

13

C NMR (100

MHz, CDCl3) δ 153.6, 142.2, 127.8, 115.3, 61.5, 47.1, 45.9, 41.1, 40.9, 38.8, 36.8, 36.3,
35.9, 35.4, 34.8, 34.5, 33.9, 33.0, 32.1, 27.3, 24.4 ppm.
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Methyl 4-hydroxy-3-methylbenzoate (2.32).

To a solution of 4-hydroxy-3-

methylbenzoic acid 2.31 (5.000 g, 0.033 mol) in anhydrous methanol (80 mL) was added
dropwise through an addition funnel SOCl2 (5 mL, 0.066 mol) over 1 h while stirring at 0
°C. After 30 min the system was heated at reflux overnight under N2. The resulting
mixture was cooled to the room temperature and diluted with water (50 mL). Methanol
was evaporated and the pH was adjusted to pH =7 with saturated sodium bicarbonate
solution (15 mL). The resulting solution was extracted with ethyl acetate (3 × 40 mL).
The combined organic extracts were washed with brine (20 mL), dried (Na2SO4), and
concentrated to give methyl ester 2.32 (4.80 g, 88%) as a light orange solid. mp 124-125
°C. 1H NMR (400 MHz, CDCl3)  7.84 (s, 1H), 7.78 (d, J = 8.3 Hz, 1H), 6.83 (d, J = 8.4
Hz, 1H), 6.48 (s, OH), 3.89 (s, 3H), 2.27 (s, 3H) ppm.

13

C NMR (100 MHz, CDCl3) 

168.0, 158.9, 133.1, 129.6, 124.4, 122.0, 115.4, 52.4, 16.0 ppm. The 1H and
spectral data are consistent with the literature values. 117-118

13

C NMR
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Methyl 4-((tert-butyldimethylsilyl)oxy)-3-methylbenzoate (2.33). To a stirred solution
of 2.32 (0.500 g, 3.01 mmol) in anhydrous CH2Cl2 (25 mL) at 0 ˚C under N2, was added
imidazole (0.410 g, 6.02 mmol). After 30 min tert-butyldimethyl silyl chloride (0.680 g,
4.52 mmol) was added at 0 ˚C and mixture was gradually warmed to room temperature
overnight. The resulting mixture was diluted with brine (25 mL) and partitioned with
CH2Cl2 (2 x 20 mL). The combined organic extracts were dried (Na2SO4), concentrated in
vacuo and purified by column chromatography (SiO2, hexanes-ethyl acetate = 10:90) to
give 2.33 (0.712 g, 84%) as a colorless gum. 1H NMR (400 MHz, CDCl3)  7.84 (d, J =
2.3 Hz, 1H), 7.77 (dd, J = 2.3, 8.4 Hz, 1H), 6.77 (d, J = 8.4 Hz, 1H), 3.86 (s, 3H), 2.22 (s,
3H), 1.01 (s, 9H), 0.23 (s, 6H) ppm.

13

C NMR (100 MHz, CDCl3)  167.2, 158.4, 132.7,

129.1, 128.8, 123.1, 118.1, 51.9, 25.9, 18.3, 16.9, -3.8 ppm.

5-(4-((tert-Butyldimethylsilyl)oxy)-3-methylphenyl)nona-1,8-dien-5-ol (2.34).

Dry

magnesium turnings (2.65 g, 0.110 mol) were placed in a flame dried three-necked flask
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under N2 followed by THF (25 mL). A solution of 4-bromo-1-butene (6.70 mL, 0.066 mol)
in THF (20 mL) was loaded to the addition funnel and a small amount of bromobutene
solution (2 mL) was added slowly to the magnesium turnings. The solution was heated at
65 ˚C to reflux. Once the Grignard formation was started, the remaining bromide solution
was added dropwise over 45 min. The reaction was stirred until most of the magnesium
had reacted and solution of 2.33 (3.086 g, 0.011 mol) in THF (15 mL) was filled into the
addition funnel and added dropwise over 30 min. The mixture was gradually cooled and
stirred at ambient temperature overnight. A solution of saturated NH4Cl (30 mL) was
slowly added in order to quench the reaction and resultant emulsion was stirred for 1 h.
The mixture was extracted with ether (3 x 30 mL) and the combined organic extracts were
washed with brine (2 x 20 mL) and dried (Na2SO4). The solvent was removed to give
alcohol 2.34 (2.217 g, 56%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.13 (d, J =
2.4 Hz, 1H), 7.03 (dd, J = 2.6, 8.4 Hz, 1H), 6.74 (d, J = 8.4 Hz, 1H), 5.85-5.74 (m, 2H),
4.99–4.88 (m, 4H), 2.22 (s, 3H), 2.11–1.97 (m, 2H), 1.93-1.81 (m, 7H), 1.02 (s, 9H), 0.22
(s, 6H) ppm.

13

C NMR (100 MHz, CDCl3) δ 152.5, 139.2, 138.1, 128.5, 128.1, 123.6,

118.1, 114.6, 77.1, 42.2, 28.3, 25.9, 18.4, 17.4, -4.0 ppm.

1-(4-((tert-Butyldimethylsilyl)oxy)-3-methylphenyl)cyclohept-4-en-1-ol

(2.35).

Alcohol 2.34 (0.974 g, 2.70 mmol) was cyclized using Grubbs’ catalyst I (0.090 g, 0.108
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mmol, 4%) in a fashion similar to the preparation of 2.14. Purification of the crude product
by column chromatography (SiO2, hexanes-diethyl ether = 80:20) gave 2.35 (0.573 g, 64%)
as a light green oil. 1H NMR (400 MHz, CDCl3) δ 7.28 (br d, J = 2.3 Hz, 1H), 7.18 (dd, J
= 2.5, 8.4 Hz, 1H), 6.72 (d, J = 8.5 Hz, 1H), 5.87-5.82 (m, 2H), 2.50 (br t, J = 13.3 Hz, 2H),
2.22 (s, 3H), 2.11–1.97 (m, 4H), 1.91-1.83 (m, 2H), 1.68 (s, 1H), 1.02 (s, 9H), 0.22 (s, 6H)
ppm.

13

C NMR (100 MHz, CDCl3)  152.6, 142.7, 132.3, 128.4, 127.7, 122.9, 117.9, 77.1,

40.3, 25.9, 23.3, 18.5, 17.2, -4.0 ppm.

tert-Butyl(4-(cyclohept-4-en-1-yl)-2-methylphenoxy)dimethylsilane (2.36).

Ionic

reduction of tertiary alcohol 2.35 (0.209 g, 0.623 mmol) in anhydrous CH2Cl2 (15 mL)
with triethylsilane (0.1 mL, 0.626 mmol) and TFA (0.5 mL, 6.23 mmol) was carried out in
a fashion similar to the preparation of 2.15. Purification of the crude product by column
chromatography (SiO2, hexanes = 100%) gave 2.36 (0.113 g, 57%) as a colorless oil. 1H
NMR (400 MHz, CDCl3)  7.00 (d, J = 2.2 Hz, 1H), 6.91 (dd, J = 8.1, 2.2 Hz, 1H), 6.72
(d, J = 8.4 Hz, 1H), 5.94-5.90 (m, 2H), 2.68 (tt, J = 11.5, 3.4 Hz, 1H), 2.38-2.28 (m, 2H),
2.27-2.16 (m, 5H), 1.95-1.87 (m, 2H), 1.58-1.44 (m, 2H), 1.06 (s, 9H), 0.26 (s, 6H) ppm.
13

C NMR (100 MHz, CDCl3)  151.9, 142.1, 132.7, 129.5, 128.8, 125.1, 118.4, 49.7, 35.1,

28.1, 25.9, 18.3, 17.2, -4.0 ppm.
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4-(4-((tert-Butyldimethylsilyl)oxy)-3-methylphenyl)cycloheptan-1-ol (2.37).

The

hydroboration-oxidation of cycloheptene 2.36 (0.334 g, 1.06 mmol) was carried out in a
fashion similar to the preparation of 2.16. Purification of the crude product by column
chromatography (SiO2, hexanes-ethyl acetate = 80:20) gave 2.37 (0.116 g, 33%) as a
colorless oil. This was determined to be a mixture of diastereoisomers by 1H and 13C NMR
spectroscopy. 1H NMR (400 MHz, CDCl3) δ 6.94 (d, J = 7.9 Hz, 1H), 6.84 (br t, J = 7.4
Hz, 1H), 6.66 (d, J = 8.3 Hz, 1H), 4.06-3.99 and 3.98-3.89 (2× m, 1H total), 2.66-2.49 (m,
1H), 2.18 (s, 3H), 2.13-2.05 (m, 1H), 2.02-1.48 (m, 10H), 1.00 (s, 9H), 0.20 (s, 6H) ppm.
13

C NMR (100 MHz, CDCl3) δ 151.9, 141.9, 141.8, 129.4, 128.7, 124.6, 118.3, 73.1, 71.9,

46.4, 46.1, 38.3, 37.9, 37.3, 37.2, 37.0, 35.9, 31.9, 29.8, 26.0, 21.5, 18.4, 17.2, -4.0 ppm.
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4-(4-Hydroxy-3-methylphenyl)cycloheptan-1-ol (2.38). To a solution of 2.37 (0.100 g,
0.299 mmol) in anhydrous THF (15 mL) was added a solution of tetrabutylammonium
fluoride (1M in THF, 1.2 mL, 1.2 mmol). The mixture was heated at 70 ˚C overnight and
cooled to room temperature. The solution was partitioned between ethyl acetate (2 x 15
mL) and water (2 x 10 mL). The organic layer was washed with brine, dried (Na2SO4) and
concentrated. Purification by column chromatography (SiO2, hexanes-ethyl acetate =
50:50) gave 2.38 (0.035g, 53%) as a colorless solid. 1H NMR (400 MHz, CDCl3) δ 6.92
(d, J = 8.2 Hz, 1H), 6.86 (br t, J = 7.3 Hz, 1H), 6.69 (d, J = 8.2 Hz, 1H), 5.84 (s, OH) 4.084.01 and 4.00-3.90 (2 x m, 1H total), 2.66-2.44 (m, 1H), 2.22 (s, 3H), 2.16-1.48 (m, 11H)
ppm.

13

C NMR (100 MHz, CDCl3) δ 152.4, 141.4, 129.4, 124.9, 124.0, 114.9, 73.2, 72.1,

46.4, 46.1, 38.4, 37.9, 37.1, 37.0, 36.9, 35.7, 31.9, 29.8, 23.5, 21.5, 16.2 ppm.
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4-(6-Oxabicyclo[3.2.2]nonan-5-yl)phenol (2.42).

Cyclic ether formation of 4-(4-

(hydroxymethyl)cycloheptyl)phenol 2.10 (0.075 g, 0.34 mmol) was carried out in a
fashion similar to the preparation of 3.8. Purification by column chromatography (SiO2,
hexanes-ethyl acetate = 60: 40) gave 2.42 (0.049 g, 66%) as a light yellow viscous oil. 1H
NMR (400 MHz, CDCl3) δ 7.15 and 6.58 (AA’BB’, JAB = 7.8 Hz, 4H), 6.30 (s, 1H), 4.07–
3.96 (m, 1H), 3.90–3.84 (m, 1H), 2.25–1.60 (m, 11H) ppm.

13

C NMR (100 MHz, CDCl3)

δ 154.3, 142.5, 125.6, 114.9, 76.5, 69.9, 42.9, 33.8, 32.5, 30.3, 22.6, 21.5 ppm.

4-(4-methoxyphenyl)

Cyclohexanone

(2.40).

To

a

solution

of

4-(4-

hydroxyphenyl)cyclohexanone (0.500 g, 2.63 mmol) in DMF (10 mL) was added K2CO3
(0.545 g, 3.94 mmol) and iodomethane (0.21 mL, 0.485 g, 3.42 mmol). The reaction was
heated at reflux overnight. The reaction was cooled, diluted with H 2O and extracted with
ethyl acetate. The organic extracts were combined and washed with brine, dried (Na 2SO4)

144

and concentrated. The residue was purified by column chromatography (hexanes-ethyl
acetate = 80:20) to give 2.40 (0.238 g, 44%) as a colorless solid. mp 70-74 °C. [lit. mp 74
°C].90 1H NMR (CDCl3) δ 7.17 and 6.87 (AA’BB’, JAB = 8.6 Hz, 4H), 3.79 (s, 3H), 2.98
(tt, J = 11.9, 3.8 Hz, 1H), 2.56-2.44 (m, 4H), 2.24-2.15 (m, 2H) and 1.97-1.84 (m, 2H) ppm.
The NMR data was consistent with the literature values. 90

3-(4-Methoxyphenyl)cyclopentane-1-carboxylic acid (2.41).

To a solution of

cyclohexanone 2.40 (0.100 g, 0.490 mmol) in a heavy-walled reaction vessel was added
diphenyldiselinide (0.002 g, 0.005 mmol), t-BuOH (4 mL) and 30% H2O2 (0.4 mL). The
reaction vessel was sealed and heated at 100 °C for 4 d. After cooling the reaction vessel
was opened and 10% Pd/C (20 mg) was added and solvent was distilled off. The residue
was treated with 10% aqueous Na2CO3 (40 mL) and extracted with CH2Cl2 (3 × 20 mL).
The aqueous phase was adjusted to pH 1 with HCl and extracted with CH2Cl2 (3 × 25 mL).
The combined extracts were dried (Na2SO4) and concentrated. The residue was purified
by column chromatography (SiO2, hexanes-ethyl acetate = 60:40) to give 2.41 (0.044 g,
41%) as a colorless oil. This product was determined to be a mixture of cis- and transstereoisomers on the basis of 1H and 13C NMR spectroscopy. 1H NMR (400 MHz, CDCl3)
δ 7.18, 7.06 and 6.84 (AA’BB’, JAB = 8.7 Hz, 4H total), 3.79 (s, 3H), 3.24–3.16 (m, 0.4H),
3.15–2.92 (m, 1.6H), 2.72–2.63 (m, 0.3H), 2.42–2.33 (m, 0.7H), 2.21–1.69 (m, 5H) ppm.
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13

C NMR (100 MHz, CDCl3) δ 182.7, 179.9, 158.2, 136.5, 135.9, 128.9, 128.2, 114.0,

113.9, 59.5, 55.5, 45.7, 43.6, 38.5, 37.6, 34.2, 29.3, 27.7 ppm. The 1H NMR data for this
compound were consistent with the literature values. 92

(3-(4-Methoxyphenyl)cyclopentyl)methanol (2.42). To a solution of 2.41 (0.083 g, 0.377
mmol) in anhydrous THF (5 mL) at 0 °C under N2 was slowly added LiAlH4 (0.043 g, 1.13
mmol).

After addition was completed the reaction was gradually warmed to room

temperature and continued to stir for 3 h. The mixture was cautiously quenched with water
and extracted with ethyl acetate (3× 15 mL). The combined extracts were dried (Na 2SO4)
and concentrated. The residue was purified by column chromatography (SiO 2, hexanesethyl acetate = 80:20) to give 2.42 (0.042 g, 54%) as a colorless oil. This product was
determined to be a mixture of cis- and trans- stereoisomers on the basis of 1H and 13C NMR
spectroscopy. 1H NMR (400 MHz, CDCl3) δ 7.17 and 6.84 (AA’BB’, JAB = 8.7 Hz, 4H),
3.79 (s, 3H), 3.61 (d, J = 6.7 Hz, 1.7H), 3.57 (d, J = 7.1 Hz, 0.3H), 3.08–2.97 (m, 1H),
2.40–2.15 (m, 2H), 2.13–1.98 (m, 1H), 1.94–1.81 (m, 1H), 1.68–1.52 (m, 2H), 1.34–1.23
(m, 1H) ppm.

13

C NMR (100 MHz, CDCl3) δ 157.9, 137.7, 128.0, 113.8, 67.7, 67.6, 55.4,

45.3, 43.9, 42.0, 41.4, 38.5, 37.1, 35.1, 33.7, 29.4, 28.4 ppm.
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4-(3-(Hydroxymethyl)cyclopentyl)phenol (2.43). To a solution of 2.42 (0.030 g, 0.145
mmol) in anhydrous CH2Cl2 (8 mL) at -78 ˚C, was added dropwise a solution of boron
tribromide (1M in CH2Cl2, 0.44 mL, 0.44 mmol). After complete addition, the reaction
mixture was stirred for 30 min at -78˚C and gradually warmed to room temperature over a
2 h period. The mixture was quenched with water (10 mL) and the aqueous layer was
extracted with CH2Cl2 (3 × 15 mL). The combined organic extracts were washed with
brine, dried (MgSO4) and concentrated.

The residue was purified by column

chromatography (SiO2, hexanes-ethyl acetate = 50:50) to give 2.43 (0.010 g, 36%) as a
colorless solid.

This product was determined to be a mixture of cis- and trans-

stereoisomers on the basis of 1H and 13C NMR spectroscopy. 1H NMR (400 MHz, CDCl3)
δ 7.10 and 6.76 (AA’BB’, JAB = 8.2 Hz, 4H), 3.62 (d, J = 6.7 Hz, 1.6H), 3.58 (d, J = 7.2
Hz, 0.4H), 3.06–2.93 (m, 1H), 2.40–2.14 (m, 2H), 2.11–1.94 (m, 1H), 1.93–1.71 (m, 1H),
1.67–1.49 (m, 2H), 1.33–1.20 (m, 1H) ppm.

13

C NMR (100 MHz, CDCl3) δ 153.9, 137.7,

128.2, 115.3, 67.8, 67.7, 45.3, 44.0, 42.0, 41.4, 38.5, 37.2, 35.0, 33.7, 29.4, 28.4 ppm.
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4-(4-((tert-Butyldiphenylsilyl)oxy)phenyl)cyclohexan-1-one (3.2). To a solution of 4(4-hydroxyphenyl)cyclohexanone (0.815 g, 4.28 mmol) in dry CH 2Cl2 (30 ml ) at 0 °C,
was added imidazole (0.583 g 8.57 mmol). After stirring for 30 min, a solution of tbutyldiphenylsilyl chloride (1.60 mL, 5.57 mmol) in CH2Cl2 (9 mL) was added dropwise
while maintaining the temperature at 0 °C. The reaction mixture was slowly warmed to
room temperature and stirred for 12 h. The mixture was diluted with water (20 mL) and
partitioned with CH2Cl2 (40 mL). The organic portion was separated, washed with brine,
dried (Na2SO4), and concentrated. The residue was purified by column chromatography
(SiO2, hexanes-ethyl acetate = 80: 20) to give 3.2 (1.70 g, 93%) as a colorless solid. mp
83-84 °C. 1H NMR (400 MHz, CDCl3) δ 7.74-7.70 (m, 4H), 7.45-7.34 (m, 6H), 6.96 and
6.71 (AA’BB’, JAB = 8.6 Hz, 4H), 2.90 (tt, J = 12.1, 3.3 Hz, 1H), 2.49–2.42 (m, 4H), 2.19–
2.10 (m, 2H), 1.91–1.77 (m, 2H), 1.09 (s, 9H) ppm.

13

C NMR (100 MHz, CDCl3) δ 211.6,

154.3, 137.3, 135.7, 133.2, 130.1, 127.9, 127.5, 119.8, 42.1, 41.6, 34.3, 26.7, 19.7.
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tert-Butyl(4-(4-methylenecyclohexyl)phenoxy)diphenylsilane (3.3).
n

A solution of

butyllithium in hexane (1.6 M, 1.5 mL, 2.4 mmol) was added to a stirring solution of

methyltriphenylphosphonium bromide (0.836 g, 2.34 mmol) in dry THF (20 mL) at -10
°C. After 30 min, a solution of 4-(4-butyldiphenylsilyloxyphenyl)cyclohexanone 3.2
(0.502 g, 1.17 mmol) in dry THF (8 mL) was added dropwise. The reaction mixture was
slowly warmed to room temperature and stirred overnight. After this time, the mixture was
diluted with water (20 mL), extracted with ethyl acetate (2 ×25 mL), dried (Na 2SO4) and
concentrated. The residue was purified by column chromatography (SiO 2, hexanes-ethyl
acetate = 80:20) to give 3.3 (0.423 g, 85%) as a colorless oil. 1H NMR (400 MHz, CDCl3)
δ 7.75-7.71 (m, 4H), 7.46-7.34 (m, 6H), 6.93 and 6.69 (AA’BB’, J AB = 8.6 Hz, 4H), 4.65
(t, J = 1.7 Hz, 2H), 2.55 (tt, J = 12.0, 3.3 Hz, 1H), 2.42–2.34 (m, 2H), 2.20–2.09 (m, 2H),
1.95–1.87 (m, 2H), 1.50–1.38 (m, 2H), 1.10 (s, 9H) ppm.

13

C NMR (100 MHz, CDCl3) δ

153.8, 149.2, 139.5, 135.7, 133.3, 130.0, 127.9, 127.6, 119.5, 107.4, 43.4, 35.9, 35.4, 26.7,
19.7 ppm.
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4-(4-(Hydroxymethyl)cyclohexyl)phenol (3.4a). A solution of borane-THF complex in
THF (1 M, 1.22 mL, 1.22 mmol) was added to a solution of 3.3 (0.261 g, 0.611 mmol) in
THF (6 mL) at 0 °C. The reaction mixture was slowly warmed to room temperature and
stirred for 20 h. The mixture was then cooled to 0 °C, followed by sequential addition of
ethanol (50 mL), hydrogen peroxide solution (30% in water, 1.00 mL) and 3N NaOH
solution (5.0 mL). The mixture was warmed to room temperature and stirred for 30 min.
The reaction mixture was extracted with ethyl acetate (2 ×20 mL). The organic portion
was washed with brine, dried (Na2SO4), and concentrated. The residue was recrystallized
from chloroform to give 3.4a (0.035 g, 28%) as a colorless solid. mp 118-122 °C.

1

H

NMR (400 MHz, CD3OD) δ 7.04-6.98 (m, 2H), 6.70-6.65 (m, 2H), 3.60 (d, J = 7.6 Hz,
1.5H), 3.39 (d, J = 6.6 Hz, 0.5H), 2.54–2.44 (m, 0.7H) and 2.37 (tt, J = 12.1, 3.4 Hz, 0.3H),
1.93–1.70 (m, 3H), 1.61 (d, J = 6.3 Hz, 4H), 1.46–1.37 (m, 1H), 1.14–1.02 (m, 1H) ppm.
13

C NMR (100 MHz, CD3OD) δ 156.2, 139.6, 128.7, 116.0, 68.0, 64.4, 45.2, 44.0, 41.4,

37.0, 35.4, 31.2, 30.5, 28.0 ppm.
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tert-Butyldimethyl(4-(4-methylenecyclohexyl)phenoxy)silane

(3.6).

Wittig

methenylation of compound 3.5 (2.00 g, 6.57 mmol) was carried out in a fashion similar to
the preparation of 3.3. Purification of the crude residue by column chromatography (SiO2,
hexanes-ethyl acetate = 90: 10) gave 3.6 (1.678 g, 84%) as a colorless oil. 1H NMR (400
MHz, CDCl3) δ 7.06 and 6.77 (AA’BB’, JAB = 8.3 Hz, 4H), 4.68 (s, 2H), 2.62 (tt, J = 12.1,
3.4 Hz, 1H), 2.42 (br d, J = 13.5 Hz, 2H), 2.18 (br t, J = 13.2 Hz, 2H), 2.00-1.93 (m, 2H),
1.57-1.45 (m, 2H), 0.99 (s, 9H), 0.20 (s, 6H) ppm.

13

C NMR (100 MHz, CDCl3) δ 153.9,

149.2, 139.8, 127.8, 119.9, 107.4, 43.5, 36.0, 35.4, 25.9, 18.4, -4.2 ppm. Anal. calcd. for
C19H30OSi: C, 75.43; H, 9.99. Found: C, 75.71; H, 10.02.

4-(4-(Hydroxymethyl)cyclohexyl)phenol (3.4a). Hydroboration-oxidation of 3.6 (0.350
g, 1.16 mmol) was carried out in a fashion similar to the hydroboration-oxidation of 3.3.
Purification of the residue by column chromatography (SiO2, hexanes-ethyl acetate =
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65:35) gave 3.4a (0.095 g, 40%) as a colorless solid. The 1H NMR spectral data were
consistent with previously obtained values.

(4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)cyclohexyl)methanol

(3.7).

The

hydroboration of 3.6 (0.821 g, 2.71 mmol) was carried out in a fashion similar to the
hydroboration of 3.3. After stirring for 18 h, the reaction mixture was cooled to 0 °C,
followed by sequential addition of 1 N sodium hydroxide solution (3.2 mL) and hydrogen
peroxide solution (30% in water, 1.50 mL). The mixture was warmed to room temperature
and stirred for 1.5 h.

The reaction mixture was quenched with saturated sodium

bicarbonate solution (10 mL), diluted with water (20 mL) and extracted with ethyl acetate
(2 ×20 mL). The combined organic extracts were washed with brine, dried (Na 2SO4,) and
concentrated. The residue was purified by column chromatography (SiO 2, hexanes-ethyl
acetate = 70:30) to give 3.7 (0.572 g, 66%) as a colorless oil. 1H NMR (400 MHz, CDCl3)
δ 7.06 and 6.76 (AA’BB’, JAB = 8.5 Hz, 4H), 3.69 (d, J = 7.4 Hz, 1.3H), 3.50 (d, J = 6.5
Hz, 0.7H), 2.59-2.51 (m, 0.5H), 2.42 (tt, J = 12.1, 3.8 Hz, 0.5H), 1.96-1.84 (m, 2H), 1.801.37 (m, 7H), 0.98 (s, 9H), 0.19 (s, 6H) ppm.

13

C NMR (100 MHz, CDCl3) δ 153.7, 140.4,

140.0, 127.8, 119.9, 68.9, 64.6, 43.8, 42.6, 40.3, 36.2, 34.1, 30.0, 29.4, 27.0, 25.9, 18.4, 4.2 ppm.
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4-(4-(Hydroxymethyl)cyclohexyl)phenol (3.4a). To a solution of 3.7 (0.594 g, 1.85
mmol) in anhydrous THF (10 mL) was added a solution of TBAF (1M in THF, 7.5 mL,
7.5 mmol) while stirring. The mixture was heated to reflux at 70 ˚C overnight and cooled
to room temperature. The solution was partitioned between ethyl acetate and water. The
organic layer was washed with brine, dried (Na2SO4) and concentrated. Purification by
column chromatography (SiO2, hexanes-ethyl acetate = 60:40) gave 3.4a (0.280 g, 73%)
as a colorless solid. mp 118-122 °C. The 1H NMR spectral data is consistent with that
previously obtained.

4-(2-Oxabicyclo[2.2.2]octan-1-yl)phenol

(3.8)

and

trans-4-(4-

(Hydroxymethyl)cyclohexyl)phenol (3.4b). To a solution of a mixture of cis- and trans4-(4-(hydroxymethyl) cyclohexyl)phenol 3.4a (0.050 g, 0.242 mmol) in anhydrous CH2Cl2
(15 mL) at -10 °C, was slowly added a suspension of 2,3-dichloro-5,6-dicyano-1,4-
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benzoquinone (0.059 g, 0.262 mmol ) in CH2Cl2 ( 5 mL) over a period of 30 min. The
green solution continued to stir at 0 °C for 2 h and gradually warmed to room temperature
and stirred for another 3 h. The mixture was quenched by slow addition of saturated
sodium bicarbonate solution at 0 °C. After a few minutes, the layers were separated and
the aqueous layer was extracted with CH2Cl2 (2 × 20 mL). The combined organic extracts
were washed with brine, dried (Na2SO4), and concentrated. The residue was purified by
column chromatography (SiO2, hexanes-ethyl acetate = 60: 40) to give 3.8 (0.020 g, 40%)
followed by 3.4b (0.010 g, 20%) both as colorless solids. 3.8: mp 120-124 °C. 1H NMR
(400 MHz, CD3OD) δ 7.18 and 6.64 (AA’BB’, JAB = 7.9 Hz, 4H), 4.04 (s, 2H), 2.01 (t, J =
7.8 Hz, 4H), 1.94–1.73 (m, 5H) ppm.

13

C NMR (100 MHz, CD3OD) δ 157.2, 138.9, 127.1,

115.6, 73.0, 71.3, 34.5, 27.3, 25.9 ppm. Anal. calcd for C13H16O2: C, 76.44; H, 7.89.
Found: C, 76.39; H, 7.97. 3.4b: mp 115-120 °C. 1H NMR (400 MHz, CD3OD) δ 7.00 and
6.68 (AA’BB’, JAB = 8.7 Hz, 4H), 3.39 (d, J = 6.7 Hz, 2H), 2.36 (tt, J = 12.1, 3.0 Hz, 1H),
1.87 (br t, J = 15.4, 4H), 1.55–1.36 (m, 3H), 1.14–1.02 (m, 2H) ppm.

13

C NMR (100 MHz,

CD3OD) δ 156.3, 139.8, 128.6, 116.0, 68.8, 45.1, 41.4, 35.3, 31.2 ppm. Anal. calcd for
C13H18O2: C, 75.69; H, 8.79. Found: C, 75.66; H, 9.09.
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4-(4-Hydroxycyclohexyl)phenol (3.9). Cyclohexanone 3.1 (0.200 g, 1.05 mmol) was
dissolved in anhydrous methanol (15 mL) and NaBH4 (0.400 g, 10.6 mmol) was added
while stirring at room temperature. Reaction was continued for 3 h and mixture was
extracted with ethyl acetate (3× 20 mL). The combined extracts were concentrated to give
product 3.9 (0.181 g, 90%) as a colorless solid. mp 196-208 °C.

1

H NMR (400 MHz,

CD3OD) δ 7.00 and 6.67 (AA’BB’, JAB = 8.7 Hz, 4H), 3.61–3.53 (m, 1H), 2.38 (tt, J =
11.8, 3.4 Hz, 1H), 2.05–1.98 (m, 2H), 1.87–1.78 (m, 2H), 1.56–1.30 (m, 4H) ppm.

13

C

NMR (100 MHz, CD3OD) δ 156.5, 139.1, 128.7, 116.0, 71.3, 49.3, 44.2, 36.8, 34.1 ppm.
HRMS m/z 191.1077 [calcd for C12H15O2– (M–H+) 191.1078].

4-(4-Hydroxyphenyl)cyclohexanone oxime (3.10). To a solution of cyclohexanone 3.1
(0.050 g, 0.26 mmol) in ethanol (10 mL), were added Amberlyst (0.060 g) and
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hydroxylamine hydrochloride (0.039 g, 0.560 mmol). The mixture was stirred at room
temperature for 2 h and then filtered. The filtrate was concentrated and extracted with ethyl
acetate (2 × 10 mL) and water (2 × 10 mL). The combined organic extracts were
concentrated and dried (MgSO4). Evaporation of the solvent gave 3.10 as a colorless solid
(0.037 g, 70%). mp 171-174 °C. 1H NMR (400 MHz, CD3OD) δ 7.00 and 6.69 (AA’BB’,
JAB = 8.2 Hz, 4H), 3.39 (br d, J = 13.5 Hz, 1H), 2.67 (t, J = 12.8 Hz, 1H), 2.41 (br d, J =
14.0 Hz, 1H), 2.20 (td, J = 14.6, 5.4 Hz, 1H), 1.93 (br t, J = 15.8 Hz, 2H), 1.81 (td, J = 14.0,
5.2 Hz, 1H), 1.61–1.42 (m, 2H) ppm.

13

C NMR (100 MHz, CD3OD) δ 160.8, 156.7, 138.3,

128.6, 116.2, 44.1, 35.8, 34.6, 32.8, 25.1 ppm.

4-(4-Hydroxy-4-methylcyclohexyl)phenol (3.11). To a solution of 3.1 (0.100 g, 0.526
mmol) in dry Et 2O (20 mL) at -78 °C under N2, was added slowly a solution of
methyllithium-lithium bromide complex (1.5 M in ether, 0.78 mL, 1.2 mmol). The mixture
was stirred for another 30 min at -78 °C, warmed to room temperature and stirred for
another 1 h. The mixture was cooled to 0 °C and quenched with water. The mixture was
extracted with diethyl ether (2 × 30 mL), dried (Na2SO4) and concentrated. The residue
was purified from column chromatography (SiO2, hexanes-ethyl acetate = 80:20) to give
3.11 (0.040 g, 37%) as a colorless solid. mp 126-131 °C. 1H NMR (400 MHz, CD3OD) δ
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7.03 and 6.67 (AA’BB’, JAB = 8.3 Hz, 4H), 2.35 (tt, J =12.4, 3.6 Hz, 1H), 1.87–1.69 (m,
4H), 1.61–1.44 (m, 4H), 1.21 (s, 3H) ppm.

13

C NMR (100 MHz, CD3OD) δ 156.3, 139.9,

129.6, 116.0, 69.3, 44.3, 39.9, 31.8, 30.9 ppm.

HRMS m/z 205.1234 [calcd for

C13H17O2– (M–H+) 205.1234].

4-(4-Methylenecyclohexyl)phenol (3.12). To a solution of 3.6 (0.739 g, 2.44 mmol) in
anhydrous THF (20 mL) was added a solution of TBAF (1M in THF, 9.8 mL, 9.8 mmol).
The mixture was heated to reflux at 70 ˚C for 5 h and cooled to room temperature. The
solution was partitioned between ethyl acetate (2 × 30 mL) and water (20 mL). The
combined organic layers were washed with brine, dried (Na2SO4) and concentrated.
Purification of the crude material by column chromatography (SiO2, hexanes-ethyl acetate
= 80:20) gave 3.12 (0.379 g, 82%) as a colorless solid. mp 82-84 °C. 1H NMR (400 MHz,
CD3OD) δ 6.99 and 6.67 (AA’BB’, JAB = 8.5 Hz, 4H), 4.63 (t, J =1.7 Hz, 2H), 2.57 (tt, J
=12.3, 4.3 Hz, 1H), 2.41–2.33 (m, 2H), 2.22–2.11 (m, 2H), 1.94–1.85 (m, 2H), 1.45 (qd, J
=12.3, 4.3 Hz, 2H) ppm.

13

C NMR (100 MHz, CD3OD) δ 156.5, 150.2, 139.1, 128.6,

116.0, 107.7, 44.7, 37.1, 36.2 ppm. HRMS m/z 187.1128 [calcd for C13H15O– (M–H+)
187.1128].
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4-(4-Methylcyclohexyl)phenol (3.13). To a solution of 3.12 (0.150 g, 0.797 mmol) in
methanol (10 mL) was added 10% Pd/C (0.085 g, 10 mol %) and the mixture was stirred
under a balloon filled with H2 at room temperature for 12 h. The reaction mixture was
filtered through a pad of celite, dried (Na2SO4) and concentrated. The residue was purified
by column chromatography (SiO2, hexanes-ethyl acetate = 80:20) to give 3.13 (0.121 g,
80%) as a colorless solid. mp = 93-99 °C. [lit. mp 108°C].119

1

H NMR (400 MHz,

CD3OD) δ 7.05–6.96 (m, 2H), 6.70–6.64 (m, 2H), 2.48–2.28 (m, 1H), 1.83–1.34 (m, 8H),
1.13–1.04 (m, 1H), 1.03 (d, J = 7.2 Hz, 1H), 0.92 (d, J = 6.6 Hz, 2H) ppm.

13

C NMR (100

MHz, CD3OD) δ 156.3, 140.0, 128.6, 116.0, 44.7, 36.9, 35.9, 33.7, 33.1, 30.0, 23.1 ppm.
The NMR spectral data for this compound were consistent with the literature values. 120
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4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)-1-(hydroxymethyl)cyclohexan-1-ol (3.14).
To a solution of 3.6 (0.280 g, 0.926 mmol) and N-methylmorpholine-N-oxide (0.15 g, 1.3
mmol) in acetone (6 mL) and distilled water (0.3 mL) was added a 2.5% solution of OsO 4
in tert-butanol (90 µL). The mixture was stirred overnight and a saturated solution of
NaHSO3 (10 mL) was added to quench the reaction. The mixture was diluted with ether
(20 mL) and extracted with water (2 × 10 mL). The organic layer was dried (MgSO 4) and
concentrated. Purification of the residue by column chromatography (SiO 2, hexanes-ethyl
acetate = 20:80) gave 3.14 (0.267 g, 86%) as a colorless solid. mp 80-86 °C. 1H NMR
(400 MHz, CDCl3) δ 7.04 and 6.76 (AA’BB’, J AB = 8.5 Hz, 4H), 3.69 (s, 1.7H), 3.47 (s,
0.3H), 2.58-2.39 (m, 1H), 2.04–1.72 (m, 4H, solvent peak overlapped), 1.61–1.37 (m, 4H),
0.97 (s, 9H), 0.18 (s, 6H) ppm.

13

C NMR (100 MHz, CDCl3) δ 154.0, 138.9, 127.7, 120.0,

72.4, 66.2, 42.8, 35.4, 31.3, 25.9, 18.4, -4.2 ppm.
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4-(4-Hydroxy-4-(hydroxymethyl)cyclohexyl)phenol (3.15). To a solution of 3.14 (0.230
g, 0.683 mmol) in anhydrous THF (10 mL) was added a solution of TBAF (1M in THF,
2.8 mL, 2.8 mmol). The mixture was heated to reflux at 70 ˚C for 6 h and cooled to room
temperature. The solution was partitioned between ethyl acetate (2 × 20 mL) and water
(20 mL). The combined organic layers were washed with brine, dried (Na 2SO4) and
concentrated. Purification of the crude material by column chromatography (SiO2, ethyl
acetate-methanol = 90:10) gave 3.15 (0.118 g, 78%) as a colorless solid. mp 182-188 °C.
1

H NMR (400 MHz, CD3OD) δ 7.02 and 6.68 (AA’BB’, JAB = 8.5 Hz, 4H), 3.62 (s, 2H),

2.53–2.42 (m, 1H), 1.99–1.89 (m, 2H), 1.85–1.68 (m, 2H), 1.58–1.43 (m, 4H) ppm.

13

C

NMR (100 MHz, CD3OD) δ 156.5, 138.7, 128.6, 116.0, 73.0, 66.5, 44.2, 35.8, 32.5 ppm.
Anal. calcd. for C13H18O3: C, 70.24; H, 8.16. Found: C, 70.18; H, 7.78.
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2-Hydroxy-5-(4-methylenecyclohexyl)benzaldehyde (3.16).

To a solution of 3.13

(0.100 g, 0.532 mmol) in dry CH3CN (20 mL) was added magnesium chloride (0.076 g,
0.797) and triethylamine (0.28 mL, 2.0 mmol), followed by paraformaldehyde (0.108 g,
3.59 mmol). The reaction mixture was heated at reflux for 6 h. The mixture was cooled
to room temperature and quenched with 10% HCl (10 mL) and extracted with ethyl acetate
(2 × 25 mL). The combined extracts were washed with brine, dried (Na 2SO4) and
concentrated. Purification of the residue by column chromatography (SiO 2, hexanesdiethyl ether = 80:20) gave 3.16 (0.046 g, 40%) as a colorless oil.

1

H NMR (400 MHz,

CD3OD) δ 9.96 (s, 1H), 7.50 (s, 1H), 7.39 (d, J = 8.5 Hz, 1H), 6.85 (d, J = 8.5 Hz, 1H),
4.65 (t, J = 1.7 Hz, 2H), 2.68 (tt, J = 12.0, 3.4 Hz, 1H), 2.44–2.34 (m, 2H), 2.24–2.13 (m,
2H), 1.97–1.89 (m, 2H), 1.49 (qd, J = 13.0, 4.0 Hz, 2H) ppm.

13

C NMR (100 MHz,

CD3OD) δ 197.3, 160.9, 149.6, 139.8, 136.9, 131.5, 122.3, 118.0, 108.1, 44.1, 36.7, 36.0
ppm.
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(E)-2-Hydroxy-5-(4-methylenecyclohexyl)benzaldehyde oxime (3.17). To a solution of
3.16 (0.050 g, 0.232 mmol) in pure ethanol (10 mL), were added sodium bicarbonate (0.024
g, 0.278 mmol) and hydroxylamine hydrochloride (0.025 g, 0.348 mmol). The reaction
was heated at 80°C for 5 h, cooled and the mixture was extracted with ethyl acetate (2 ×
20 mL).

The combined organic extracts were dried (MgSO 4) and concentrated.

Purification of the residue by column chromatography (SiO 2, hexanes-ethyl acetate =
65:35) gave 3.17 (0.037 g, 69%) as a colorless solid. This was determined to be a mixture
of E- and Z-oxime stereoisomers by 1H NMR spectroscopy. mp 120-125 °C. 1H NMR
(400 MHz, CD3OD) δ 8.20 (s, 1H), 7.09–7.06 (m, 1H), 7.05 (d, J = 2.4 Hz, 1.8H), 6.99 (d,
J = 7.9 Hz, 0.2H), 6.78 (d, J = 8.1 Hz, 0.8H), 6.68 (d, J = 8.6 Hz, 0.2H), 4.63 (t, J = 1.6
Hz, 2H), 2.60 (tt, J = 12.2, 3.3 Hz, 1H), 2.42–2.33 (m, 2H), 2.22–2.10 (m, 2H), 1.94–1.85
(m, 2H), 1.46 (qd, J =12.5, 4.0 Hz, 2H) ppm.

13

C NMR (100 MHz, MeOD) δ 156.4, 152.2,

150.0, 139.3, 130.1, 129.0, 128.6, 118.3, 117.0, 116.0, 107.8, 107.7, 44.6, 44.4, 37.1, 36.9,
36.2, 36.1 ppm. HRMS m/z 230.1187 [calcd for C14H16NO2– (M–H+) 230.1186].
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5-(2-Oxabicyclo[2.2.2]octan-1-yl)-2-hydroxybenzaldehyde (3.18) and 4-Hydroxy-4'(hydroxymethyl)-2',3',4',5'-tetrahydro-[1,1'-biphenyl]-3-carbaldehyde (3.19). To a
solution of 3.8 (0.050 g, 0.25 mmol) in dry CH3CN (15 mL) was added magnesium chloride
(0.035 g, 0.367 mmol) and triethylamine (0.13 mL, 0.09 mmol) and the mixture was heated
at reflux for 8 h. The mixture was cooled to room temperature and quenched with 10%
HCl (10 mL) and extracted with ethyl acetate (2 × 25 mL). The combined organic extracts
were washed with brine, dried (Na2SO4) and concentrated. Purification of the crude
material by column chromatography (SiO2, hexanes-ethyl acetate = 65:35) gave 3.18
(0.010 g, 17%) followed by 3.19 (0.005 g, 8%) both as light-yellow oils. 3.18:

1

H NMR

(400 MHz, CD3OD) δ 9.99 (s, 1H), 7.69 (br s, 1H), 7.57 (br d, J = 8.7 Hz, 1H), 6.87 (d, J
= 8.7 Hz, 1H), 4.06 (s, 2H), 2.12–1.75 (m, 9H) ppm.

13

C NMR (100 MHz, CD3OD) δ

197.3, 161.3, 140.0, 134.9, 130.1, 128.8, 117.7, 72.6, 71.3, 34.5, 27.3, 25.9 ppm. 3.19: 1H
NMR (400 MHz, CD3OD) δ 10.01 (s, 1H), 7.69 (s, 1H), 7.62 (d, J = 8.5 Hz, 1H), 6.89 (d,
J = 8.7 Hz, 1H), 6.10 (s, 1H), 3.49 (d, J = 6.1 Hz, 2H), 2.54–2.28 (m, 3H), 2.05–1.73 (m,
3H), 1.47–1.35 (m, 1H) ppm.

13

C NMR (100 MHz, CD3OD) δ 197.5, 161.4, 136.3, 135.6,

134.6, 129.8, 123.9, 122.2, 118.0, 67.7, 37.2, 29.9, 27.9, 26.9 ppm. HRMS m/z 231.1027
[calcd for C14H15O3– (M–H+) 231.1027].

163

4'-(Hydroxymethyl)-2',3',4',5'-tetrahydro-[1,1'-biphenyl]-4-ol (3.20). To a solution of
3.8 (0.103 g, 0.505 mmol) was in dry CH3CN (25 mL) was added magnesium chloride
(0.072g, 0.756 mmol) and triethylamine (0.26 mL, 1.89 mmol). The mixture was heated
at reflux for 8. The mixture was cooled to room temperature and quenched with 10% HCl
(15 mL) and extracted with ethyl acetate (2 × 25 mL). The combined extracts were washed
with brine, dried (Na2SO4) and concentrated. Purification of the crude material by column
chromatography (SiO2, hexanes- ethylacetate = 65:35) gave 3.20 (0.080 g, 78%) as a
colorless solid. mp 177-184°C. 1H NMR (400 MHz, CDCl3) δ 7.20 and 6.69 (AA’BB’,
JAB = 8.6 Hz, 4H), 5.97–5.92 (m, 1H), 3.48 (dd, J = 6.4, 2.6 Hz, 2H), 2.49–2.23 (m, 3H),
2.01–1.71 (m, 4H), 1.43–1.31 (m, 1H) ppm.

13

C NMR (100 MHz, CDCl3) δ 157.4, 137.5,

135.0, 127.1, 122.0, 115.8, 67.8, 37.3, 30.0, 28.1, 27.1 ppm. HRMS m/z 203.1078 [calcd
for C12H15O2– (M–H+) 203.1077].
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4-(4-(Hydroxymethyl)cyclohexyl)phenol (3.4a). Method A: To a solution of 3.8 (0.020
g, 0.098 mmol) dry CH2Cl2 (10 mL) was added triethylsilane (0.02 mL, 0.12 mmol)
followed by trifluoroacetic acid (0.08 mL, 0.98 mmol). The reddish mixture was stirred at
room temperature overnight and the solution was extracted with ethyl acetate (2 × 10 mL).
The combined organic extracts were washed with H2O (2 × 15 mL), dried (Na2SO4) and
concentrated to give 3.4a (0.012 g, 59%) as a colorless solid. The 1H NMR spectrum
showed the formation of a 2:3(cis: trans) mixture of isomers.
Method B: To a solution of 3.8 (0.050 g, 0.25 mmol) in dry THF (15 mL) cooled to -78
°C was added NaCNBH3 (0.154 g, 2.48 mmol). The mixture was stirred at this temperature
for 1 h and BF3.Et2O (2.5 mL, 14 mmol) was added dropwise. The mixture was warmed
to room temperature overnight, quenched with water (10 mL) and extracted with ether (2
× 20 mL). The combined organic extracts were washed with NaHCO3 solution, brine, dried
(Na2SO4) and concentrated to give 3.4a (0.030, 60%) as a colorless solid. The 1H NMR
spectrum showed the formation of a 1:4 (cis: trans) mixture of isomers.
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4-(4-(Hydroxymethyl)cyclohexyl)phenol (3.4a). To a solution of compound 3.20 (0.046
g, 0.23 mmol) in methanol (8 mL) was added 10% Pd/C (0.025 g, 10 mol %) and mixture
was stirred under a balloon of H2 at room temperature for 12 h. The reaction mixture was
filtered through a pad of celite, and concentrated in vacuo to give 3.4a (0.031g, 65%) as a
colorless solid. The 1H NMR spectrum showed the formation of a 3:2 (cis: trans) mixture
of isomers.

Methyl 2-(4-(4-((tert-butyldiphenylsilyl)oxy)phenyl)cyclohexylidene)acetate (3.21).
Sodium hydride (40 mg, 55% in mineral oil, 0.980 mmol) was added to a stirring solution
of trimethyl phosphonoacetate (0.160 mL, 0.980 mmol) in dry THF (5 mL) at 0 °C. After
45 min, a solution of 4-(4’-t-butyldiphenylsilyloxyphenyl)cyclohexanone 3.2 (0.350 g,
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0.818 mmol) in dry THF (5 mL) was added and the reaction mixture was stirred at room
temperature for 8 h. The mixture was diluted with water (25 mL) and the resulting mixture
was extracted with ether (2 × 30 mL), dried (MgSO4) and concentrated. The residue was
purified by column chromatography (SiO2, hexanes–ethyl acetate = 90:10) to give
compound 3.21 (0.376 g, 95%) as colorless gum. 1H NMR (400 MHz, CDCl3) δ 7.74- 7.68
(m, 4H), 7.44-7.32 (m, 6H), 6.91 and 6.69 (AA’BB’, JAB = 8.6 Hz, 4H), 5.65 (s, 1H), 3.963.88 (m, 1H), 3.69 (s, 3H), 2.66 (tt, J = 12.1, 3.4 Hz, 1H), 2.38-2.24 (m, 2H), 2.04-1.93 (m,
3H), 1.59-1.46 (m, 2H), 1.08 (s, 9H) ppm.

13

C NMR (100 MHz, CDCl3) δ 167.4, 162.7,

154.0, 138.6, 135.7, 133.3, 130.0, 127.9, 127.5, 119.6, 113.3, 51.1, 43.3, 37.9, 35.9, 35.1,
29.7, 26.7, 19.7 ppm.

2-(4-(4-((tert-Butyldiphenylsilyl)oxy)phenyl)cyclohexylidene)ethan-1-ol (3.22). To a
solution of 3.21 (0.109 g, 0.225 mmol) in dry CH2Cl2 (2 mL) under nitrogen at –40 ˚C was
added a solution of diisobutylaluminum hydride (0.50 mL, 1.2 M in CH2Cl2, 0.60 mmol).
After 90 min, saturated aqueous potassium sodium tartrate was added and reaction mixture
was warmed to room temperature. After 4 h the mixture was filtered through a pad of celite
and extracted several times with water (2 × 20 mL). The combined organic layers were
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dried (MgSO4), and concentrated to give 3.22 (0.059 g, 58%) as a colorless gum. This was
used without further purification in the next step. 1H NMR (400 MHz, CDCl3) δ 7.72 (d,
J = 7.2 Hz, 4H), 7.45-7.33 (m, 6H), 6.91 and 6.68 (AA’BB’, J AB = 8.4 Hz, 4H), 5.42 (t, J
= 7.2 Hz, 1H), 4.17 (d, J = 7.2 Hz, 2H), 2.72 (br d, J = 13.9 Hz, 1H), 2.58 (tt, J = 12.1, 3.2
Hz, 1H), 2.37-2.26 (m, 1H), 2.23-2.13 (m, 1H), 1.97-1.85 (m, 3H), 1.51-1.34 (m, 2H), 1.08
(s, 9H) ppm.

13

C NMR (100 MHz, CDCl3) δ 153.8, 143.4, 139.2, 135.7, 133.3, 130.0,

127.9, 127.5, 121.1, 119.6, 58.8, 43.8, 37.0, 35.9, 35.4, 28.7, 26.7, 19.6 ppm.

2-(4-(4-((tert-Butyldiphenylsilyl)oxy)phenyl)cyclohexyl)ethan-1-ol (3.23).

To a

solution of compound 45 (0.130 g, 0.285 mmol) in methanol (10 mL) was added, 10%
Pd/C (0.012 g, 4 mol %). The reaction mixture was stirred under H 2 (30 psi) for 12 h. The
reaction mixture was filtered through a pad of celite, and the solution was concentrated to
give 3.23 (0.062 g, 48%) as a colorless oil. The product was used in the next step without
further purification. 1H NMR (400 MHz, CDCl3) δ 7.79-7.72 (m, 4H), 7.47-7.35 (m, 6H),
6.99-6.92 (m, 2H), 6.76- 6.69 (m, 2H), 3.76-3.66 (m, 2H), 2.37 (t, J = 12.5 Hz,1H), 2.27
(t, J = 6.4 Hz, 1H), 1.86 (d, J = 11.2 Hz, 3H), 1.73-1.56 (m, 3H), 1.56-1.49 (m, 1H), 1.481.27 (m, 3H), 1.13 (s, 9H) ppm.

13

C NMR (100 MHz, CDCl3) δ 153.7, 140.2, 135.7, 133.3,

130.0, 127.9, 127.5, 119.4, 61.0, 43.7, 40.4, 34.5, 33.7, 30.3, 29.1, 26.7, 19.6 ppm.
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4-(4-(2-Hydroxyethyl)cyclohexyl)phenol (3.24). To a solution of 3.2 (0.063 g, 0.138
mmol) in anhydrous THF (8 mL) was added a solution of TBAF (1M in THF, 1.2 mL, 1.2
mmol) while stirring. The mixture was heated to reflux at 70 ˚C overnight and cooled to
room temperature. The solution was partitioned between ethyl acetate and water. The
organic layer was washed with brine, dried (Na2SO4) and concentrated. Purification by
column chromatography (SiO2, hexanes-ethyl acetate = 60:40) gave 3.24 (6 mg, 20%) as a
colorless solid. mp 120-125 °C. 1H NMR (300 MHz, (CD3)2CO) δ 8.02 (s, 1H), 7.08-7.01
(m, 2H), 6.77-6.71 (m, 2H), 3.65- 3.56 and 3.43-3.37 (m, 3H total), 2.52-2.33 (m, 1H),
1.91-1.00 (m, 11H) ppm.
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1',2',3',6'-tetrahydro-[1,1'-biphenyl]-4-ol (3.25b). Method A.

To a solution of 3.9

(0.040 g, 0.21 mmol) in CH2Cl2 (10 mL) at room temperature under N2 was added
Deoxofluor (0.08 mL, 0.43 mmol) in CH2Cl2 (5 mL). The mixture was stirred for 20 h,
after which saturated NaHCO3 (10 mL) was poured into the mixture. After CO2 evolution
ceased the mixture was extracted into CH2Cl2 (2 × 20 mL). The combined extracts were
dried (MgSO4) and concentrated. The residue was purified by column chromatography
(SiO2, hexanes-ethyl acetate = 70:30) to give 3.25b (0.023 g, 63%) as a colorless solid. mp
79-84 °C. 1H NMR (400 MHz, CDCl3) δ 7.12 and 6.80 (AA’BB’, JAB = 8.6 Hz, 4H), 5.79–
5.76 (m, 2H), 4.92 (s, 1H), 2.81–2.71 (m, 1H), 2.32–2.07 (m, 4H), 1.95–1.88 (m, 1H),
1.78–1.66 (m, 1H) ppm.

13

C NMR (100 MHz, CDCl3) δ 153.8, 139.9, 128.1, 127.2, 127.0,

115.3, 39.4, 33.8, 30.2, 26.1 ppm.
Method B. To a solution of 3.9 (0.054 g, 0.28 mmol) in THF (20 mL) at room temperature
under N2 was added DAST (0.08 mL, 0.61 mmol) in THF (3 mL). The mixture was stirred
for 20 h, then saturated NaHCO3 (15 mL) was poured into the mixture. After CO2 evolution
ceased the mixture was extracted into ethyl acetate (2 × 10 mL). The combined extracts
were dried (Na2SO4) and concentrated.

The residue was purified by column

chromatography (SiO2, hexanes-ethyl acetate = 70:30) to give 3.25b (0.025 g, 51%) as a
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colorless solid. The NMR spectral data were consistent with the previously obtained
values.

4-(-4-(Fluoromethyl)cyclohexyl)phenol (3.26b). To a solution of 3.4b (0.065 g, 0.315
mmol) in CH2Cl2 (12 mL) at -78 ˚C under N2 was added a solution of Deoxofluor (0.09
mL, 0.473 mmol) in CH2Cl2 (3 mL). The mixture was gradually warmed to room
temperature. On completion, saturated aqueous NaHCO3 (10 mL) was poured in to the
mixture and after CO2 evolution ceased the mixture was extracted into CH2Cl2 (2 × 20 mL).
The combined extracts were dried (Na2SO4) and concentrated. The residue was purified
by column chromatography (SiO2, hexanes-ethyl acetate = 80:20) to give 3.26b (0.037 g,
56%) as a colorless solid. mp 103-109 °C. 1H NMR (400 MHz, CD3OD) δ 7.00 and 6.68
(AA’BB’, JAB = 8.5 Hz, 4H), 4.23 (d, J = 48.1 Hz, 2H), 2.37 (tt, J = 12.3, 2.8 Hz, 1H),
1.90–1.80 (m, 4H), 1.78–1.59 (m, 2H), 1.52–1.37 (m, 2H), 1.24–1.09 (m, 2H) ppm.

13

C

NMR (100 MHz, CD3OD) δ 156.5, 139.7, 128.6, 116.0, 89.4 (d, J = 166 Hz), 44.9, 39.6
(d, J = 17 Hz), 35.0, 30.0, 29.9 ppm.
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1-(benzyloxy)-4-bromo-2-fluorobenzene (3.3.).

To a solution of 4-bromo-2-

fluorophenol 3.29 (1.00 g, 5.24 mmol) in DMF (8 mL), benzyl bromide (1.16 g, 0.81 mL,
6.81 mmol) and potassium carbonate (0.941 g, 6.81 mmol) were added and the mixture
was heated at reflux for 6 h. After cooling to room temperature the mixture was poured
into ice-cold water. The resulting mixture was partitioned with ethyl acetate (2 x 20 mL)
and washed with brine (2 x 20 mL). The combined organic extracts were dried (Na 2SO4),
concentrated and purified by column chromatography (SiO 2, hexanes -ethyl acetate =
90:10) to give 3.30 (1.397 g, 95%) as a colorless solid. mp 55-60 ˚C. 1H NMR (400 MHz,
CDCl3) δ 7.47-7.32 (m, 5H), 7.26 (dd, J = 10.6, 2.3 Hz, 1H), 7.19-7.13 (m, 1H), 6.88 (t, J
= 8.7 Hz, 1H), 5.13 (s, 2H) ppm.

13

C NMR (100 MHz, CDCl3) δ 152.9 (d, JC-F = 250 Hz),

146.3 (d, JC-F = 10 Hz), 136.2, 128.9, 128.4, 127.6, 127.3, 120.0 (d, JC-F = 20 Hz), 117.1,
(d, JC-F = 10 Hz), 112.8 (d, JC-F = 10 Hz), 71.7 ppm. The NMR spectral data for this
compound are consistent with the literature values. 121
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8-(4-(Benzyloxy)-3-fluorophenyl)-8-hydroxy-1,4-dioxaspiro[4.5]decane (3.31).

Dry

magnesium turnings (0.384 g, 0.016 mol) were placed in a flame dried three-necked flask
followed by THF (10 mL). The system was flushed with N2 and fitted with a REFLUX
condenser and an addition funnel. The addition funnel was filled with a solution of 3.30
(0.900 g, 3.20 mmol) in THF (10 mL). A little amount of the bromobenzene solution (3
mL) was added slowly to the magnesium turnings, and the contents were heated at reflux.
Once the Grignard formation had started, the remaining bromide solution was added
dropwise and the mixture was stirred until most of the magnesium had reacted. A solution
of 1,4-cyclohexanedione monoethylene acetal (0.250 g, 1.60 mmol) in THF (10 mL) was
added dropwise over 20 min. After stirring overnight at room temperature, a saturated
solution of NH4Cl (15 mL) was slowly added to quench the reaction. The resultant
emulsion was stirred for 15 min and the solution was extracted with ether (3 x 20 mL).
The combined organic layers were washed with brine (20 mL), dried (MgSO4) and
concentrated. The residue was purified by column chromatography (SiO2, hexanes-ethyl
acetate = 70:30) to give 3.31 (0.470 g, 82%) as a colorless solid. mp 137-143 ˚C. 1H NMR
(400 MHz, CDCl3) δ 7.46-7.28 (m, 5H), 7.26 (s, 1H), 7.18-7.12 (m, 1H), 6.95 (t, J = 8.4
Hz, 1H), 5.13 (s, 2H), 4.03-3.93 (m, 4H), 2.16-2.01 (m, 4H), 1.83-1.75 (m, 2H), 1.71-1.63
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(m, 2H), ppm.

13

C NMR (100 MHz, CDCl3) δ 152.7 (d, JC-F = 245 Hz), 145.5 (d, JC-F = 13

Hz), 142.6 (d, JC-F = 5 Hz), 136.8, 128.8, 128.3, 127.6, 120.3 (d, JC-F = 4 Hz), 115.4 (d, JCF=

2 Hz), 113.3 (d, JC-F = 20 Hz), 108.5, 72.1, 71.5, 64.5, 64.4, 36.7, 30.9 ppm.

4-(4-Benzyloxy-3-fluorophenyl)-3-cyclohexanone (3.32). Method A: Compound 3.31
(0.100 g, 0.279 mmol) was dissolved in THF: Water-4:1 mixture (10 mL) to give a
colorless solution. Then 2-3 drops of Conc sulfuric acid was slowly added and the mixture
was heated at reflux for 5 h. After completion, the solution was diluted with brine and
extracted with ethyl acetate (2 x 10 mL). The combined organic layers were washed with
brine (20 mL), dried (Na2SO4) and concentrated. The residue was purified by column
chromatography (SiO2, hexanes-ethyl acetate = 80:20) to give 3.32 (0.043 g, 52%) as a
light yellow solid. mp 74-82 ˚C. 1H NMR (400 MHz, CDCl3) δ 7.50-7.30 (m, 5H), 7.16
(dd, J = 12.6, 2.1 Hz, 1H), 7.10-7.03 (m, 1H), 6.96 (t, J = 8.6 Hz, 1H), 6.02 (nr t, J = 3.9
Hz, 1H), 5.15 (s, 2H), 3.05 (br s, 2H), 2.82 (t, J = 6.4 Hz, 2H), 2.67-2.59 (m, 2H) ppm.

13

C

NMR (100 MHz, CDCl3) δ 210.0, 152.8 (d, JC-F = 245 Hz), 146.1 (d, JC-F = 11 Hz), 136.6,
136.3 (d, JC-F = 2 Hz), 134.6 (d, JC-F = 6 Hz), 128.8, 128.4, 127.6, 121.0 (d, JC-F = 3 Hz),
120.7, 115.6 (d, JC-F = 2 Hz), 113.4 (d, JC-F = 19 Hz), 71.6, 40.0, 38.8, 27.9 ppm.
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Method B: To a solution of 3.31(1.189 g, 3.317 mmol) was dissolved in dry CH2Cl2 (20
mL) was added TFA (3.5 mL, 0.046 mol) and the mixture was stirred at room temperature
for 4h while monitoring the reaction by TLC. Once completed, saturated aqueous NaHCO3
(10 mL) was added and stirred for another 10 minutes. The resulting solution was extracted
with CH2Cl2, washed with brine (10 mL), dried (Na2SO4) and concentrated. Purification
of the crude material by column chromatography (SiO2, hexanes-ethyl acetate = 80:20)
gave 3.32 (0.883 g, 90%) as a light yellow solid.

4-(3-Fluoro-4-hydroxyphenyl)cyclohexanone (3.33). To a solution of 3.32 (1.000 g,
3.374 mmol) in ethyl acetate (15 mL), was added 10% Pd/C (0.360 g, 10 mol %) and the
mixture was stirred under a balloon of H2 at room temperature for 12 h. The reaction
mixture was filtered through a pad of celite, concentrated, and the residue was purified by
column chromatography (SiO2, hexanes-ethyl acetate = 60:40) to give 3.33 (0.315 g, 45%)
as a colorless solid. mp 137-145 °C. 1H NMR (400 MHz, CD3OD) δ 6.97 (dd, J = 12.4,
2.1 Hz, 1H), 6.91-6.87 (m, 1H), 6.86-6.79 (m, 1H), 3.00 (tt, J = 12.1, 3.5 Hz, 1H), 2.58 (td,
J = 14.0, 6.1 Hz, 2H), 2.41-2.33 (m, 2H), 2.19-2.10 (m, 2H), 1.86 (qd, J = 12.8, 4.2 Hz,
2H) ppm.

13

C NMR (100 MHz, CD3OD) δ 214.1, 152.8 (d, JC-F = 240 Hz), 144.5 (d, JC-F
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= 20 Hz), 138.6 (d, JC-F = 10 Hz), 123.7 (d, JC-F = 10 Hz), 118.7 (d, JC-F = 10 Hz), 115.2 (d,
JC-F = 20 Hz), 42.8, 42.1, 35.3 ppm.

4-(4-(Benzyloxy)-3-fluorophenyl)cyclohexan-1-one (3.34). To a solution of 3.33 (0.205
g, 0.984 mmol) in DMF (10 mL), was added benzyl bromide (0.219 g, 0.15 mL, 1.28 mmol)
and potassium carbonate (0.177 g, 1.28 mmol) and the mixture was heated at reflux for 6
h. After cooling to room temperature, the mixture was poured into ice-cold water. The
mixture was extracted with ethyl acetate (2 x 15 mL) and the combined extracts were
washed with brine (15 mL), dried (Na2SO4), and concentrated. Purification of the residue
by column chromatography (SiO2, hexanes-ethyl acetate = 90:10) gave 3.34 (0.232 g, 79
%) as a colorless solid. mp 81-87 °C. 1H NMR (400 MHz, CDCl3) 7.49-7.29 (m, 5H),
7.02-6.88 (m, 3H), 5.11(s, 2H), 2.95 (tt, J = 12.2, 6.9 Hz, 1H), 2.51-2.43 (m, 3H), 2.222.13 (m, 2H), 1.92-1.79 (m, 2H) ppm.
F

13

C NMR (100 MHz, CDCl3) δ 211.0, 152.9 (d, JC-

= 240 Hz), 145.3 (d, JC-F = 10 Hz), 138.7 (d, JC-F = 10 Hz), 136.7, 128.7, 128.2, 127.5,

122.3 (d, JC-F = 10 Hz), 115.9, 114.7 (d, JC-F = 20 Hz), 71.6, 41.8, 41.3, 34.0 ppm
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1-(Benzyloxy)-2-fluoro-4-(4-methylenecyclohexyl)benzene (3.35).
n

A solution of

butyllithium in hexane (2.5 M, 0.47 mL, 1.17 mmol) was slowly added to a solution of

methyltriphenylphosphonium bromide (0.556 g, 1.56 mmol) in dry THF (20 mL) at -10
°C. After 20 min, a solution of 3.34 (0.232 g, 0.778 mmol) in dry THF (10 mL) was added
dropwise. The reaction mixture was slowly warmed to room temperature and stirred
overnight. The mixture was diluted with water (10 mL), extracted with ethyl acetate (2
×25 mL), dried (Na2SO4) and concentrated. The crude residue was purified by column
chromatography (SiO2, hexanes-ethyl acetate = 90:10) to give 3.35 (0.165 g, 72 %) as a
colorless solid. 1H NMR (400 MHz, CDCl3) 7.56-7.29 (m, 5H), 7.02-6.83 (m, 3H), 5.13
(s, 2H), 4.71 (s, 2H), 2.63 (tt, J = 12.2, 3.3 Hz, 1H), 2.49-2.37 (m, 2H), 2.27-2.12 (m, 2H),
2.04-1.92 (m, 2H), 1.57-1.43 (m, 2H) ppm.

13

C NMR (100 MHz, CDCl3) δ 153.0 (d, JC-F

= 250 Hz), 148.6, 144.9, 141.0, 137.0, 133.9 (d, JC-F = 20 Hz), 128.7, 128.2, 127.6, 122.3,
115.8, 114.9 (d, JC-F = 20 Hz), 107.8, 71.7, 43.3, 35.7, 35.2 ppm.
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(4-(4-(Benzyloxy)-3-fluorophenyl)cyclohexyl)methanol (3.36). A solution of 9-BBN in
THF (0.5 M, 1.46 mL, 0.729 mmol) was added to a solution of 3.35 (0.108 g, 0.364 mmol)
in THF (15 mL) at 0 °C. The reaction mixture was slowly warmed to room temperature
and stirred for 20 h. The mixture was cooled to 0 °C hydrogen peroxide solution (30% in
water, 0.20 mL) and 1N NaOH solution (0.50 mL) was sequentially added. The resulting
mixture was warmed to room temperature, stirred for 15 min and extracted with ethyl
acetate (2 ×20 mL). The combined organic extracts were dried (Na2SO4), and concentrated.
The residue was purified by column chromatography (SiO2, hexanes-ethyl acetate = 60:40)
to give 3.36 (0.025 g, 22%) as a colorless solid. This was determined to be a 1:2 mixture
of cis- and trans-stereoisomers by 1H NMR integration. 1H NMR (400 MHz, CDCl3) 7.507.28 (m, 5H), 7.01-6.80 (m, 3H), 5.11 (s, 2H), 3.67 (d, J = 7.9 Hz, 0.7H), 3.50 (d, J = 6.2
Hz, 1.3H), 2.60-2.50 (m, 0.3H), 2.47-2.36 (m, 0.7H), 1.98-1.33 (m, 8H), 1.17-1.03 (m, 1H)
ppm.

13

C NMR (100 MHz, CDCl3) δ 154.2, 151.8, 144.8, 141.6, 137.0, 128.8, 128.2,

127.6, 122.4, 122.3, 115.9, 115.1, 114.9, 114.7, 71.8, 68.7, 64.6, 43.7, 42.2, 40.2, 36.2,
33.9, 29.8, 29.3, 26.8 ppm.
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2-Fluoro-4-(4-(hydroxymethyl)cyclohexyl)phenol (3.37). To a solution of 3.36 (0.050
g, 0.159 mmol) in ethyl acetate (10 mL) was added 10% Pd/C (0.017 g, 10 mol %) and
mixture was stirred under a balloon of H2 at room temperature for 12 h. The reaction
mixture was filtered through a pad of celite, concentrated, and the residue was purified by
column chromatography (SiO2, hexanes-ethyl acetate = 60:40) to give 3.37 (0.018 g, 51%)
as a colorless solid. This was determined to be a 1:2 mixture of cis- and trans-stereoisomers
by 1H NMR integration. 1H NMR (400 MHz, CD3OD) 6.92-6.85 (m, 1H), 6.84-6.76 (m,
2H), 3.60 (d, J = 7.4 Hz, 0.7H), 3.39 (d, J = 6.5 Hz, 1.3H), 2.55-2.33 (m, 1H), 1.94-1.34
(m, 8H), 1.15-1.01 (m, 1H) ppm.

13

C NMR (100 MHz, CD3OD) δ 154.0, 151.6, 143.9,

141.1, 123.5, 118.5, 115.0, 68.8, 64.4, 45.0, 41.3, 37.1, 35.2, 31.0, 30.4, 29.5, 27.8 ppm.
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2-Fluoro-4-(4-hydroxycyclohexyl)phenol (3.38). To a solution of 3.33 (0.033 g, 0.159
mmol) in anhydrous methanol (10 mL) was added NaBH4 (0.090 g, 2.38 mmol). The
mixture was stirred at room temperature for 2 h and then diluted with water. The resulting
mixture was extracted with ethyl acetate (2× 15 mL), combined extracts were dried
(Na2SO4) and concentrated. Purification of the crude material by column chromatography
(SiO2, hexanes-ethyl acetate = 65:35) gave the 3.38 (0.020 g, 61%) as a colorless solid. mp
179-186 °C. 1H NMR (400 MHz, CD3OD) δ 6.91-6.85 (m, 1H), 6.83-6.74 (m, 2H), 3.603.52 (m, 1H), 2.39 (tt, J = 12.0, 3.1 Hz, 1H), 2.05-1.96 (m, 2H), 1.88-1.79 (m, 2H), 1.521.20 (m, 4H) ppm.
F

13

C NMR (100 MHz, CD3OD) δ 152.8 (d, JC-F = 240 Hz), 144.0 (d, JC-

= 10 Hz), 140.3, 123.6, 118.5, 115.1 (d, JC-F = 10 Hz), 71.1, 44.0, 36.6, 33.8 ppm.
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5-(4-Methoxyphenyl)-1,2-cycloheptanediol (2.5b). Epoxide 2.5a (0.103 g, 0.469 mmol)
was dissolved in 0.5 M sulfuric acid solution (50 mL) and heated to reflux for 24 h. The
organic oil turned to a brown color and the mixture was allowed to cool and extracted with
ether (3 × 30 mL). The combined ethereal extracts were washed with water (2 × 20 mL),
dried (MgSO4) and concentrated to give a crude residue. The residue was purified by
column chromatography (SiO2, ethyl acetate = 100%) to give 2.5b (0.064g, 65%) as a
colorless solid. mp 66-70 ˚C. 1H NMR (400 MHz, CDCl3)  7.08 and 6.82 (AA’BB’, JAB
= 8.5 Hz, 4H), 3.79 (s, 3H), 3.67-3.51 (m, 2H), 2.92 (s, 2H), 2.69-2.60 (m, 1H), 2.02-1.77
(m, 6H), 1.68-1.54 (m, 2H) ppm. 13C NMR (400 MHz, CDCl3)  157.8, 141.0, 127.4, 113.8,
78.5, 77.2, 55.3, 44.1, 33.2, 31.9, 30.8, 29.8 ppm

4-(4-((tert-Butyldimethylsilyl)oxy)phenyl)cyclohexane-1-carboxaldehyde (3.7-I). To
a solution of 3.7 (0.315 g, 0.983 mmol) in CH2Cl2 (15 mL) at room temperature, was added
Dess–Martin periodinane (0.625 g, 1.47 mmol) and water (10 drops) and mixture was
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stirred at room temperature for 6 h.
thiosulfate:sodium bicarbonate solution.

The mixture was quenched with 1:1 sodium
The resulting mixture was stirred at room

temperature for 30 min, and extracted with ethyl acetate (2 x 20 mL), dried (MgSO 4), and
concentrated to give the product 3.7-I (0.282 g, 90%) as a mixture of stereoisomers.

1

H

NMR (400 MHz, CDCl3) δ 9.78 and 9.67 (2 x s, 1H total), 7.10-6.97 (m, 2H), 6.80-6.71
(m, 2H), 2.56-1.32 (m, 10H), 0.97 (s, 9H), 0.18 (s, 6H) ppm.

13

C NMR (100 MHz, CDCl3)

δ 205.9, 153.9, 139.9, 127.8, 119.9, 46.5, 42.9, 42.8, 41.6, 33.6, 33.3, 31.1, 30.8, 29.4, 27.6,
26.6, 25.9, 25.2, 18.4, -4.2 ppm.

4-(4-(((tert-Butyldimethylsilyl)oxy)methyl)cyclohexyl)phenol (3.4a-I). To a solution of
4-(4-(hydroxymethyl)cyclohexyl)phenol 3.4a (0.225 g, 1.09 mmol) in dry CH2Cl2 (30 ml)
at 0 °C, was added imidazole (0.223 g, 3.27 mmol) and the mixture was stirred for a 30
min. A solution of t- butyldimethylsilyl chloride (0.115 g, 0.764 mmol) was added, and
the mixture was slowly warmed to room temperature and stirred for 8 h. The mixture was
diluted with water (20 mL) and extracted with CH2Cl2 (2 × 20 mL). The combined organic
extracts were washed with brine, dried (Na2SO4), and concentrated. The residue was
purified by column chromatography (SiO2, hexanes-ethyl acetate = 90: 10) to give the
product 3.4a-I (0.090 g, 26%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.14-7.04
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(m, 2H), 6.82-6.73 (m, 2H), 5.14 (s, 1H), 3.67 (d, J = 7.6 Hz, 1.2 H), 3.49 (d, J = 6.2 Hz,
0.8H), 2.60-2.48 (m, 0.6 H), 2.41 (br t, J = 11.5 Hz, 0.4 H), 1.96-1.34 (m, 9H), 0.94 (s, 9H),
0.10 (s, 6H) ppm.

13

C NMR (100 MHz, CDCl3) δ 153.8, 140.0, 139.6, 128.1, 115.3, 69.1,

64.9, 43.9, 42.5, 40.2, 35.8, 34.2, 30.1, 29.6, 26.9, 26.2, 18.6, -5.0 ppm.

4-(4-(((tert-Butyldiphenylsilyl)oxy)methyl)cycloheptyl)phenol (2.10-I). To a solution
of 4-(4-(hydroxymethyl)cycloheptyl)phenol 2.10 (0.158 g, 0.717 mmol) in dry CH2Cl2 (15
ml) at 0 °C, was added imidazole (0.122 g, 1.79 mmol). The mixture was stirred for 30
min and then a solution of t-butyldiphenylsilyl chloride (0.15 mL, 0.574 mmol) in CH2Cl2
(2 mL) was added. The mixture was slowly warmed to room temperature and stirred
overnight. The mixture was diluted with brine (20 mL) and extracted with CH 2Cl2 (2 × 20
mL). The combined organic extracts were dried (Na2SO4), and concentrated. The residue
was purified by column chromatography (SiO2, hexanes-ethyl acetate = 80: 20) to give the
product 2.10-I (0.135 g, 41%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.79-7.68
(m, 4H), 7.51-7.38 (m, 6H), 7.13-7.04 (m, 2H), 6.82-6.74 (m, 2H), 5.05 (s, 1H), 3.53 (s,
2H), 2.75-2.50 (m, 1H), 2.02-1.42 (m, 11H), 1.12 (s, 9H) ppm.

13

C NMR (100 MHz,

CDCl3) δ 153.4, 142.1, 135.8, 134.2, 129.7, 127.8, 115.3, 69.3, 69.1, 47.4, 46.2, 42.0, 41.1,
39.0, 36.9, 36.5, 33.0, 31.5, 30.6, 30.0, 28.5, 27.4, 24.3, 19.5 ppm.
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APPENDIX

Table 1 Crystal data and structure refinement for ISP163-PK1
Identification code
ISP163PK-1 (don2e)
Empirical formula
C14H20O2
Formula weight
220.30
Temperature/K
99.90(14)
Crystal system
orthorhombic
Space group
P212121
a/Å
9.9579(5)
b/Å
10.1803(8)
c/Å
24.0251(12)
α/°
90.00
β/°
90.00
γ/°
90.00
Volume/Å3
2435.5(3)
Z
8
3
ρcalcg/cm
1.202
-1
μ/mm
0.617
F(000)
960.0
3
Crystal size/mm
0.3986 × 0.202 × 0.0143
Radiation
Cu Kα (λ = 1.54184)
2Θ range for data collection/° 7.36 to 148.1
Index ranges
-9 ≤ h ≤ 12, -10 ≤ k ≤ 12, -29 ≤ l ≤ 27
Reflections collected
12560
Independent reflections
4845 [Rint = 0.0642, Rsigma = 0.0740]
Data/restraints/parameters
4845/0/293
2
Goodness-of-fit on F
1.052
Final R indexes [I>=2σ (I)] R1 = 0.0807, wR2 = 0.1991
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Final R indexes [all data]
R1 = 0.1259, wR2 = 0.2335
Largest diff. peak/hole / e Å-3 0.34/-0.31
Flack parameter
-1.1(5)
Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic
Displacement Parameters (Å2×103) for don2e. Ueq is defined as 1/3 of of the trace of
the orthogonalised UIJ tensor.
Atom
x
y
z
U(eq)
1257(4)
1630(3)
813.4(12)
52.5(8)
O1
3907(3)
358(4)
5117.3(13)
59.1(9)
O2
1195(4)
854(4)
2522.1(16)
37.3(9)
C1
1216(4)
2128(5)
2308.6(18)
44.1(10)
C2
1228(4)
2376(5)
1742.0(18)
44.4(10)
C3
1263(4)
1325(5)
1370.9(17)
43(1)
C4
1255(5)
56(5)
1570.3(18)
47.4(10)
C5
1227(4)
-190(5)
2138.3(17)
42.8(9)
C6
1205(4)
595(5)
3144.6(17)
40.8(9)
C7
2613(4)
837(6)
3378.8(19)
50.9(12)
C8
2777(4)
415(6)
3985.6(19)
51.3(12)
C9
2505(5)
1489(6)
4415(2)
55.6(13)
C10
1114(6)
2141(7)
4353(2)
72.2(17)
C11
21(5)
1331(6)
4067(2)
59.9(14)
C12
73(4)
1388(6)
3436.0(18)
51.2(12)
C13
2660(4)
1019(6)
5005(2)
57.4(13)
C14
3775(3)
5782(4)
587.8(12)
50.2(8)
O1A
2794(4)
6197(4)
5279.3(14)
63(1)
O2A
3762(4)
6250(4)
2321.7(17)
40.8(9)
C1A
3683(4)
4998(5)
2084.0(18)
43.2(10)
C2A
3678(4)
4818(5)
1513.4(17)
41.2(9)
C3A
3766(4)
5923(4)
1159.4(18)
41.8(9)
C4A
3875(5)
7157(5)
1385(2)
47.8(10)
C5A
3867(5)
7312(5)
1957(2)
46.3(10)
C6A
3723(4)
6485(5)
2944.2(18)
46.8(10)
C7A
2439(5)
6014(11)
3195(2)
109(3)
C8A
2148(5)
6604(11)
3763(2)
127(4)
C9A
2678(5)
5945(7)
4266(2)
71.9(18)
C10A
4048(7)
5372(7)
4195(3)
80(2)
C11A
5045(4)
6139(9)
3868(2)
82(2)
C12A
4968(4)
6014(8)
3225(2)
69.7(19)
C13A
2565(6)
6837(7)
4755(2)
73.8(18)
C14A
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Table 3 Anisotropic Displacement Parameters (Å2×103) for don2e. The Anisotropic
displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…].
Atom
U11
U22
U33
U23
U13
U12
49.1(16)
69(2) 39.9(16) -0.5(15) 3.0(14) -11.0(18)
O1
39.9(15)
87(3) 50.0(19) 11.3(18) -3.4(14) -4.1(18)
O2
26.1(15)
41(2)
45(2) -4.6(17) 0.6(16) -6.3(18)
C1
31.1(17)
52(3)
49(2)
-8(2) 1.0(19)
-6(2)
C2
34.3(18)
45(2)
54(3)
2(2) 1.5(19)
-2(2)
C3
26.5(16)
55(3)
47(2)
-2(2) 2.1(17)
-7(2)
C4
38.2(19)
52(3)
52(3)
-8(2)
7(2)
-3(2)
C5
37.2(18)
44(2)
48(2) -4.4(19) 3.5(19)
1(2)
C6
28.4(16)
48(2)
46(2) -2.7(18) -1.1(17)
1.2(19)
C7
27.0(18)
76(4)
49(3)
-5(2) -0.6(17)
2(2)
C8
32.5(18)
69(3)
53(3)
-3(2) -6.2(18)
9(2)
C9
48(2)
68(4)
50(3)
-7(2)
-9(2)
-5(2)
C10
68(3)
92(4)
57(3)
-20(3)
-16(3)
26(4)
C11
39(2)
81(4)
59(3)
-3(3)
5(2)
14(2)
C12
26.2(17)
80(4)
47(3)
0(2) 1.8(17)
6(2)
C13
41(2)
85(4)
46(3)
-3(3) -2.3(19)
4(2)
C14
41.1(14)
66(2) 43.4(17)
2.6(14) 0.9(13) -11.1(17)
O1A
73(2)
73(3) 43.3(19)
1.9(17) -2.3(16)
-24(2)
O2A
30.4(16)
42(2)
50(2)
-2.5(19)
-1.4(17)
1.5(19)
C1A
31.2(18)
53(3)
45(2)
5.8(19) 4.1(17) -4.0(19)
C2A
32.4(18)
41(2)
50(2) -1.7(19) 0.9(17)
0.3(18)
C3A
26.3(15)
50(3)
50(2)
6.7(19) -1.6(17) -5.7(19)
C4A
39(2)
45(3)
60(3)
11(2)
-4(2)
-7(2)
C5A
39(2)
36(2)
65(3)
-2(2)
-7(2)
0(2)
C6A
35.7(19)
58(3)
46(2)
-8(2)
-5.8(18)
5(2)
C7A
36(2) 253(11)
39(3)
-31(4)
3(2)
-25(4)
C8A
38(2) 303(14)
40(3)
-34(5)
-10(2)
42(5)
C9A
59(3)
111(5)
46(3)
-21(3)
18(2)
-36(3)
C10A
107(5)
69(4)
63(4)
12(3)
4(3)
31(4)
C11A
30(2)
170(7)
46(3)
18(4)
-8(2)
-8(3)
C12A
30(2)
138(6)
42(3)
3(3) 0.8(18)
4(3)
C13A
75(4)
111(5)
35(3)
-7(3)
-8(2)
21(3)
C14A
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Table 4 Bond Lengths for don2e.
Atom Atom Length/Å Atom Atom
1.375(5) O1A C4A
O1 C4
1.437(6) O2A C14A
O2 C14
1.395(7) C1A C2A
C1 C2
1.408(6) C1A C6A
C1 C6
1.519(6) C1A C7A
C1 C7
1.384(6) C2A C3A
C2 C3
1.393(6) C3A C4A
C3 C4
1.378(7) C4A C5A
C4 C5
1.388(6) C5A C6A
C5 C6
1.530(5) C7A C8A
C7 C8
1.553(6) C7A C13A
C7 C13
1.529(7) C8A C9A
C8 C9
1.528(7) C9A C10A
C9 C10
1.544(7) C10A C11A
C10 C11
1.505(7) C10A C14A
C10 C14
1.528(8) C11A C12A
C11 C12
1.517(7) C12A C13A
C12 C13

Table 5 Bond Angles for don2e.
Atom Atom Atom
Angle/˚
117.4(4)
C2 C1 C6
121.6(4)
C2 C1 C7
120.9(4)
C6 C1 C7
122.1(4)
C3 C2 C1
119.3(4)
C2 C3 C4
116.7(4)
O1 C4 C3
123.4(4)
O1 C4 C5
119.8(4)
C5 C4 C3
120.7(4)
C4 C5 C6
120.6(4)
C5 C6 C1
109.9(3)
C1 C7 C8
110.4(4)
C1 C7 C13
114.6(4)
C8 C7 C13
113.8(4)
C9 C8 C7
115.1(5)
C10 C9 C8
113.6(4)
C9 C10 C11
113.0(5)
C14 C10 C9
108.7(4)
C14 C10 C11

Length/Å
1.381(5)
1.436(7)
1.398(6)
1.395(6)
1.515(6)
1.383(6)
1.413(6)
1.372(7)
1.384(7)
1.493(7)
1.490(6)
1.519(8)
1.479(10)
1.494(8)
1.490(8)
1.489(9)
1.551(7)

Atom Atom Atom
C2A C1A C7A
C6A C1A C2A
C6A C1A C7A
C3A C2A C1A
C2A C3A C4A
O1A C4A C3A
C5A C4A O1A
C5A C4A C3A
C4A C5A C6A
C5A C6A C1A
C8A C7A C1A
C13A C7A C1A
C13A C7A C8A
C7A C8A C9A
C10A C9A C8A
C9A C10A C11A
C9A C10A C14A
C14A C10A C11A

Angle/˚
123.1(4)
117.0(4)
119.9(4)
121.7(4)
119.4(4)
121.1(4)
119.2(4)
119.7(4)
119.8(4)
122.4(4)
111.7(4)
112.0(4)
115.2(5)
113.5(6)
119.2(8)
114.1(4)
109.9(6)
113.4(5)
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C12
C13
C12
O2

C11
C12
C13
C14

C10
C11
C7
C10

116.8(5)
113.9(5)
117.1(4)
114.4(4)

C12A C11A C10A
C11A C12A C13A
C7A C13A C12A
O2A C14A C10A

Table 6 Hydrogen Bonds for don2e.
D
H
A
d(D-H)/Å
d(H-A)/Å
0.84
1.80
O1 H1
O21
2
0.84
2.11
O2 H2
O1A
3
0.84
1.82
O1A H1A O2A
4
0.84
1.93
O2A H2AA O1

d(D-A)/Å
2.631(5)
2.896(5)
2.655(5)
2.726(5)

117.7(6)
116.7(6)
117.8(4)
113.7(6)

D-H-A/°
167.6
156.0
175.7
158.1

11/2-X,-Y,-1/2+Z; 21-X,-1/2+Y,1/2-Z; 31/2-X,1-Y,-1/2+Z; 41/2-X,1-Y,1/2+Z

Table 7 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement
Parameters (Å2×103) for don2e.
Atom
x
y
z
U(eq)
1276
935
625
H1
4412
420
4839
H2
1221
2849
2560
H2A
1213
3254
1608
H3
1270
-659
1316
H5
1229
-1071
2269
H6
999
-357
3199
H7
3273
354
3148
H8A
2822
1785
3348
H8B
2160
-328
4059
H9A
3705
90
4039
H9B
3193
2191
4355
H10
789
2380
4729
H11A
1230
2967
4141
H11B
107
404
4186
H12A
-868
1652
4192
H12B
164
2320
3325
H13A
-800
1072
3291
H13B
2584
1783
5258
H14A
1911
413
5092
H14B
3305
5130
498
H1A
3190
6716
5496
H2AA

79
89
53
53
57
51
49
61
61
62
62
67
87
87
72
72
61
61
69
69
75
95
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H2AB
H3A
H5A
H6A
H7A
H8AA
H8AB
H9AA
H9AB
H10A
H11C
H11D
H12C
H12D
H13C
H13D
H14C
H14D

3632
3615
3956
3935
3721
2474
1690
2497
1161
2063
4429
3947
5955
4941
5737
5091
3221
1656

4252
3960
7902
8172
7461
5046
6234
7514
6662
5189
5219
4502
5867
7078
6500
5076
7560
7231

2321
1361
1150
2108
2992
3230
2940
3763
3804
4342
4570
4015
3987
3966
3065
3129
4713
4759

52
49
57
56
56
131
131
153
153
86
96
96
98
98
84
84
89
89
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Table 1 Crystal data and structure refinement for ISP163-PK3.
Identification code
ISP163-PK3 (don2d)
Empirical formula
C14H20O2
Formula weight
220.30
Temperature/K
100.00(10)
Crystal system
monoclinic
Space group
P21
a/Å
10.0103(7)
b/Å
10.1468(8)
c/Å
12.2271(9)
α/°
90.00
β/°
103.012(8)
γ/°
90.00
3
Volume/Å
1210.05(16)
Z
4
3
ρcalcg/cm
1.209
-1
μ/mm
0.621
F(000)
480.0
3
Crystal size/mm
0.2462 × 0.1633 × 0.0221
Radiation
Cu Kα (λ = 1.54184)
2Θ range for data collection/° 7.42 to 148.44
Index ranges
-12 ≤ h ≤ 11, -12 ≤ k ≤ 12, -14 ≤ l ≤ 15
Reflections collected
15025
Independent reflections
4596 [Rint = 0.0583, Rsigma = 0.0618]
Data/restraints/parameters
4596/1/305
Goodness-of-fit on F2
1.029
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Final R indexes [I>=2σ (I)] R1 = 0.0528, wR2 = 0.1256
Final R indexes [all data]
R1 = 0.0730, wR2 = 0.1399
-3
Largest diff. peak/hole / e Å 0.28/-0.25
Flack parameter
0.0(3)
Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic
Displacement Parameters (Å2×103) for don2d. Ueq is defined as 1/3 of of the trace of
the orthogonalised UIJ tensor.
Atom
x
y
z
U(eq)
3964(2)
4063(2)
1458.7(16)
30.5(4)
O1
7030(2)
6822(2)
10051.0(17)
33.9(5)
O2
5101(3)
4152(3)
4982(2)
26.6(5)
C1
3716(3)
4102(3)
4424(2)
29.8(6)
C2
3325(3)
4072(3)
3253(2)
28.0(6)
C3
4309(3)
4102(3)
2620(2)
25.5(5)
C4
5691(3)
4153(3)
3157(2)
28.8(6)
C5
6061(3)
4162(3)
4325(2)
28.4(6)
C6
5523(3)
4186(3)
6257(2)
26.7(6)
C7
4760(3)
5290(3)
6723(2)
33.7(7)
C8
5481(3)
5899(3)
7855(2)
31.7(6)
C9
6122(3)
4950(3)
8812(2)
27.5(6)
C10
5385(3)
3632(3)
8797(2)
31.3(6)
C11
5806(4)
2622(3)
8006(3)
34.2(7)
C12
5262(3)
2835(3)
6748(2)
32.1(6)
C13
6212(3)
5645(3)
9938(2)
32.9(7)
C14
-429(2)
6584(2)
1371.8(17)
33.8(5)
O1A
1553(2)
5163(3)
10642.6(17)
41.3(6)
O2A
-226(3)
6766(3)
4824(2)
27.8(6)
C1A
954(3)
6672(3)
4404(2)
30.8(6)
C2A
872(3)
6620(3)
3249(2)
32.7(6)
C3A
-399(3)
6647(3)
2508(2)
28.2(6)
C4A
-1590(3)
6727(3)
2902(2)
30.6(6)
C5A
-1484(3)
6790(3)
4059(2)
29.8(6)
C6A
-183(3)
6805(3)
6074(2)
30.4(6)
C7A
32(3)
5426(3)
6601(2)
31.3(6)
C8A
-555(3)
5270(4)
7643(2)
35.8(7)
C9A
261(3)
5862(3)
8769(2)
29.9(6)
C10A
1373(3)
6864(4)
8679(2)
34.3(6)
C11A
863(4)
8053(3)
7923(3)
36.7(7)
C12A
820(4)
7856(4)
6671(3)
38.7(7)
C13A
866(4)
4736(4)
9545(2)
37.8(7)
C14A
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Table 3 Anisotropic Displacement Parameters (Å2×103) for don2d. The Anisotropic
displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…].
Atom
U11
U22
U33
U23
U13
U12
34.0(11) 26.7(12)
27(1)
2.2(9) -0.8(8)
5.1(9)
O1
39.7(11) 22.1(11) 34.2(10) -0.4(9) -3.4(9)
-1.1(9)
O2
29.8(13) 17.6(13) 30.1(12) -0.3(11) 1.7(10) -1.7(11)
C1
29.6(13) 26.9(15) 32.4(14) -1.0(13) 6.1(11) -3.7(12)
C2
24.3(12) 22.4(14) 32.7(14) 3.2(12) -3.1(10) -1.1(11)
C3
30.6(13) 16.3(13) 26.7(12) -1.0(11) 0.4(10)
0.8(11)
C4
31.7(14) 21.9(14) 31.3(13) 0.4(12) 3.6(11)
2.0(12)
C5
24.2(12) 22.1(14) 35.2(14) -0.5(13) -1.4(11) -0.2(11)
C6
31.2(14) 21.0(14) 26.2(13) -0.7(11) 3.0(11) -0.7(11)
C7
39.1(16) 27.0(17) 29.4(14) -3.0(12) -4.2(12)
6.6(13)
C8
40.8(16) 23.6(15) 27.7(15) -0.5(12) 1.5(12)
1.4(13)
C9
29.3(14) 22.8(15) 28.7(13) -1.0(11) 3.1(11) -1.4(11)
C10
39.4(15) 22.5(15) 31.3(14) -0.7(12) 6.8(12) -7.5(12)
C11
48.4(18) 18.6(15) 33.5(16) 0.5(11) 4.5(13) -1.9(12)
C12
41.8(16) 21.5(15) 30.7(15) 0.0(12) 3.7(12) -1.8(12)
C13
40.4(16) 26.6(17) 29.9(15) -0.9(11) 4.3(12) -2.6(12)
C14
38.3(12) 37.7(14) 23.8(10)
1.8(9)
3.7(9)
5.7(10)
O1A
44.2(13) 47.9(15)
27(1) 1.1(10) -2.4(9) 16.2(11)
O2A
33.8(14) 22.7(14) 25.4(13) -0.6(12) 3.3(11) -1.0(12)
C1A
26.3(13) 30.9(16) 30.6(13) 0.5(12) -3.4(10) -1.4(12)
C2A
30.0(14) 37.0(19) 31.0(14) 1.8(13) 7.1(11) -0.4(13)
C3A
34.8(14) 21.9(15) 26.1(13) 1.1(11) 3.4(11)
1.0(12)
C4A
27.2(13) 30.5(16) 30.5(14) 0.3(13)
-1(1)
1.4(12)
C5A
29.4(13) 28.7(16) 30.7(13) -1.3(12) 5.5(11)
0.3(12)
C6A
31.8(13) 31.4(17) 25.9(13) -3.5(12) 2.4(11)
1.5(13)
C7A
36.8(15) 28.8(16) 26.7(13) -2.4(12) 3.5(11) -3.5(12)
C8A
37.0(15) 38.0(19) 29.7(14) -0.4(13) 1.5(12) -10.9(14)
C9A
2.2(13)
C10A 31.0(14) 31.6(17) 24.8(13) -0.9(11) 1.4(11)
C11A 32.6(14) 36.4(18) 29.9(14) -2.6(13) -1.2(11) -4.7(14)
C12A 50.0(19) 27.0(17) 30.9(15) -8.0(12) 4.4(13) -9.9(14)
C13A 54.3(19) 27.5(17) 33.1(16) -3.2(13) 7.3(14) -9.9(15)
7.5(14)
C14A 45.1(18) 37.3(19) 28.1(15) -1.3(13) 2.3(13)
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Table 4 Bond Lengths for don2d.
Atom Atom Length/Å Atom Atom
1.384(3) O1A C4A
O1 C4
1.438(4) O2A C14A
O2 C14
1.402(4) C1A C2A
C1 C2
1.384(4) C1A C6A
C1 C6
1.521(4) C1A C7A
C1 C7
1.397(4) C2A C3A
C2 C3
1.384(4) C3A C4A
C3 C4
1.392(4) C4A C5A
C4 C5
1.393(4) C5A C6A
C5 C6
1.537(4) C7A C8A
C7 C8
1.542(4) C7A C13A
C7 C13
1.539(4) C8A C9A
C8 C9
1.539(4) C9A C10A
C9 C10
1.526(4) C10A C11A
C10 C11
1.531(4) C10A C14A
C10 C14
1.532(4) C11A C12A
C11 C12
1.528(4) C12A C13A
C12 C13

Table 5 Bond Angles for don2d.
Atom Atom Atom
Angle/˚
121.0(3)
C2 C1 C7
117.2(3)
C6 C1 C2
121.7(3)
C6 C1 C7
121.2(3)
C3 C2 C1
120.1(2)
C4 C3 C2
118.5(2)
O1 C4 C5
121.9(2)
C3 C4 O1
119.6(2)
C3 C4 C5
119.4(3)
C4 C5 C6
122.4(3)
C1 C6 C5
110.5(2)
C1 C7 C8
110.3(2)
C1 C7 C13
111.2(2)
C8 C7 C13
117.0(2)
C7 C8 C9
117.6(3)
C8 C9 C10
114.9(3)
C11 C10 C9
110.1(2)
C11 C10 C14
109.0(2)
C14 C10 C9

Length/Å
1.384(3)
1.430(4)
1.394(4)
1.389(4)
1.520(4)
1.396(4)
1.387(4)
1.384(4)
1.397(4)
1.535(5)
1.532(4)
1.527(4)
1.555(4)
1.530(4)
1.521(4)
1.536(5)
1.535(4)

Atom Atom Atom
C2A C1A C7A
C6A C1A C2A
C6A C1A C7A
C1A C2A C3A
C4A C3A C2A
O1A C4A C3A
C5A C4A O1A
C5A C4A C3A
C4A C5A C6A
C1A C6A C5A
C1A C7A C8A
C1A C7A C13A
C13A C7A C8A
C9A C8A C7A
C8A C9A C10A
C11A C10A C9A
C14A C10A C9A
C14A C10A C11A

Angle/˚
122.5(2)
117.9(2)
119.5(2)
120.9(3)
119.8(3)
117.7(3)
121.7(3)
120.6(2)
118.7(3)
122.1(3)
111.6(3)
111.4(3)
114.8(3)
113.6(3)
118.4(3)
116.0(2)
108.6(3)
110.5(3)

205

C10
C13
C12
O2

C11
C12
C13
C14

C12
C11
C7
C10

113.1(2)
117.0(3)
117.7(2)
112.7(2)

C10A C11A C12A
C13A C12A C11A
C7A C13A C12A
O2A C14A C10A

Table 6 Torsion Angles for don2d.
A B C D
Angle/˚
A
B
C
D
-178.6(3) O1A C4A C5A C6A
O1 C4 C5 C6
-0.5(5) C1A C2A C3A C4A
C1 C2 C3 C4
-152.1(3) C1A C7A C8A C9A
C1 C7 C8 C9
171.7(3) C1A C7A C13A C12A
C1 C7 C13 C12
1.4(5) C2A C1A C6A C5A
C2 C1 C6 C5
-52.0(4) C2A C1A C7A C8A
C2 C1 C7 C8
71.3(4) C2A C1A C7A C13A
C2 C1 C7 C13
179.4(3) C2A C3A C4A O1A
C2 C3 C4 O1
0.4(5) C2A C3A C4A C5A
C2 C3 C4 C5
0.5(5) C3A C4A C5A C6A
C3 C4 C5 C6
-1.5(5) C4A C5A C6A C1A
C4 C5 C6 C1
-0.4(5) C6A C1A C2A C3A
C6 C1 C2 C3
128.3(3) C6A C1A C7A C8A
C6 C1 C7 C8
C6 C1 C7 C13 -108.4(3) C6A C1A C7A C13A
179.9(3) C7A C1A C2A C3A
C7 C1 C2 C3
-178.9(3)
C7 C1 C6 C5
C7A C1A C6A C5A
-46.7(4)
C7 C8 C9 C10
C7A C8A C9A C10A
-65.4(3) C8A C7A C13A C12A
C8 C7 C13 C12
-31.4(4) C8A C9A C10A C11A
C8 C9 C10 C11
C8 C9 C10 C14 -155.6(3) C8A C9A C10A C14A
83.1(3) C9A C10A C11A C12A
C9 C10 C11 C12
-59.6(3)
C9 C10 C14 O2
C9A C10A C14A O2A
-73.8(4)
C10 C11 C12 C13
C10A C11A C12A C13A
173.4(2) C11A C10A C14A O2A
C11 C10 C14 O2
53.9(4) C11A C12A C13A C7A
C11 C12 C13 C7
85.1(3) C13A C7A C8A C9A
C13 C7 C8 C9
-153.3(3)
C14 C10 C11 C12
C14A C10A C11A C12A

114.6(2)
115.4(3)
115.7(3)
113.4(3)

Angle/˚
-179.9(3)
-0.7(5)
-153.1(2)
175.5(3)
-0.2(5)
-78.5(4)
51.2(4)
-179.6(3)
0.1(5)
0.4(5)
-0.4(5)
0.8(5)
99.7(3)
-130.5(3)
179.0(3)
-178.5(3)
-77.5(4)
-56.5(4)
16.0(4)
-109.1(3)
56.6(4)
-175.4(3)
-86.4(3)
56.3(3)
64.3(4)
79.0(3)
-179.3(3)
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Table 7 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement
Parameters (Å2×103) for don2d.
Atom
x
y
z
U(eq)
3290(40)
4440(40)
1220(30)
23(9)
H1
6610(40)
7460(50)
9600(40)
52(12)
H2
3031
4088
4850
36
H2A
2381
4032
2890
34
H3
6375
4181
2730
35
H5
7007
4176
4685
34
H6
6529
4375
6479
32
H7
3864
4938
6802
40
H8A
4570
6006
6159
40
H8B
4807
6457
8120
38
H9A
6215
6488
7719
38
H9B
7081
4760
8744
33
H10
4383
3781
8563
38
H11A
5582
3266
9567
38
H11B
6820
2605
8158
41
H12A
5502
1741
8200
41
H12B
4259
2685
6576
38
H13A
5667
2149
6346
38
H13B
5275
5874
10012
39
H14A
6610
5030
10554
39
H14B
-1140(50)
6720(50)
1020(30)
57(13)
H1A
900(50)
5610(60)
10900(40)
79(16)
H2AA
1826
6643
4910
37
H2AB
1685
6566
2973
39
H3A
-2461
6739
2394
37
H5A
-2298
6850
4332
36
H6A
-1115
7095
6145
36
H7A
-403
4768
6034
38
H8AA
1027
5235
6806
38
H8AB
-674
4316
7761
43
H9AA
-1481
5671
7476
43
H9AB
-415
6324
9125
36
H10A
2095
6410
8387
41
H11C
1798
7189
9442
41
H11D
-71
8281
8005
44
H12C
1464
8815
8196
44
H12D
577
8707
6282
46
H13C
1752
7618
6592
46
H13D
120
4122
9614
45
H14C
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H14D

1523

4245

9203

45
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Table 1 Crystal data and structure refinement for ISP163-PK4.
Identification code
ISP163-PK4 (don2c)
Empirical formula
C14H20O2
Formula weight
220.30
Temperature/K
99.90(14)
Crystal system
monoclinic
Space group
P21
a/Å
10.0043(3)
b/Å
10.1405(4)
c/Å
12.2188(3)
α/°
90.00
β/°
103.121(3)
γ/°
90.00
3
Volume/Å
1207.22(6)
Z
4
ρcalcg/cm3
1.212
-1
μ/mm
0.623
F(000)
480.0
3
Crystal size/mm
0.8254 × 0.4513 × 0.0546
Radiation
CuKα (λ = 1.54184)
2Θ range for data collection/° 7.42 to 148.64
Index ranges
-12 ≤ h ≤ 12, -12 ≤ k ≤ 12, -15 ≤ l ≤ 14
Reflections collected
7992
Independent reflections
7992 [Rint = 0.0000, Rsigma = 0.0091]
Data/restraints/parameters
7992/1/306

209

Goodness-of-fit on F2
1.062
Final R indexes [I>=2σ (I)] R1 = 0.0688, wR2 = 0.1938
Final R indexes [all data]
R1 = 0.0696, wR2 = 0.1948
-3
Largest diff. peak/hole / e Å 0.48/-0.25
Flack parameter
-0.1(2)
Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic
Displacement Parameters (Å2×103) for don2c. Ueq is defined as 1/3 of of the trace of
the orthogonalised UIJ tensor.
Atom
x
y
z
U(eq)
6036.6(17)
5934.1(17)
8540.7(12)
24.9(3)
O1
2970.2(16)
3174.2(18)
-54.6(13)
27.7(4)
O2
4897(2)
5849(2)
5011.7(18)
21.2(4)
C1
6281(2)
5899(2)
5572.3(18)
23.3(4)
C2
6675(2)
5927(2)
6742.1(18)
23.8(4)
C3
5689(2)
5899(2)
7383.4(17)
21.3(4)
C4
4305(2)
5854(2)
6841.0(17)
23.2(4)
C5
3924(2)
5837(2)
5673.1(18)
23.1(4)
C6
4475(2)
5811(2)
3739.4(17)
21.4(4)
C7
5250(3)
4704(3)
3278.6(19)
28.7(5)
C8
4522(2)
4099(2)
2145.5(19)
26.1(5)
C9
3877(2)
5049(2)
1185.7(18)
22.2(4)
C10
4614(2)
6376(2)
1204.0(19)
26.3(5)
C11
4188(3)
7377(2)
1996(2)
28.6(5)
C12
4737(3)
7167(2)
3257.9(19)
26.8(5)
C13
3795(2)
4357(2)
61.7(18)
25.3(5)
C14
426.7(18)
3417.3(18)
8623.7(13)
27.1(4)
O1A
-1557(2)
4841(2)
-642.8(14)
34.3(4)
O2A
231(2)
3231(2)
5173.3(17)
22.8(4)
C1A
-958(2)
3335(3)
5590.8(18)
26.2(5)
C2A
-870(2)
3392(3)
6746.1(18)
25.5(5)
C3A
402(2)
3353(2)
7495.6(18)
23.4(4)
C4A
1600(2)
3268(3)
7099.3(18)
25.3(5)
C5A
1490(2)
3208(2)
5941.9(19)
24.6(5)
C6A
195(2)
3181(2)
3924.1(18)
24.2(5)
C7A
-34(2)
4575(2)
3395.9(17)
24.6(5)
C8A
555(2)
4725(3)
2352.1(18)
27.8(5)
C9A
-258(2)
4136(3)
1229.4(18)
25.9(5)
C10A
-1378(2)
3137(3)
1319.4(19)
29.3(5)
C11A
-863(3)
1944(3)
2073.4(19)
30.9(5)
C12A
-837(3)
2150(3)
3320.6(19)
30.7(5)
C13A
-863(3)
5270(3)
452.9(19)
30.9(5)
C14A
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Table 3 Anisotropic Displacement Parameters (Å2×103) for don2c. The Anisotropic
displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…].
Atom
U11
U22
U33
U23
U13
U12
31.0(8)
18.9(9)
22.6(7)
0.7(6)
1.2(6)
2.3(7)
O1
33.2(8)
16.8(9)
28.5(8)
-1.0(6) -2.3(6)
-2.8(7)
O2
26.4(10)
11.0(9)
23.4(9)
0.3(8)
0.0(7)
-2.0(8)
C1
25.4(10)
16.9(11)
26.8(10)
1.1(9)
4.1(8)
-1.3(9)
C2
22.6(10)
17.9(12)
27.6(10)
0.8(9) -1.2(8)
-2.1(9)
C3
28.4(11)
9.7(10)
23.4(9)
0.1(8)
0.9(8)
1.3(8)
C4
26.5(10)
16.0(11)
26.5(10)
1.1(9)
4.9(8)
0.3(9)
C5
21.7(10)
16.3(11)
28.6(10)
1.2(9)
0.6(8)
0.5(8)
C6
24.6(10)
14.6(10)
22.2(9)
-0.7(8) -0.6(7)
-1.7(8)
C7
37.4(13)
19.3(12)
25.3(10)
-1.5(9) -1.6(9)
4.4(10)
C8
34.8(12)
14.6(12)
26.4(10)
-0.4(9)
2.0(8)
2.6(10)
C9
25.3(10)
16.5(12)
23.9(9)
0.2(8)
3.5(8)
-1.2(8)
C10
35.2(11)
16.5(11)
26.7(10)
0.5(8)
6.3(9) -5.4(10)
C11
44.0(14)
12.9(12)
26.9(11)
2.3(8)
4(1)
0.8(10)
C12
38.0(12)
15.0(11)
25.2(10)
0.1(8)
2.6(9)
-0.9(9)
C13
32.5(12)
17.6(12)
24.1(10)
-0.6(8)
2.8(8)
-3.7(9)
C14
31.3(9)
27.7(10)
21.2(7)
0.4(7)
3.8(6)
4.3(7)
O1A
37.8(10)
37.4(11)
23.4(8)
-1.3(7)
-2.0(7)
14.4(9)
O2A
29.6(11)
14.5(11)
22.7(10)
0.1(8)
2.5(8)
-0.1(9)
C1A
25(1)
22.9(12)
27.6(10)
1.2(9) -0.2(8)
1.3(9)
C2A
24.6(11)
24.2(13)
27.3(10)
1.4(10)
5.2(8)
2.6(9)
C3A
29.4(11)
16.3(11)
23.5(10)
-0.1(9)
4.2(8)
1.7(9)
C4A
26.1(10)
21.6(12)
26.2(10)
-1.7(9)
1.6(8)
1.4(9)
C5A
25.1(10)
21.1(12)
27(1)
-1.1(9)
4.4(8)
0.1(9)
C6A
27.5(10)
20.4(12)
23.3(10)
-1.0(8)
2.6(8)
0.1(9)
C7A
29.4(11)
19.3(12)
22.6(9)
-1.1(8)
0.9(8)
-2.1(9)
C8A
30.3(11)
27.9(13)
22.5(9)
0.9(9)
0.4(8) -6.7(10)
C9A
29.0(11)
25.1(13)
21.4(9)
-1.4(9)
1.2(8)
0.3(10)
C10A
29.1(11)
29.2(14)
26.3(10) -3.2(10) -0.8(8) -4.9(10)
C11A
43.7(14)
20.7(13)
26.2(10)
-4.3(9)
3.3(9) -7.3(10)
C12A
43.7(13)
20.1(12)
27.3(11)
-1.9(9)
6.1(9) -6.4(10)
C13A
41.6(13)
25.0(13)
22.8(10)
0.7(9)
0.8(9)
6.6(11)
C14A
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Table 4 Bond Lengths for don2c.
Atom Atom Length/Å Atom Atom
1.378(2) O1A C4A
O1 C4
1.445(3) O2A C14A
O2 C14
1.399(3) C1A C2A
C1 C2
1.399(3) C1A C6A
C1 C6
1.516(3) C1A C7A
C1 C7
1.394(3) C2A C3A
C2 C3
1.392(3) C3A C4A
C3 C4
1.394(3) C4A C5A
C4 C5
1.391(3) C5A C6A
C5 C6
1.541(3) C7A C8A
C7 C8
1.542(3) C7A C13A
C7 C13
1.539(3) C8A C9A
C8 C9
1.542(3) C9A C10A
C9 C10
1.532(3) C10A C11A
C10 C11
1.528(3) C10A C14A
C10 C14
1.529(3) C11A C12A
C11 C12
1.530(3) C12A C13A
C12 C13

Table 5 Bond Angles for don2c.
Atom Atom Atom
Angle/˚
117.27(19)
C2 C1 C6
121.2(2)
C2 C1 C7
121.6(2)
C6 C1 C7
121.4(2)
C3 C2 C1
120.35(19)
C4 C3 C2
122.08(19)
O1 C4 C3
118.74(19)
O1 C4 C5
119.17(19)
C3 C4 C5
119.9(2)
C6 C5 C4
121.9(2)
C5 C6 C1
110.28(19)
C1 C7 C8
109.68(18)
C1 C7 C13
111.50(19)
C8 C7 C13
116.41(19)
C9 C8 C7
117.8(2)
C8 C9 C10
114.86(19)
C11 C10 C9
108.95(19)
C14 C10 C9
110.07(18)
C14 C10 C11

Length/Å
1.374(3)
1.429(3)
1.400(3)
1.390(3)
1.519(3)
1.395(3)
1.389(3)
1.394(3)
1.395(3)
1.549(3)
1.535(3)
1.529(3)
1.547(3)
1.533(3)
1.526(3)
1.537(4)
1.533(3)

Atom Atom Atom
C2A C1A C7A
C6A C1A C2A
C6A C1A C7A
C3A C2A C1A
C4A C3A C2A
O1A C4A C3A
O1A C4A C5A
C3A C4A C5A
C4A C5A C6A
C1A C6A C5A
C1A C7A C8A
C1A C7A C13A
C13A C7A C8A
C9A C8A C7A
C8A C9A C10A
C11A C10A C9A
C14A C10A C9A
C14A C10A C11A

Angle/˚
122.69(18)
118.0(2)
119.3(2)
120.51(19)
120.3(2)
117.7(2)
122.00(19)
120.2(2)
118.6(2)
122.3(2)
110.80(19)
111.45(19)
113.69(19)
113.0(2)
118.4(2)
115.93(19)
108.4(2)
110.43(19)
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C12
C11
C12
O2

C11
C12
C13
C14

C10
C13
C7
C10

112.95(19)
117.2(2)
117.11(19)
112.46(18)

C10A C11A C12A
C13A C12A C11A
C12A C13A C7A
O2A C14A C10A

Table 6 Hydrogen Bonds for don2c.
D
H
A
d(D-H)/Å
d(H-A)/Å
0.90(4)
1.74(4)
O1 H1
O2A1
2
0.91(4)
2.08(4)
O2 H2
O1
3
0.79(4)
1.91(4)
O1A H1A O2
4
0.80(4)
1.96(5)
O2A H2AB O1A

d(D-A)/Å
2.632(2)
2.955(2)
2.698(2)
2.763(3)

114.32(19)
114.6(2)
115.3(2)
113.1(2)

D-H-A/°
172(3)
161(4)
172(5)
177(4)

11+X,+Y,1+Z; 21-X,-1/2+Y,1-Z; 3+X,+Y,1+Z; 4+X,+Y,-1+Z

Table 7 Torsion Angles for don2c.
A B C D
Angle/˚
A
B
C
D
Angle/˚
179.0(2) O1A C4A C5A C6A
-179.9(2)
O1 C4 C5 C6
0.3(4)
0.3(4)
C1 C2 C3 C4
C1A C2A C3A C4A
152.3(2) C1A C7A C8A C9A 153.47(19)
C1 C7 C8 C9
C1 C7 C13 C12 -171.6(2) C1A C7A C13A C12A -175.2(2)
-1.0(3) C2A C1A C6A C5A
0.8(4)
C2 C1 C6 C5
51.7(3) C2A C1A C7A C8A
77.9(3)
C2 C1 C7 C8
-71.5(3) C2A C1A C7A C13A
-49.8(3)
C2 C1 C7 C13
-179.5(2)
179.8(2)
C2 C3 C4 O1
C2A C3A C4A O1A
-0.6(3) C2A C3A C4A C5A
0.6(4)
C2 C3 C4 C5
0.0(3) C3A C4A C5A C6A
-0.7(4)
C3 C4 C5 C6
0.8(4) C4A C5A C6A C1A
0.0(4)
C4 C5 C6 C1
0.4(4) C6A C1A C2A C3A
-0.9(4)
C6 C1 C2 C3
-128.5(2) C6A C1A C7A C8A
-100.5(3)
C6 C1 C7 C8
108.4(2)
131.8(3)
C6 C1 C7 C13
C6A C1A C7A C13A
-179.7(2) C7A C1A C2A C3A
-179.3(2)
C7 C1 C2 C3
179.1(2) C7A C1A C6A C5A
179.2(2)
C7 C1 C6 C5
46.8(3) C7A C8A C9A C10A
77.8(3)
C7 C8 C9 C10
65.9(3) C8A C7A C13A C12A
58.7(3)
C8 C7 C13 C12
31.0(3) C8A C9A C10A C11A
-15.9(3)
C8 C9 C10 C11
155.0(2)
108.9(3)
C8 C9 C10 C14
C8A C9A C10A C14A
-83.0(2) C9A C10A C11A C12A
-57.1(3)
C9 C10 C11 C12
60.0(2) C9A C10A C14A O2A
175.8(2)
C9 C10 C14 O2
74.1(3) C10A C11A C12A C13A
87.4(3)
C10 C11 C12 C13
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C11 C10 C14 O2 173.22(18)
-54.2(3)
C11 C12 C13 C7
-85.6(3)
C13 C7 C8 C9
153.6(2)
C14 C10 C11 C12

C11A C10A C14A O2A

-56.2(3)

C11A C12A C13A C7A
C13A C7A C8A C9A
C14A C10A C11A C12A

-66.4(3)
-80.1(3)
179.2(2)

Table 8 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement
Parameters (Å2×103) for don2c.
Atom
x
y
z
U(eq)
6860(40)
5540(40)
8760(30)
39(9)
H1
3360(40)
2640(40)
530(30)
48(10)
H2
6966
5915
5147
28
H2A
7621
5966
7104
29
H3
3621
5834
7269
28
H5
2977
5818
5314
28
H6
3469
5619
3514
26
H7
6145
5059
3200
34
H8A
5441
3989
3844
34
H8B
3787
3510
2282
31
H9A
5194
3539
1879
31
H9B
2916
5235
1250
27
H10
5617
6229
1440
32
H11A
4415
6744
434
32
H11B
3173
7386
1844
34
H12A
4483
8262
1802
34
H12B
4330
7850
3661
32
H13A
5741
7319
3432
32
H13B
3400
4972
-556
30
H14A
4734
4127
-8
30
H14B
1180(40)
3290(50)
8980(40)
61(12)
H1A
-970(40)
4420(50)
-830(30)
59(12)
H2AB
-1831
3365
5084
31
H2AA
-1682
3458
7021
31
H3A
2473
3251
7607
30
H5A
2305
3150
5669
30
H6A
1124
2884
3851
29
H7A
-1031
4762
3190
29
H8AA
400
5235
3963
29
H8AB
1481
4322
2521
33
H9AA
677
5679
2233
33
H9AB
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H10A
H11C
H11D
H12C
H12D
H13C
H13D
H14C
H14D

417
-1810
-2096
-1457
77
-625
-1767
-1517
-115

3671
2815
3594
1178
1724
1295
2416
5764
5881

874
556
1617
1797
2000
3713
3388
797
382

31
35
35
37
37
37
37
37
37
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Table 1 Crystal data and structure refinement for ISP358-2.
Identification code
ISP358-2 (don2f)
Empirical formula
C13H18O2
Formula weight
206.27
Temperature/K
100.00(10)
Crystal system
orthorhombic
Space group
Pbca
a/Å
12.0669(2)
b/Å
8.09601(18)
c/Å
22.4321(4)
α/°
90.00
β/°
90.00
γ/°
90.00
Volume/Å3
2191.46(7)
Z
8
3
ρcalcg/cm
1.250
-1
μ/mm
0.653
F(000)
896.0
Crystal size/mm3
0.25 × 0.15 × 0.01
Radiation
Cu Kα (λ = 1.54184)
2Θ range for data collection/° 7.88 to 148.36
Index ranges
-10 ≤ h ≤ 14, -9 ≤ k ≤ 8, -19 ≤ l ≤ 27
Reflections collected
9115
Independent reflections
2181 [Rint = 0.0318, Rsigma = 0.0235]
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Data/restraints/parameters
2181/0/138
Goodness-of-fit on F2
1.043
Final R indexes [I>=2σ (I)] R1 = 0.0414, wR2 = 0.1109
Final R indexes [all data]
R1 = 0.0503, wR2 = 0.1190
-3
Largest diff. peak/hole / e Å 0.23/-0.20

Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic
Displacement Parameters (Å2×103) for don2f. Ueq is defined as 1/3 of of the trace of
the orthogonalised UIJ tensor.
Atom
x
y
z
U(eq)
6398.2(8)
5568.4(12)
5152.2(4)
27.0(2)
O1
6894.3(8)
2635.2(13)
9776.1(4)
30.9(3)
O2
6163.1(10)
5414.5(15)
7017.2(5)
21.2(3)
C1
6978.5(11)
6355.0(17)
6734.5(6)
25.2(3)
C2
7075.8(11)
6425.1(17)
6119.5(6)
25.5(3)
C3
6335.5(11)
5541.8(15)
5766.6(6)
22.5(3)
C4
5517.3(11)
4598.7(16)
6031.9(6)
24.9(3)
C5
5437.1(11)
4537.3(16)
6652.7(6)
24.0(3)
C6
6135.1(10)
5371.5(15)
7694.9(5)
21.4(3)
C7
7066.4(11)
4283.3(17)
7941.1(6)
24.6(3)
C8
7105.2(11)
4268.6(17)
8619.6(5)
23.8(3)
C9
5996.7(11)
3692.7(16)
8874.8(6)
23.5(3)
C10
5066.9(11)
4813.0(18)
8648.1(6)
26.6(3)
C11
5026.6(10)
4848.1(18)
7965.8(6)
25.7(3)
C12
6009.6(12)
3638.7(18)
9550.2(6)
28.0(3)
C13

Table 3 Anisotropic Displacement Parameters (Å2×103) for don2f. The Anisotropic
displacement factor exponent takes the form: -2π2[h2a*2U11+2hka*b*U12+…].
Atom
O1
O2
C1
C2
C3
C4
C5
C6
C7
C8

U11
30.6(5)
37.5(6)
20.6(6)
24.5(6)
25.5(6)
25.0(6)
25.0(7)
22.1(6)
20.0(6)
21.9(6)

U22
30.7(5)
28.1(5)
20.6(6)
27.4(7)
26.7(7)
22.4(6)
23.8(6)
23.7(6)
22.9(6)
29.4(7)

U33
19.9(5)
27.0(5)
22.4(6)
23.7(7)
24.4(7)
20.0(6)
26.1(7)
26.1(7)
21.2(6)
22.6(6)

U23
-1.3(4)
5.6(4)
-0.1(5)
-2.7(5)
0.5(5)
-1.6(5)
-2.6(5)
1.1(5)
-0.1(5)
1.0(5)

U13
-0.7(4)
-5.5(4)
-0.7(5)
-2.6(5)
1.3(5)
-1.5(5)
-4.4(5)
-0.9(5)
-0.7(5)
2.4(5)

U12
-3.2(4)
-3.4(4)
2.8(5)
-5.7(5)
-4.5(5)
4.8(5)
-1.7(5)
-1.3(5)
-1.3(5)
4.0(5)
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C9
C10
C11
C12
C13

22.7(6)
26.2(7)
22.9(7)
19.7(6)
30.4(7)

26.6(7)
22.2(6)
31.3(7)
32.2(7)
29.3(7)

22.1(6)
22.2(6)
25.5(7)
25.1(7)
24.1(7)

Table 4 Bond Lengths for don2f.
Atom Atom Length/Å Atom Atom
1.3805(15) C5 C6
O1 C4
O2 C13 1.4340(17) C7 C8
1.3964(18) C7 C12
C1 C2
1.3931(18) C8 C9
C1 C6
1.5209(16) C9 C10
C1 C7
1.3858(18) C10 C11
C2 C3
1.3915(18) C10 C13
C3 C4
1.3827(19) C11 C12
C4 C5

Table 5 Bond Angles for don2f.
Atom Atom Atom
Angle/˚
118.82(11)
C2 C1 C7
117.03(12)
C6 C1 C2
124.13(12)
C6 C1 C7
122.29(12)
C3 C2 C1
119.40(12)
C2 C3 C4
121.65(12)
O1 C4 C3
118.52(11)
O1 C4 C5
119.83(12)
C5 C4 C3
119.88(12)
C4 C5 C6
121.57(12)
C1 C6 C5
110.94(10)
C1 C7 C8

1.8(5)
-0.7(5)
0.9(5)
1.5(5)
0.5(5)

Length/Å
1.3967(18)
1.5310(17)
1.5291(17)
1.5226(17)
1.5279(18)
1.5297(18)
1.5159(17)
1.5315(17)

Atom Atom Atom
C1 C7 C12
C12 C7 C8
C9 C8 C7
C8 C9 C10
C9 C10 C11
C13 C10 C9
C13 C10 C11
C10 C11 C12
C7 C12 C11
O2 C13 C10

Table 6 Hydrogen Bonds for don2f.
D H A d(D-H)/Å
d(H-A)/Å
d(D-A)/Å
0.84
1.82 2.6594(14)
O1 H1 O21
0.84
1.97 2.7924(14)
O2 H2 O12
13/2-X,1-Y,-1/2+Z; 2+X,1/2-Y,1/2+Z

-1.7(5)
0.4(5)
3.4(5)
-0.5(5)
1.4(5)

Angle/˚
115.03(11)
109.83(10)
112.81(10)
110.49(11)
109.67(11)
111.98(11)
110.91(11)
111.50(11)
111.99(11)
112.15(11)

D-H-A/°
172.7
165.1

1.8(5)
-2.5(5)
-0.7(5)
-0.4(5)
-2.6(6)
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Table 7 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement
Parameters (Å2×103) for don2f.
Atom
x
y
z
U(eq)
6910
6208
5046
H1
6660
1674
9839
H2
7484
6968
6972
H2A
7643
7070
5940
H3
5011
3994
5792
H5
4874
3882
6830
H6
6284
6522
7836
H7
6962
3139
7796
H8A
7785
4688
7786
H8B
7274
5393
8768
H9A
7702
3519
8755
H9B
5852
2549
8726
H10
5184
5948
8800
H11A
4348
4412
8804
H11B
4828
3736
7816
H12A
4442
5627
7836
H12B
6090
4776
9707
H13A
5294
3195
9695
H13B

41
46
30
31
30
29
26
30
30
29
29
28
32
32
31
31
34
34
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